Serological markers for improved diagnosis of porcine cysticercosis by Deckers, Nynke
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE USE OF ANTI-OSTERTAGIA OSTERTAGI 
ANTIBODIES IN MILK TO STUDY THE 
EPIDEMIOLOGY AND IMPACT ON PRODUCTION OF 
GASTROINTESTINAL-NEMATODE INFECTIONS IN 
DAIRY COWS 
 
 
 
 
Proefschrift ter verkrijging van de graad van doctor in de 
diergeneeskundige wetenschappen aan de faculteit 
diergeneeskunde 
Universiteit Gent, 2007 
 
door Johannes Charlier 
 
 
 
 
 
Promotoren 
Prof. dr. J. Vercruysse 
Prof. dr. E. Claerebout 
 
 
 
 
Vakgroep Virologie, Parasitologie en Immunologie 
Faculteit Diergeneeskunde, Universiteit Gent 
Salisburylaan 133, B-9820 Merelbeke 
Serological ma ker for improv d diagnosis of porcine
cysticercosis
Nynke Deckers
Proefschrift voorgedragen tot het behalen van de graad van
Doctor in de Diergeneeskundige Wetenschappen, 2009
Promotoren:
Prof. Dr. P. Dorny
Prof. Dr. J. Vercruysse
Vakgroep Virologie, Parasitologie en Immunologie
Faculteit Diergeneeskunde, Universiteit Gent
Salisburylaan 133, B-9820 Merelbeke
“I have not failed, I have merely found 10, 000 ways
that do not work.”
Thomas A. Edison
Acknowledgments - Dankwoord
Dit werk kwam tot stand in het kader van een
specialisatiebeurs van het IWT-Vlaanderen
(Instituut voor de aanmoediging van Innovatie door
Wetenschap en Technologie in Vlaanderen).
ii
Acknowledgments - Dankwoord iii
Een doctoraat is een werk van lange adem, toch e´e´n van vier en een half jaar in mijn
geval. En dat werk doe je niet alleen. Daarom wil ik hier alle mensen bedanken die hun
steentje hebben bijgedragen.
In de eerste plaats wil ik mijn promotoren, Prof. Dorny en Prof. Vercruysse, bijzonder
bedanken.
Pierre, het moet gezegd: zonder u had ik vandaag niet gestaan waar ik nu ben. U was
reeds promoter van mijn scriptie in derde proef diergeneeskunde. Dankzij u kon ik aan
het ITG de opleiding Master of Science in Tropical Animal Health volgen en aansluitend
beginnen aan mijn doctoraat. Dit gaf mij de mogelijkheid een stukje van de wereld te
verkennen. Ik kan met recht en rede zeggen dat u van mij een rijker persoon heeft gemaakt,
niet alleen op wetenschappelijk vlak. U stond altijd klaar met goede raad en een steunend
woord maar liet me ook mijn eigen weg gaan. Van je fouten leer je het meest, zegt men.
Kortom, bedankt voor alles!
Prof. Vercruysse, bedankt voor uw hulp. Uw kritische opmerkingen waren voor mij een
goede drijfveer om het onderste uit de kan te halen. Als het niet van een leien dakje liep,
stond u mij met raad en daad bij. Ook al was mijn “thuisbasis” te Antwerpen, dankzij u
kon ik ook meegenieten van de sfeer in Gent.
Verder wil ik zeker Prof. Muyldermans, Prof. De Baetselier, Dirk Saerens, Katja Con-
rath en alle “CMIMers” bedanken, zonder wie er van Nanobodies geen sprake zou geweest
zijn. Al sinds begin 2005 was ik een vaste klant in Brussel, altijd stonden jullie klaar voor
hulp bij het labowerk, advies of een leuke babbel. Jullie hebben veel van jullie eigen tijd
opgeofferd om dit werk mogelijk te maken. Daarom: Dirk, Katja, Nick, Jochen, Mireille,
Christiane, Ce´cile, Reza, Jan en alle anderen: een welgemeende dankuwel!
Serge, ook bedankt om dit manuscript te lezen en voor de mooie figuren die u ter
beschikking stelde.
I would also like to thank Dr. Ndao, Dr. Ward, Adam Rainczuk, Veerle Lejon and all
my friends in Montreal. Momar, although we sometimes had a different opinion on how
to proceed with the SELDI work, you always supported me and yes. . . we got there in the
end!
Muchas gracias a todos en Peru: Prof. Gonzalez, Prof. Garcia, Rafael Manzanedo-
Garcia, Lelia Sanchez, Lily Chou, all the staff at UNMSM in Lima and students at
the “Gringo house”. My visit to Peru was my first encounter with the real world of
cysticercosis, not just as some serum samples in a lab, but as the real situation in the
villages around Tumbes and Cerro de Pasco and the Santo Toribio de Mogrovejo hospital
in Lima. Armando, I would also like to thank you for providing serum samples for my
lab work.
iv
I would like to express my gratitude to Prof. Phiri, Kabemba Mwape, Chummy Sika-
sunge, the staff at the Department of Clinical Studies, Faculty of Veterinary Medicine,
UNZA and all my friends at Marshlands for the wonderful stay in Zambia. Prof. Phiri,
thank you for the warm welcome and support during the sample collection.
Many thanks to Dr. Wilkins and Dr. Willingham for reading this manuscript.
Patty, I would like to thank you for all your help with the Nanobody work and for pro-
viding the Western blot strips. I very much enjoyed our discussions and I have learned a
lot from you. I hope I can put your advise into practice and become a good scientist.
Lee, thank you for inviting me to the meetings of CWGESA and the European Cysticer-
cosis Group. You gave me the opportunity to do another important research activity —
networking. . .
Kirezi, jij bracht de bal aan het rollen toen je me vroeg of ik geen zin had om te
doctoreren. Zonder jou was er helemaal geen doctoraatsonderzoek geweest. Het was wel
even schrikken toen je na enkele maanden andere oorden ging opzoeken, maar dat heeft
me wel geleerd om zelfstandig te werken. Toch kon ik altijd op je rekenen voor goede raad
of een opmonterend gesprekje. Een dikke merci!
Bjorn, ik ben samen met jou aan het “kamelenavontuur” begonnen. Ook daarna was je
altijd bereid om me te helpen, of het nu labo werk was of eerste hulp bij computerperikelen.
Dankzij jou heb ik LATEX ontdekt en werd het schrijven van deze thesis kinderspel! Ook
voor jou, een dikke merci!
Daarnaast wil ik ook graag Nicolas, Anke, Lieve, Ko, Dorien, Sarah, Danielle, Jef en
alle andere (oud)-collega’s van het ITG bedanken voor de hulp en vooral ook de leuke
werksfeer!
Tamara Gelaude en Basile Midinhouevi, bedankt voor de hulp bij het labo werk.
Mieke, bedankt om alle “UGent” administratie altijd zo snel en efficie¨nt te regelen!
Dirk, bedankt voor de hulp bij de opmaak van dit boekje.
Ik wil ook enkele heel bijzondere mensen bedanken. Vooreerst mijn ouders, voor alle
kansen die jullie mij hebben gegeven, voor jullie onvoorwaardelijke steun en voor de veilige
haven die jullie mij bieden. Jullie zijn mijn trouwste supporters!
En tenslotte Jes, voor die weken, soms maanden dat ik weg was. Voor al die keren dat
je samen met mij lachte, zuchtte, triomfeerde, vloekte. . . Because you’re the one for me,
fatty. . .
List of Figures
1.1 Taenia solium life cycle. Humans are the definitive host (harboring the
adult Taenia tapeworm in the intestine); the infective eggs are shed into
the environment with the feces. The natural intermediate host is the pig
(harboring the larval stage or cysticercus). Humans can be also infected
with the larval stage (accidental intermediate host). (Adapted from: http:
//www.aafp.org/afp/20070701/91.html) . . . . . . . . . . . . . . . . . . 2
1.2 Global distribution of Taenia solium taeniosis/cysticercosis (Source: http:
//www.who.int). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Typical antibody reactions in the enzyme-linked immunoelectrotransfer
blot (EITB) for cysticercosis. The positions of the seven diagnostic gly-
coproteins are marked and designated according to their relative mobilities
in SDS-PAGE (in kDa) (Adapted from: http://www.dpd.cdc.gov/DPDx/
HTML/ImageLibrary/Cysticercosis_il.htm). . . . . . . . . . . . . . . . . 9
2.1 ProteinChip Array with its different chromatographic surfaces. The upper
arrays represent chemically modified surfaces and the bottom arrays are
biochemically modified surfaces (Source: Ciphergen Basic Course). . . . . . 22
2.2 Schematic of SELDI-TOF mass spectrometer. The time-of-flight mass
spectrometer measures the MW of the proteins retained on the ProteinChip
Array. The software associated with the instrument can display the result
either as a spectrum, map or gel view (Source: Issaq et al., 2002). . . . . . 22
2.3 Schematic representation of conventional and Heavy-chain antibodies and
derived antigen binding fragments. VH, VHH = variable domain of the
heavy chain, VL = variable domain of the light chain, CH = constant
domain of the heavy chain, CL = constant domain of the light chain. . . . 30
v
vi
2.4 Schematic representation of the gene sequence differences between VH and
VHH. The position of the CDR in between the framework regions is in-
dicated. The CDR1 and CDR3 of a VHH are larger than in VH genes,
and they are often connected by a disulfide bond (blue line). The hallmark
amino acid substitutions in framework 1 and 2 are given. The numbering
is according to the Kabat numbering (Kabat, 1988). . . . . . . . . . . . . . 32
2.5 Schematic overview of cloning and selection of antigen-specific VHHs from
an immunized dromedary. See text for explanation (Adapted from: Muyl-
dermans, 2001). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.6 Schematic representation of the phagemid vector pHEN4 and expression
vector pHEN6, the latter containing the Nanobody cAblys3 gene. . . . . . 37
2.7 Schematic representation of M13 philamentous phage with a VHH (in
red) fused to its minor coat protein 3. The VHH gene is included in the
phagemid genome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
3.1 The serological antigen () and antibody () response of 1-month-old (A),
3-months-old (B) and 5-months-old (C) piglets after oral infection with one
Taenia solium proglottid. Sera were analyzed weekly during the first month
p.i., and every 2 weeks thereafter: time points depicted are 0, 1, 2, 3, 4, 6,
8, 10 and 12 weeks p.i. Antigen levels are expressed as ratio = OD value of
sample/cut-off value (calculated based on the mean OD value (492 nm) of
eight non-infected control samples). Antibody values are expressed as OD
values as measured with the Taenia crassiceps antibody ELISA. . . . . . . 51
3.2 The correlation between the concentration of circulating antigen and the
number of viable cysts in Taenia solium infected animals and non-infected
control animals (n = 98). Antigen concentrations were calculated following
transformation of the OD value using the equation of a reference curve
obtained after serial dilution of Taenia saginata excretion-secretion products. 53
vii
4.1 Example of the 3.60 kDa and 3.63 kDa protein biomarkers as discovered
by SELDI-TOF analysis (CM10 ProteinChip Array) of serum samples from
experimentally infected pigs. The 3.60 kDa biomarker is present in serum
samples from pigs with only degenerated cysts at necropsy (degenerated
phenotype). Note the absence of the biomarker in the pre-infection control
samples and serum samples from pigs with viable cysts at necropsy. The
3.63 kDa biomarker is present in serum samples from pigs with viable cysts
at necropsy (viable phenotype). (A) Spectral view of the protein profiles
in the range 3–4 kDa. (B) Close-up spectral view (range 3,500–3,700 Da).
(C) Gel view. D = sera from experimentally infected pigs with degenerated
cysts; V = sera from experimentally infected pigs with viable cysts; C =
pre-infection control sera. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.2 Example of the 5.57 kDa protein biomarker as discovered by SELDI-TOF
analysis (CM10 ProteinChip Array) of serum samples from experimentally
infected pigs. The biomarker is present (arrow) in serum samples from pigs
with viable cysts at necropsy (viable phenotype) (A) Spectral view of the
protein profiles in the range 3.5–9 kDa. (B) Close-up spectral view (range
5,450–5,700 Da). (C) Gel view. D = sera from experimentally infected
pigs with degenerated cysts; V = sera from experimentally infected pigs
with viable cysts; C = pre-infection control sera. . . . . . . . . . . . . . . . 67
viii
4.3 Box-and-whisker diagrams of the peak intensities of 3 biomarkers discov-
ered by SELDI-TOF analysis (CM10 ProteinChip Array) of serum samples
of pigs experimentally or naturally infected with Taenia solium. The left
panels (1A, 2A, 3A) represent the experimental sample group (groups C,
D and V), the right panels (1B, 2B, 3B) the field sample group (groups
C, Df and Vf). (1) 8.6 kDa marker. In the experimental sample group,
the 8.6 kDa marker has a significant elevated serum expression in the sam-
ples of pigs infected with viable cysts, whereas in the field sample group,
it has a significant decreased serum expression in samples from pigs with
degenerated cysts and pigs with viable cysts. (2) 28.5 kDa marker. In the
experimental sample group, the 28.5 kDa marker has a significant elevated
serum expression in the samples of pigs infected with degenerated cysts,
whereas in the field sample group, it has a significant decreased serum
expression in samples from pigs with viable cysts. (3) 55.8 kDa marker.
In the experimental sample group, the 55.8 kDa marker has a significant
elevated serum expression in the samples of pigs infected with degener-
ated cysts, whereas in the field sample group, it has a significant decreased
serum expression in samples from pigs with viable cysts. . . . . . . . . . . 71
5.1 Amino acid sequence of the isolated Nanobodies from two dromedary im-
mune libraries against Taenia solium antigen (TsAg), named Nbsol. The
IMGT numbering and CDR designation are used (The International Im-
munogenetics Information System, http://imgt.cines.fr). A to D de-
note the different epitope-binding groups based on the results of competi-
tion ELISA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
5.2 Specificity of Nanobodies raised against Taenia solium cyst fluid tested
in ELISA with cyst fluid from T. solium (TsAg) and Taenia hydatigena
(ThAg), Trichinella spiralis excretion-secretion antigens (TspAg), Tae-
nia saginata somatic antigens (TsaAg) and Taenia crassiceps cyst fluid
(TcrAg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.3 Rate plane with Isoaffinity Diagonals (RaPID) plot of the Taenia solium
antigen (TsAg) binding Nanobodies (Nb). The kinetic rate values kon and
koff for a particular Nb as determined by biosensor measurements are plot-
ted on a two-dimensional diagram so that Nbs located on the same diagonal
line have identical KD values. . . . . . . . . . . . . . . . . . . . . . . . . . 84
ix
5.4 Western blotting with Taenia solium-specific Nanobodies (Nb). (A) Im-
munodetection of T. solium cyst fluid with Nbs after 15% SDS-PAGE and
blotting on nitrocellulose membrane. Two major bands of approximately
50 and 32 kDa (marked with asterisks) were consistently recognized. Only
Nbsol60 and Nbsol62 show a low reactivity with the antigen. The posi-
tion of the MW markers is indicated. (B) Blotting of T. solium cyst fluid
on polyvinylidene fluoride (PVDF) membrane and stained with Coomassie
blue after 15% SDS-PAGE. The bands marked with an asterisk were cut
out and identified by N-terminal sequencing, they both contained a 14 kDa
glycoprotein. (C) Immunodetection of the 8 kDa diagnostic glycoproteins
Ts14 (a), Ts18var1 (b), TsRS1 (c) and TsRS2 (d) with Nbs (RHS: rabbit
hyperimmune serum raised against T. solium cyst fluid). . . . . . . . . . . 85
5.5 Epitope mapping of Taenia solium-specific Nanobodies (Nb). (A) Com-
petition ELISA for the detection of T. solium cyst fluid using biotiny-
lated Nbsol60 as detector antibody. Increasing concentrations of non-
biotinylated competing Nb are added. OD is presented as percentage
positivity (ODNbsol60(5µg/ml) = 100%). (B) ELISA using a dilution se-
ries of biotinylated Nbsol60 as detector antibody. A constant concentra-
tion of either Nbsol130 or Nbsol41 is added to confirm the interaction
between the Nbs: enhanced binding of Nbsol60 is noticed in presence
of either Nbsol130 or Nbsol41. OD is presented as percentage positivity
(ODNbsol60(5µg/ml) = 100%). . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5.6 Antigen capturing by Nanobodies (Nb). (A) Sandwich ELISA with Nbs
for the detection of Taenia solium (TsAg) and Taenia hydatigena (ThAg)
cyst fluid and serum antigens (negative serum, serum from T. solium and
T. hydatigena-infected pigs). The four best combinations are presented
here, the first Nb noted is the capturing antibody, the second is the detector
antibody. (B) Inhibition ELISA for the detection of TsAg in PBS and
serum antigen (negative serum, negative serum spiked with TsAg, serum
from T. solium and T. hydatigena-infected pigs). . . . . . . . . . . . . . . 89
List of Tables
1.1 Diagnostic criteria for neurocysticercosis (Source: Del Brutto et al., 2001). 7
1.2 List of Taenia solium proteins used in antibody detection. . . . . . . . . . 10
1.3 Morphological differences between Taenia solium, Taenia saginata and
Taenia saginata asiatica (Source: Dorny et al., 2005). . . . . . . . . . . . . 15
2.1 Examples of studies applying SELDI-TOF MS for discovery of cancer
biomarkers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.2 Pre- and post-analytical aspects important for protein profiling studies
(Source: Bons et al., 2005). . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.3 Examples of therapeutic applications of Nanobodies (Nb). . . . . . . . . . 40
3.1 Number and classification of cysts following necropsy of piglets infected
with Taenia solium at the age of 1, 3 or 5 months. . . . . . . . . . . . . . . 49
3.2 Concentration of circulating antigen (ng/mL) at 3, 6 and 10 weeks p.i.
(WPI) in serum of piglets infected with Taenia solium at the age of 1, 3 or
5 months. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.1 Summary of serum samples used in the study. No. control = number
of samples from pigs prior to experimental infection; No. Degenerated =
number of samples from pigs with only degenerated cysts; No. Viable =
number of samples from pigs with only viable cysts; No. Mixed = number
of samples from pigs with mixed infections (viable and degenerated cysts). 64
4.2 Overview of significant biomarkers after SELDI-TOF analysis of serum
samples from experimentally infected pigs. . . . . . . . . . . . . . . . . . . 68
4.3 Overview of significant biomarkers after SELDI-TOF analysis of 86 serum
samples from naturally infected pigs in Zambia and Peru and comparison
with biomarkers found after SELDI-TOF analysis of 30 serum samples from
experimentally infected pigs. . . . . . . . . . . . . . . . . . . . . . . . . . . 70
x
xi
5.1 Screening of Nanobodies for competition for Taenia solium cyst fluid anti-
gens (TsAg) in indirect ELISAs. . . . . . . . . . . . . . . . . . . . . . . . . 87
Table of Contents
Acknowledgments - Dankwoord ii
List of Figures v
List of Tables x
1 Diagnosis of Taenia solium infection:
a literature review 1
1.1 General introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Diagnosis of cysticercosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.1 Porcine cysticercosis: Tongue and carcass inspection . . . . . . . . . 5
1.2.2 Human cysticercosis: Clinical diagnosis and imaging techniques . . 5
1.2.3 Immunodiagnosis: Antibody detection . . . . . . . . . . . . . . . . 6
1.2.4 Immunodiagnosis: Antigen detection . . . . . . . . . . . . . . . . . 12
1.2.5 Molecular techniques . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.3 Diagnosis of taeniosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.3.1 Questioning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.2 Coproscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.3 Antibody detection . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.4 Copro-antigen detection . . . . . . . . . . . . . . . . . . . . . . . . 16
1.3.5 Molecular techniques . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.4 Conclusion: application of immunodiagnostic tools for diagnosis of cys-
ticercosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2 Laser beams and dromedaries. . .
Review of SELDI-TOF MS and Nanobodies 19
2.1 General introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.2 Surface enhanced laser desorption and ionization time-of-flight mass spec-
trometry (SELDI-TOF MS) . . . . . . . . . . . . . . . . . . . . . . . . . . 20
xii
xiii
2.2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.2.2 General methodology . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2.3 Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2.4 SELDI: subject of debate . . . . . . . . . . . . . . . . . . . . . . . . 24
2.3 Nanobodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3.2 Heavy-chain antibodies . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.3.3 Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.3.4 Production of antigen-specific VHH . . . . . . . . . . . . . . . . . . 34
2.3.5 Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.3.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Objectives 42
3 Serological responses in porcine cysticercosis: a link with the parasito-
logical outcome of infection 44
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.2.1 Animals and experimental design 1 . . . . . . . . . . . . . . . . . . 46
3.2.2 Animals and experimental design 2 . . . . . . . . . . . . . . . . . . 46
3.2.3 Detection of circulating antigen . . . . . . . . . . . . . . . . . . . . 47
3.2.4 Total IgG detection by ELISA . . . . . . . . . . . . . . . . . . . . . 47
3.2.5 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3.1 Infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3.3.2 Levels of circulating antigen . . . . . . . . . . . . . . . . . . . . . . 50
3.3.3 Total IgG ELISA with T. crassiceps antigen . . . . . . . . . . . . . 50
3.3.4 Relationship between antigen titers and number of cysts . . . . . . 50
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4 Identification of biomarkers for different stages of porcine cysticercosis
using SELDI-TOF MS 57
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
4.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2.1 Serum samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2.2 Sample fractionation . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.2.3 ProteinChip preparation . . . . . . . . . . . . . . . . . . . . . . . . 60
4.2.4 Data acquisition and processing . . . . . . . . . . . . . . . . . . . . 61
xiv
4.2.5 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.2.6 Protein purification and identification . . . . . . . . . . . . . . . . . 62
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.3.1 Infection status of the animals . . . . . . . . . . . . . . . . . . . . . 63
4.3.2 Discovery of Protein Biomarkers in the experimental samples . . . . 64
4.3.3 Discovery of protein biomarkers in the field samples . . . . . . . . . 69
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5 Nanobodies, a promising tool for species-specific diagnosis of Taenia
solium cysticercosis 75
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.2 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.2.1 Antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
5.2.2 Serum samples . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5.2.3 Immunization of animals . . . . . . . . . . . . . . . . . . . . . . . . 77
5.2.4 Nanobody library construction and selection of binders . . . . . . . 77
5.2.5 Nanobody protein production . . . . . . . . . . . . . . . . . . . . . 78
5.2.6 Binding specificity . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
5.2.7 Binding affinity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.2.8 Western blotting and TsAg protein identification . . . . . . . . . . 79
5.2.9 Epitope mapping . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.2.10 Antigen capturing . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5.2.11 Animal ethical approval . . . . . . . . . . . . . . . . . . . . . . . . 81
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.3.1 Selection of Ag-specific Nbs . . . . . . . . . . . . . . . . . . . . . . 81
5.3.2 Production and purification of the different binders . . . . . . . . . 81
5.3.3 Binding specificity . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.3.4 Binding affinity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.3.5 Western blot and protein identification . . . . . . . . . . . . . . . . 84
5.3.6 Epitope mapping . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.3.7 Antigen capture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
6 General discussion, conclusions and recommendations 92
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
6.2 Serological responses in experimentally infected pigs . . . . . . . . . . . . . 93
6.3 Biomarkers for active and inactive cysticercosis . . . . . . . . . . . . . . . 94
6.4 Specific diagnosis of porcine cysticercosis . . . . . . . . . . . . . . . . . . . 96
xv
6.5 Conclusions and recommendations . . . . . . . . . . . . . . . . . . . . . . . 98
Bibliography 100
Summary 131
Samenvatting 136
1
Diagnosis of Taenia solium infection:
a literature review
Chapter 1 2
1.1 General introduction
Cysticercosis in pigs is caused by the larval stage of the tapeworm Taenia solium. Man
is the only definitive host, harboring the adult tapeworm in the small intestine (taenio-
sis). During defecation, gravid proglottids containing eggs are shed into the environment.
These eggs are the source of infection with the larval stage, Cysticercus cellulosae. The
natural intermediate host is the pig, harboring larval cysts anywhere in its body, mostly
without clinical symptoms. Man can also act as intermediate host. Humans become
infected with cysts by accidental ingestion of T. solium infective eggs by fecal-oral con-
tamination (Figure 1.1).
Figure 1.1: Taenia solium life cycle. Humans are the definitive host (harboring the
adult Taenia tapeworm in the intestine); the infective eggs are shed into the environment
with the feces. The natural intermediate host is the pig (harboring the larval stage or
cysticercus). Humans can be also infected with the larval stage (accidental intermediate
host). (Adapted from: http://www.aafp.org/afp/20070701/91.html)
In man, cysts can develop in different parts of the body (subcutaneous tissue, the eye,
the muscles); however, cysts preferably tend to lodge in the central nervous system, caus-
ing neurocysticercosis (NCC). This can result in severe symptoms ranging from headache,
various neurological symptoms, epilepsy, hydrocephalus and even death (Del Brutto,
2005).
Taenia solium cysticercosis is a major public health problem in developing countries,
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where free-roaming pigs have access to human feces and hygienic conditions are poor.
Figure 1.2 shows the global distribution of T. solium taeniosis/cysticercosis. According
to data collected in Peru, there would be an estimated 23, 500 to 39, 000 inhabitants
with symptomatic NCC among whom 19, 000 to 31, 000 would be associated with seizures
(Bern et al., 1999). Extrapolating these results to other developing countries in Latin
America, there are 75 million people living in areas of endemicity and 400, 000 cases
of symptomatic NCC in Latin America alone. NCC is considered as the main cause
of epilepsy worldwide (International League Against Epilepsy, 1994). Due to increased
travelling and immigration, there are more and more imported cases of NCC in developed
countries (Schantz et al., 1998; Chatel et al., 1999; Townes et al., 2004). For instance,
cysticercosis has emerged as a cause of severe neurological disease in the United States
(Sorvillo et al., 2007). A total of 221 cysticercosis deaths were identified for 1990–2002.
Fatal cysticercosis affected mainly immigrants from Mexico and other Latin American
countries; however, US-born persons were also affected.
Figure 1.2: Global distribution of Taenia solium taeniosis/cysticercosis (Source:
http://www.who.int).
Porcine cysticercosis poses also an economic constraint, because of condemned car-
casses and reduced household income for poor farmers. In Eastern Cape Province of
South Africa, the estimated overall monetary burden due to T. solium cysticercosis var-
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ied from US $18.6 million to US $34.2 million depending on the method used to estimate
productivity losses (Carabin et al., 2006).
There are major discrepancies in the treatment of neurocysticercosis in part due to
the vast variation in clinical manifestations (Evans et al., 1997). Symptomatic therapy
with antiepileptic drugs is indicated to control epilepsy, often in conjunction with anti-
inflammatory drugs. Whether the use of antiparasitic drugs (albendazole or praziquantel)
is advisory, is still subject to debate (Garcia et al., 2002). Some authors claim that their
use is unnecessary because cysticidal therapy can result in severe brain inflammation and
cysts will degenerate and heal by natural evolution of the disease (Carpio et al., 1998).
However, meta-analysis of randomized trials of cysticidal drug therapy for neurocysticer-
cosis showed that cysticidal drug therapy results in better resolution of cysts, lower risk
for recurrence of seizures, and a reduction in the rate of generalized seizures (Del Brutto
et al., 2006).
In 1993, T. solium cysticercosis was listed as a potentially eradicable disease by the
International Task Force for Disease Eradication (Schantz et al., 1993). In developed coun-
tries, the main method of control was to eradicate porcine cysticercosis through improved
pig husbandry and meat inspection. This approach has typically failed in developing coun-
tries. Corralling pigs in a pen where they cannot scavenge for food, requires that they be
given additional feed, which is not affordable for many subsistence farmers. Nowadays,
T. solium taeniosis/cysticercosis is no longer considered as potentially eradicable because
of the insufficient operational experience (Molyneux et al., 2004).
Nevertheless, several other tools are available for the control of T. solium cysticercosis:
mass treatment of tapeworm carriers (Allan et al., 1997; Garcia et al., 2006), treatment
of pigs with oxfendazole (Gonzalez et al., 1996, 2001) or in the future, vaccination of
pigs (Flisser et al., 2004; Gonzalez et al., 2005; Parkhouse et al., 2008; Sciutto et al.,
2008). However, regardless of the chosen strategy, one of the most important aspects
of control and elimination of cysticercosis is prevention of infection by improving public
awareness and hygienic conditions. In this view, health and pig management education
campaigns (Sarti et al., 1997; Sarti and Rajshekhar, 2003; Ngowi et al., 2007, 2008) should
be implemented during control programs.
In order to control the disease, the first step is to assess the prevalence of taenio-
sis/cysticercosis. For porcine cysticercosis, tongue inspection and post mortem exami-
nations can be used for diagnosis (Gonzalez et al., 1990). Clinical diagnosis of human
cysticercosis is primarily done by (neuro)imaging techniques (Garcia and Del Brutto,
2003). The prevalence of human and pig infection can also be estimated using serology
based on either antibody or antigen detection (Dorny et al., 2003).
This chapter provides an overview of the current techniques for diagnosis of T. solium
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cysticercosis and taeniosis with emphasis on immunodiagnosis. From this, it will become
clear that there is a need for improved diagnostic techniques, particularly for porcine
cysticercosis.
1.2 Diagnosis of cysticercosis
1.2.1 Porcine cysticercosis: Tongue and carcass inspection
Tongue inspection and palpation consists of palpating nodules and/or visual identification
of cysticercus cysts. The pig is placed on its side and restrained, and a rod is used to
keep its mouth open. The tongue is gently pulled aside using a cloth and the base of the
tongue is examined and palpated. Tongue inspection is often performed by farmers and
pig traders at the informal markets (The Cysticercosis Working Group in Peru, 1993).
The findings of the tongue inspection determine the price of the pig to be sold. The tongue
test is very specific but lacks sensitivity: Gonzalez et al. (1990) reported a sensitivity of
70%; Pouedet et al. (2002) reported a sensitivity of 50-55% and in another study the
sensitivity was as low as 21% (Dorny et al., 2004b). In any case, the tongue examination,
being a test essentially without cost and having high specificity, can be useful as rapid
assessment tool in epidemiological surveys.
Complete carcass dissection with enumeration of the cysts is regarded as the gold
standard for diagnosing porcine cysticercosis (Dorny et al., 2004b) and can provide a
tool for validation of immunodiagnostic tests. However, routine carcass inspection at the
slaughterhouse lacks sensitivity and in many developing countries, regulations concerning
meat inspection are inadequate or non-existent (Joshi et al., 2003). Furthermore, only a
small percentage of pigs are slaughtered at an official slaughterhouse and as such subjected
to carcass inspection (The Cysticercosis Working Group in Peru, 1993).
1.2.2 Human cysticercosis: Clinical diagnosis and imaging tech-
niques
Neurocysticercosis may produce absolutely no clinical symptoms but it may also present
a variety of clinical manifestations. This pleomorphism is due to differences in num-
ber, size, localization and stage of development of cysticerci, as well as to the host’s
immune response to the parasite (Takayanagui and Odashima, 2006). The clinical symp-
toms are mostly non-specific and defining a typical syndrome of neurocysticercosis is
unrealistic. Seizures are reported to be the most common symptom, occurring in 70 −
90% of patients (White, 1997). Other clinical manifestations include: focal neurological
signs, intracranial hypertension, psychiatric disturbances, migraine-type headache, hydro-
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cephalus, cranial nerve involvement and tumor-like syndromes, acute meningitis, stroke
syndromes. . . (Sotelo and Del Brutto, 2000).
Modern neuroimaging techniques play the most important role in the diagnosis of
NCC. Previous radiological procedures such as plain roentgenograms, isotope brain scans,
pneumoencephalograms, cerebral angiography and myelography are now largely replaced
by computed tomography (CT) and magnetic resonance imaging (MRI) (Del Brutto et al.,
1998). Both CT and MRI provide objective evidence regarding the topography of the
lesions and the degree of inflammation surrounding the cysticerci (Garcia et al., 2005).
CT and MRI findings in parenchymal NCC depend on the stage of development of the
cysticerci. Cystic lesions with an eccentric hyperdense nodule representing the scolex
are characteristic of NCC. Other findings include single or multiple enhancing lesions and
hydrocephalus — the most common CT finding in patients with subarachnoid cysticercosis
(Garcia and Del Brutto, 2003). With the exception of cystic lesions, most imaging findings
are non-specific and represent a diagnostic challenge (Sotelo and Del Brutto, 2000).
Recently, diagnostic criteria for neurocysticercosis were provided based on objective
clinical, imaging, immunological and epidemiological data (Del Brutto et al., 2001). The
criteria include four categories — absolute, major, minor and epidemiologic — stratified
on the basis of their individual diagnostic strength. Interpretation of these criteria results
in two degrees of diagnostic certainty: definite and probable (Table 1.1).
The gold standard for diagnosing NCC is pathological confirmation through biopsy or
autopsy; obviously, these techniques have limitations (Dorny et al., 2003). Visualization
of a cystic lesion with scolex on CT or MRI or direct visualization of the subretinal
parasite during ophthalmic examination (absolute diagnostic criteria for NCC) can also
be regarded as gold standard tests.
Another manifestation of cysticercosis in humans, common in Asian countries, is the
presence of subcutaneous nodules (Willingham et al., 2003; Dorny et al., 2004c). Fine
needle aspiration cytology provides a safe and rapid tool for diagnosis of subcutaneous
cysticercosis (Adhikari et al., 2007).
1.2.3 Immunodiagnosis: Antibody detection
Infection with T. solium results in a specific antibody response. These antibodies can be
detected in either serum, cerebrospinal fluid (CSF) in the case of NCC (Arruda et al.,
2006) or even tear specimen in the case of ophtalmic cysticercosis (Sahu et al., 2008).
Several techniques have been described to detect antibodies to T. solium infections in
man and pigs, such as radioimmunoassay (Miller et al., 1984), hemagglutination (Larralde
et al., 1986; Ferreira et al., 1997), the complement fixation test (Garcia et al., 1995),
dipstick assay (Hayunga et al., 1991), latex agglutination (Rocha et al., 2002), ELISA
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Table 1.1: Diagnostic criteria for neurocysticercosis (Source: Del Brutto
et al., 2001).
Diagnostic criteria
Absolute criteria 1. Histologic demonstration of the parasite from biopsy of a
brain or spinal cord lesion
2. Cystic lesions showing the scolex on CT or MRI
3. Direct visualization of subretinal parasites by
fundoscopic examination
Major 1. Lesions highly suggestive of NCC on neuroimaging studies
2. Positive serum EITBa for the detection of anticysticercal
antibodies
3. Resolution of intracranial cystic lesions after therapy
with albendazole or praziquantel
4. Spontaneous resolution of small single enhancing lesions
Minor 1. Lesions compatible with NCC on neuroimaging studies
2. Clinical manifestations suggestive of NCC
3. Positive CSFb ELISA for detection of anticysticercal
antibodies or cysticercal antigens
4. Cysticercosis outside the CNS
Epidemiologic 1. Evidence of a household contact with T. solium infection
2. Individuals coming from or living in an area
where cysticercosis is endemic
3. History of frequent travel to disease-endemic areas
Diagnostic certainty
Definitive 1. Presence of one absolute criterion
2. Presence of two major plus one minor and
one epidemiological criterion
Probable 1. Presence of one major plus two minor criteria
2. Presence of one major plus one minor
and one epidemiological criterion
3. Presence of three minor plus one epidemiologic criterion
a Enzyme-linked immunoelectrotransfer blot
b Cerebrospinal fluid
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and immunoblot techniques (Escalante et al., 1999).
Initially, antigens used in antibody detection assays were either cyst fluid, excretion-
secretion (ES) products or crude homogenates from cysticerci from either T. solium or the
related parasites T. crassiceps or T. saginata (Ko and Ng, 1998; D’Souza and Hafeez, 1999;
Pinto et al., 2000; Arruda et al., 2005; Oliveira et al., 2007). However, unpurified antigens
have moderate sensitivities and relatively poor specificities (Schantz and Sarti-Gutierrez,
1989). Improved protein purification techniques and research on antigenic properties
of cyst fluid and surface proteins has led to the development of better serological tools
(Gottstein et al., 1986; Parkhouse and Harrison, 1987; Hayunga et al., 1991; Ito et al.,
1998; Assana et al., 2006).
The most specific test so far is the enzyme-linked immunoelectrotransfer blot (EITB)
with an initially reported specificity of 100% and sensitivity of 98% (Tsang et al., 1989).
This immunoblot uses an enriched fraction of glycoproteins obtained by purifying a raw
cysticercus extract through chromatography with lentil-lectin (LLGP). Reaction with any
one of seven specific bands was regarded as diagnostic for cysticercosis (Figure 1.3). How-
ever, Furrows et al. (2006) reported that the presence of a single positive 50 kDa band
may not indicate infection and thus has to be regarded as not specific. Moreover, the
sensitivity of this assay drops dramatically in cases with single cysts in the brain (Wil-
son et al., 1991; Singh et al., 1999). Recently, Prabhakaran et al. (2007) reported that
using conformation-sensitive immunoassays — with urea-induced tertiary conformations
of the lentil lectin glycoproteins — they were able to detect antibodies in 46% of 60 pa-
tients with solitary cysticercus granuloma who were serologically negative on standard
immunoblot. The EITB test has been extensively used for the diagnosis of human and
porcine cysticercosis (Tsang et al., 1991). The assay, however, has some drawbacks. It
depends on infected pigs for supplying the source material. Preparation of the antigen
and performance of the Western blot require considerable technical expertise. Further-
more, the antigen mixture is not suitable for use in an ELISA format due to the presence
of aspecific fractions. Finally, a Western blot assay is not suitable for field studies, nor is
it a suitable or affordable assay for diagnosis in countries where cysticercosis is endemic
(Hancock et al., 2003). To address these issues, the seven diagnostic LLGP antigens have
been identified, characterized and produced as either recombinant or synthetic proteins
(Greene et al., 1999, 2000; Hancock et al., 2003, 2004, 2006). These proteins have been
tested in ELISA and Western blot assays for the diagnosis of cysticercosis (Handali et al.,
2004; Scheel et al., 2005; Bueno et al., 2005; da Silva et al., 2006). When tested in ELISA,
the sensitivities and specificities of the individual proteins were well below that of the cor-
responding native LLGP proteins in the EITB, whereas results for Western blot format
closely mirrored those of the LLGP EITB.
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Figure 1.3: Typical antibody reactions in the enzyme-linked immunoelectrotrans-
fer blot (EITB) for cysticercosis. The positions of the seven diagnostic glycopro-
teins are marked and designated according to their relative mobilities in SDS-PAGE
(in kDa) (Adapted from: http://www.dpd.cdc.gov/DPDx/HTML/ImageLibrary/
Cysticercosis_il.htm).
Other researchers purified glycoproteins from cyst fluid using isoelectric focusing elec-
trophoresis (IEFE) (Ito et al., 1998). These antigens, applied both in immunoblot and
ELISA, were highly specific and sensitive for differential serodiagnosis of NCC. Later,
sera from rabbits immunized with these immunodiagnostic antigens were used to screen
a T. solium metacestode cDNA library (Sako et al., 2000). Four clones (Ag1, Ag1V1,
Ag2, Ag2V1) were characterized and the recombinant proteins were first tested in im-
munoblot. Ag1V1 and Ag2 were chosen as ELISA antigens, and the Ag1V1/Ag2 chimeric
protein was expressed. With this ELISA using either IEFE purified glycoproteins or the
chimeric protein, it was possible to detect antibody responses in pigs harboring 16 or
more cysts from 30 days p.i.; also, no cross reactions were observed with pigs infected
with T. hydatigena (Sato et al., 2003).
Recently, many other researchers reported the use of recombinant or synthetic proteins
in immunodiagnosis of cysticercosis. A Pubmed Protein database search1 on T. solium
resulted in 311 proteins, of which several are used in immunodiagnosis (Table 1.2). The
related parasites T. crassiceps and T. saginata are also the source of recombinant and
synthetic proteins used for diagnosis of T. solium cysticercosis (Gevorkian et al., 1996;
Hernandez et al., 2000; Fleury et al., 2003; Robles et al., 2005; Ferrer et al., 2007b).
Regardless of the technique used, detection of T. solium specific antibodies in serum
only indicates exposure to the parasite and not necessarily established infection, resulting
1http://www.ncbi.nlm.nih.gov/pubmed/
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in a transient antibody response (Garcia et al., 2001b). In this regard, human taenio-
sis/cysticercosis is said to resemble an “iceberg” with 3 tiers: the tip of this iceberg
consists of people who harbor established symptomatic CNS disease—that is, NCC. Be-
low this, there is a larger population with established cysticercosis infection outside the
CNS or in the CNS but without discernable symptoms and below this tier, there are many
people who were exposed to failed infections, but became seropositive (Bern et al., 1999;
Garcia et al., 2001b). Furthermore, antibodies may persist long after the parasite has
been eliminated by immune mechanisms and/or antiparasitic therapy (Harrison et al.,
1989; Garcia et al., 1997). Detection of anti-parasite antibodies in a population in an
endemic village does not necessarily reflect the true prevalence, leading to misdiagnosis
of a proportion of neurological cases (Bern et al., 1999). It can also lead to superfluous
use of antiparasitic therapy in a patient where the parasites are not viable (Garcia et al.,
2000).
Recently, a new immunodiagnostic tool was described for the diagnosis of NCC (Prasad
et al., 2008). Instead of measuring antibody responses resulting from the humoral immune
response against the parasite, a cyst fluid antigen-based lymphocyte proliferation test was
developed to measure the cellular immune response. The researchers reported a sensitivity
and specificity of 93.8% and 96.2%, respectively. However, these results still need to be
validated in other endemic areas.
Table 1.2: List of Taenia solium proteins used in antibody detection.
Protein name GenBank Reference
accession no.
B1 variant ABI23958 Bae, direct submission
M13h variant ABI23957 Bae, direct submission
RS1 variant ABI23956 Bae, direct submission
immunogenic protein AAK07745 Bin, direct submission
cysticercosis specific antigen AAF06716 Chung et al., 1999
small heat shock protein CAD36617 Ferrer et al., 2005
secreted antigen Ts8B3 CAD48847 Ferrer et al., 2007a
secreted antigen Ts8B2 CAD48846 Ferrer et al., 2007a
secreted antigen Ts8B1 CAD48845 Ferrer et al., 2007a
antigenic protein AAK18818 Gao, direct submission
H17g protein CAE46111 Garate, direct submission
filamin CAK96164 Garate, direct submission
low MW excretion secretion antigen m4 CAD44557 Garate, direct submission
low MW excretion secretion antigen b1 CAD44556 Garate, direct submission
low MW excretion secretion antigen m13h CAD44555 Garate, direct submission
hypothetical protein AAT98623 Gonzalez, direct submission
RS1 AAD51765 Greene et al., 1999, 2000
14 kDa glycoprotein TS14 precursor AAD51764 Greene et al., 1999, 2000
18 kDa glycoprotein TS18 precursor AAD51763 Greene et al., 1999, 2000
18 kDa glycoprotein TS18 variant 1 precursor AAD51767 Greene et al., 2000
Table continues on next page
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Table 1.2: List of Taenia solium proteins used in antibody detection (cont.).
Protein name GenBank Reference
accession no.
14 kDa diagnostic antigen AAF25005 Greene et al., 2000
18 kDa glycoprotein TS18 variant 3 precursor AAD51769 Greene et al., 2000
18 kDa glycoprotein TS18 variant 2 precursor AAD51768 Greene et al., 2000
8 kDa diagnostic antigen Ts14 AAM00205 Greene et al., 2000; Hancock et al., 2001, 2003
8 kDa diagnostic antigen Ts14 AAM00204 Greene et al., 2000; Hancock et al., 2001, 2003
Ts14 variant 3 AAM00208 Greene et al., 2000; Hancock et al., 2003
Ts14 variant 2 AAM00207 Greene et al., 2000; Hancock et al., 2003
Ts14 variant 1 AAM00206 Greene et al., 2000; Hancock et al., 2003
8 kDa diagnostic antigen Ts18 variant 1 AAM00199 Greene et al., 2000; Hancock et al., 2003
8 kDa diagnostic antigen TS18 variant 8 AAM00214 Hancock et al., 2003
8 kDa diagnostic antigen TsRS2 AAM00213 Hancock et al., 2003
8 kDa diagnostic antigen TsRS2 variant 1 AAM00212 Hancock et al., 2003
8 kDa diagnostic antigen TsRS1 variant 2 AAM00211 Hancock et al., 2003
8 kDa diagnostic antigen TsRS1 AAM00210 Hancock et al., 2003
8 kDa diagnostic antigen TsRS1 variant 2 AAM00209 Hancock et al., 2003
8 kDa diagnostic antigen Ts18 variant 7 AAM00203 Hancock et al., 2003
8 kDa diagnostic antigen Ts18 variant 6 AAM00202 Hancock et al., 2003
8 kDa diagnostic antigen Ts18 variant 5 AAM00201 Hancock et al., 2003
8 kDa diagnostic antigen Ts18 variant 4 AAM00200 Hancock et al., 2003
diagnostic antigen GP50 AAP49284 Hancock et al., 2004
diagnostic antigen GP50c precursor AAP49288 Hancock et al., 2004
diagnostic antigen GP50b precursor AAP49287 Hancock et al., 2004
diagnostic antigen GP50a precursor AAP49286 Hancock et al., 2004
T24 AAP47268 Hancock et al., 2006
diagnostic antigen GP50 AAP49285 Hancock, direct submission
immunogenic protein CAB42637 Hubert et al., 1999
immunogenic protein CAB42638 Hubert et al., 1999
18 kDa glycoprotein mature form AAX32919 Lee et al., 2005
14 kDa glycoprotein mature form AAX32918 Lee et al., 2005
immunogenic protein Ts76 AAF60976 Liu, direct submission
immunogenic protein Ts21 AAF60975 Liu, direct submission
immunogenic protein Ts11 AAF60974 Liu, direct submission
hypothetical protein CAD53347 Montero et al., 2003
hypothetical protein CAD38264 Montero et al., 2003
18 kDa glycoprotein variant 1 AAK21959 Obregon-Henao et al., 2001
14 kDa glycoprotein AAF67357 Obregon-Henao et al., 2001
HP6 protein CAO82075 Parkhouse et al., 2008
low MW antigen 2 variant 1 (Ag2V1) BAB18646 Sako et al., 2000
low MW antigen 2 (Ag2) BAB18645 Sako et al., 2000
low MW antigen 1 variant 1 (Ag1V1) BAB18644 Sako et al., 2000
low MW antigen 1 (Ag1) BAB18643 Sako et al., 2000
low MW antigen 1 variant 1 (Ag1V1) BAE96735 Sato et al., 2006b
low MW antigen 1 variant 1 (Ag1V1) BAE96734 Sato et al., 2006b
low MW antigen 1 variant 1 (Ag1V1) BAE96733 Sato et al., 2006b
low MW antigen 1 variant 1 (Ag1V1) BAE96732 Sato et al., 2006b
low MW antigen 1 variant 1 (Ag1V1) BAE96731 Sato et al., 2006b
low MW antigen 1 variant 1 (Ag1V1) BAE96730 Sato et al., 2006b
low MW antigen 1 variant 1 (Ag1V1) BAE96729 Sato et al., 2006b
low MW antigen 2 BAE96728 Sato et al., 2006b
low MW antigen 2 BAE96727 Sato et al., 2006b
Table continues on next page
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Table 1.2: List of Taenia solium proteins used in antibody detection (cont.).
Protein name GenBank Reference
accession no.
low MW antigen 2 BAE96726 Sato et al., 2006b
low MW antigen 2 BAE96725 Sato et al., 2006b
low MW antigen 2 BAE96724 Sato et al., 2006b
low MW antigen 2 BAE96723 Sato et al., 2006b
low MW antigen 2 BAE96722 Sato et al., 2006b
Cysticercus cellulosae-specific antigenic polypeptide AAS55469 Yang, direct submission
membrane protein T24 ABI20734 Zhang, direct submission
excretion secretion antigen b1 ABI20733 Zhang, direct submission
18 kDa glycoprotein TS18 precursor ABI20732 Zhang, direct submission
14 kDa glycoprotein TS14 precursor ABI20731 Zhang, direct submission
excretion secretion antigen M13 ABI20730 Zhang, direct submission
excretion secretion antigen M4 ABI20729 Zhang, direct submission
cysticercosis 10 kDa antigen ABI20728 Zhang, direct submission
calcium-binding protein AAM34786 Zurabian et al., 2005
1.2.4 Immunodiagnosis: Antigen detection
Considering the drawbacks of antibody detection in clinical settings, antigen detection
can provide a valuable alternative since it reflects the presence of viable parasites. In
this respect, it can also provide a tool for serological monitoring of antiparasitic therapy
(Garcia et al., 2000; Nguekam et al., 2003b). Several assays have been developed to detect
parasite antigens in serum, CSF or urine using either polyclonal or monoclonal antibodies
(Correa et al., 1989; Choromanski et al., 1990; Wang et al., 1992; Pardini et al., 2001;
Espindola et al., 2002; Parija et al., 2004; Parija and Rajesh, 2006). Because of the
localization of the cysts in the brain, antigen detection in CSF may be more appropriate
for diagnosis than in serum; however, sampling of CSF is more cumbersome than blood
sampling (Dorny et al., 2003).
Two monoclonal antibody-based tests (B158/B60 Ag-ELISA and HP10 Ag-ELISA)
have been validated and are used routinely for the detection of parasite antigens (Harrison
et al., 1989; Brandt et al., 1992; Garcia et al., 1998; Van Kerckhoven et al., 1998; Erhart
et al., 2002; Nguekam et al., 2003a,c; Dorny et al., 2004b; Somers et al., 2006; Fleury
et al., 2007; Sikasunge et al., 2008a). The sensitivity of Ag-ELISA in humans is reported
to be high: > 80% for serum and even > 90% for CSF (Garcia et al., 1998, 2000; Fleury
et al., 2007). Also, Erhart et al. (2002) noted a very high agreement between Ag-ELISA,
CT scanning and biopsy results. However, when applied to rurally reared pigs with low
cyst burdens, these well-established and reliable serodiagnostic procedures seem to be less
sensitive (Sciutto et al., 1998) although other authors were able to detect pigs harboring
one single cyst (Nguekam et al., 2003a; Dorny et al., 2004b). In addition, the genus
Chapter 1 13
specificity of these tests does not allow the differentiation between infections of T. solium
and T. hydatigena in pigs (Dorny et al., 2003).
In a recent community-based study in pigs, the B158/B60 and HP10 Ag-ELISAs were
used in a Bayesian approach (together with tongue inspection and EITB) to calculate
prevalence and sensitivity and specificity of each test (Krecek et al., 2008). This resulted
in sensitivity and specificity (assuming absence of T. hydatigena) of 76% and 84%, re-
spectively for the B158/B60 Ag-ELISA and 55% and 83%, respectively for the HP10
Ag-ELISA.
1.2.5 Molecular techniques
For the clinical diagnosis of NCC, histopathological examination of biopsy specimens can
be a useful confirmation method. However, it is not always easy to make a definitive
diagnosis of the cysticercus as a result of the preparation of tissue sections and the degree
of degeneration and/or calcification of the tissue (Yamasaki et al., 2006b). Mitochondrial
DNA analysis of biopsied lesions can confirm the initial diagnosis. Until recently, there
was only one report on DNA diagnosis of cysticercosis found in 3 black bears in California
(Theis et al., 1996). Since then, two cases of NCC and one case of intramuscular cys-
ticercosis were confirmed by mitochondrial DNA analysis (Yamasaki et al., 2004b, 2006a;
Sudewi et al., 2007). Other researchers confirmed the diagnosis of NCC by PCR detection
of T. solium DNA in CSF (Almeida et al., 2006).
Molecular identification of biopsy specimens is not only important for definitive di-
agnosis in the case of doubtful outcome of histopathological examination, but also for
differential diagnosis with other potentially zoonotic taeniid species. Indeed, cysticercosis
due to T. crassiceps has been reported in patients with HIV-AIDS (Chermette et al.,
1995; Maillard et al., 1998).
Molecular techniques such as multiplex PCR can also be important tools for molecular
epidemiology in order to determine the genotype of T. solium (Afro-American or Asian)
(Sato et al., 2006a).
1.3 Diagnosis of taeniosis
Taeniosis in man can be caused by T. solium, T. saginata or T. saginata asiatica. In
control and/or elimination programs differentiation between these Taenia spp. may not
be a critical point because any tapeworm infection in humans needs to be eliminated
(Pawlowski, 2006). However, for individual diagnosis and in epidemiological studies,
species differentiation is preferable.
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1.3.1 Questioning
The easiest method by far to diagnose a tapeworm carrier, is asking if a person observed
releasing tapeworm proglottids. Taenia saginata/T. s. asiatica carriers are often aware of
the presence of a worm, considering the motility of the proglottids that actively exit the
host’s intestine. However, this is not the case for T. solium carriers, where the expulsion
of proglottids occurs with the feces. False positive answers occur, since patients cannot
always distinguish between tapeworm proglottids and other parasites (Dorny et al., 2005).
However, after providing training to health care practitioners and informing the general
population, self-detection of tapeworm carriers can be a useful strategy (Flisser et al.,
2005).
1.3.2 Coproscopy
Using conventional fecal examinations both proglottids and eggs can be found in stool
samples. As expulsion does not occur daily, repeated fecal examinations are advised
(Dorny et al., 2005). Still, sensitivity remains low: 30–50% for finding tapeworm proglot-
tids or eggs (Pawlowski, 2006). Anthelmintic treatment and the use of a purge with
electrolyte-polyethyleneglycol salt (EPS) before and after treatment improves the recov-
ery of the scolex and the quality of the expelled proglottids (Jeri et al., 2004). However,
the scolex is recovered in only ±30% of patients.
Taeniid somata can be distinguished in several ways: based on morphological differ-
ences (Table 1.3), based on enzyme electrophoresis (Le Riche and Sewell, 1977) and based
on molecular techniques (p.17). Taeniid eggs and proglottids of T. saginata and T. s. asi-
atica can only be distinguished using molecular tools. For morphological differentiation,
mature proglottids need to be fixed and stained in order to examine the ovarian lobes and
the vaginal sphincter. Gravid proglottids can be distinguished based on the number of
unilateral uterine branches (Mayta et al., 2000). The presence or absence of rostellar hooks
on the scolex does not automatically indicate that it is T. solium or T. saginata/T. s.
asiatica since morphological abnormalities can occur (Rodriguez-Hidalgo et al., 2002).
Enzyme electrophoresis based on glucose phosphate isomerase zymogrammes is a faster
and less labor intensive technique than staining somata. However, it requires fresh or
frozen material since preservation of proglottids in alcohol or formalin destroys enzyme
activity (Le Riche and Sewell, 1978).
1.3.3 Antibody detection
Adult tapeworm carriers can be diagnosed by detecting antibodies directed against ES
antigens collected from immature T. solium tapeworms cultured in immunosuppressed
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Table 1.3: Morphological differences between Taenia solium, Taenia saginata and
Taenia saginata asiatica (Source: Dorny et al., 2005).
T. solium T. saginata T. s.asiatica
Scolex
- rostellum present absent present
- hooks 22–32 absent absent
Mature proglottids
- number of testes 375–575 800–1200 324–1216
- ovary 3 lobes 2 lobes 2 lobes
- vaginal sphincter absent present present
Gravid proglottids
- number of unilateral uterine branches 7–16 14–32 11–32
- branching pattern dendritic dichotomous dichotomous
- expulsion from host passivelya activelyb activelyb
(in groups) (single) (single)
a Usually with feces
b Outside defecation
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hamsters (Wilkins et al., 1999). The test, an immunoblot assay, was determined to be 95%
sensitive and no cross reactions with other parasitic infections, including T. saginata, were
observed. The ES antigens were characterized and two recombinant antigens of 33 kDa
and 38 kDa were produced in order to replace the native proteins (Levine et al., 2004).
Recently, these antigens were expressed by baculovirus in insect cells and tested in an
EITB format. Field testing in Peru resulted in sensitivities of 97% for rES33 and 98% for
rES38 and specificities of 100% and 91% for rES33 and rES38, respectively (Levine et al.,
2007). The major advantages of this test are that it allows species-specific diagnosis and
avoids the potential biohazard of handling feces contaminated with T. solium eggs (Allan
et al., 2003). A drawback may be that antibodies still persist even though a person may
no longer harbor the tapeworm.
Other researchers used oncosphere antigens to diagnose tapeworm carriers (Verastegui
et al., 2003). Antibodies could be detected in 95% of tapeworm carriers but also in 20%
of active NCC cases.
1.3.4 Copro-antigen detection
Antigen capture ELISA tests have been developed for the detection of parasite specific
products in the feces of the host. The antibodies used in these tests have been raised by the
hyperimmunization of rabbits. For the generation of polyclonal antibodies, rabbits were
immunized with different T. solium or T. saginata antigens such as homogenized proglot-
tids, ES antigens or surface fraction of adult tapeworms (Allan et al., 1990; Pawlowski
et al., 2005). These tests have all shown consistent results: they are genus-specific —
T. solium and T. saginata are both positive in the tests but no cross reactions occur with
other intestinal parasites, antigen can be detected several weeks prior to patency, antigen
levels are independent of egg output, coproantigen is stable for days at room tempera-
ture and for several months in formalin-fixed samples, coproantigen levels drop rapidly
following successful treatment (Allan and Craig, 2006).
These tests have been used in field studies: they gave a good specificity (over 99%)
and consistently detected 2.4 times more taeniosis cases than microscopy (Allan et al.,
1993, 1996; Garcia et al., 2003a; Margono et al., 2006).
However, there are still some practical issues to be resolved (Pawlowski et al., 2005).
The performance of the test in field studies on T. saginata remains largely unknown. The
test is still not widely available and currently no commercially available test is on the
market. Given the fact that the technology itself is not complicated, it should be feasible
to establish a system of reference laboratories that can provide the test.
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1.3.5 Molecular techniques
Various molecular techniques have been developed to identify to species level the expelled
tapeworm proglottids or eggs, including the use of DNA probes (Rishi and McManus,
1987; Harrison et al., 1990; Gonzalez et al., 2000), PCR and PCR coupled to restriction
fragment length polymorphism (RFLP) (Mayta et al., 2000; Rodriguez-Hidalgo et al.,
2002; Gonzalez et al., 2002; Nunes et al., 2005), single strand conformation polymorphism
(SSCP) (Gasser et al., 1999), random amplified polymorphic DNA (RAPD)-PCR (Mar-
avilla et al., 2003), multiplex PCR (Yamasaki et al., 2004a), nested PCR (Mayta et al.,
2008) and sequence characterized amplified region (SCAR) markers (Dias et al., 2007).
Each of these techniques has advantages and disadvantages, e.g. the use of DNA probes,
PCR-RFLP and SSCP are relatively time-consuming; however, PCR using species-specific
primers rapidly provides sensitive and reliable results (Yamasaki et al., 2006b).
The use of molecular techniques has been mostly focused on the differentiation of
T. solium from T. saginata, genetic characterization and intraspecific genetic polymor-
phism (Bowles and McManus, 1994; Gasser et al., 1999; Maravilla et al., 2003). Recently,
tests for the differential diagnosis of T. saginata, T. s. asiatica and two genoypes of
T. solium have been developed based on mitochondrial DNA (Yamasaki et al., 2002,
2004a; Somers et al., 2007).
Methods have been developed to extract DNA of Taenia spp. from fecal samples
which can be used in a copro-PCR for the diagnosis of taeniosis (Nunes et al., 2003;
Yamasaki et al., 2004a). There are still some limitations to be overcome: current DNA
extraction methods are too expensive for use as a routine test (Dorny et al., 2005); non-
amplification of target DNA can occur due to competition between template DNA and
inhibitory substances present in the feces, sample heterogeneity on stool collection and
preservation of stool samples (Yamasaki et al., 2006b). However, in a recent evaluation of
copro-PCR, Wandra et al. (2006) reported that when stool samples were stored in ethanol
properly after collection, taeniid DNA was detected in all the examined tapeworm carriers.
1.4 Conclusion: application of immunodiagnostic tools
for diagnosis of cysticercosis
Immunodiagnostic assays are a useful tool in epidemiological studies to estimate the preva-
lence and identify the risk factors associated with transmission of T. solium (Widdowson
et al., 2000; Phiri et al., 2002; Moro et al., 2003; Sikasunge et al., 2007); they also offer the
possibility of surveillance of the infection during and after control programs (Sarti et al.,
2000). The application of antibody or antigen detection depends on the information that
Chapter 1 18
is needed. Antibody detection assays only reflect exposure to the parasite whereas antigen
detection assays indicate the presence of living parasites. Ideally, a combination of both
tests is best for seroepidemiological studies and for supporting diagnosis by neuro-imaging
techniques (Dorny et al., 2004a). So far, only a few studies on NCC and epilepsy used
both antigen and antibody detection (Newell et al., 1997; Correa et al., 1999b; Zoli et al.,
2003; Prado-Jean et al., 2007).
Validation of immunodiagnostic tests is required in order to obtain accurate data on
sensitivity and specificity. In the absence of gold standard, a Bayesian approach may
be useful to draw assumptions about test characteristics (sensitivity and specificiy) and
prevalence (Pouedet et al., 2002; Dorny et al., 2004b; Krecek et al., 2008).
Recently, in a joint effort FAO, WHO and OIE 2 published a comprehensive report
with the guidelines for the surveillance, prevention and control of taeniosis/cysticercosis
(Murrell, 2005). Research priorities include the development of more sensitive and spe-
cific diagnostic tests for use in pigs and a better way to identify people infected with the
disease (Eddi et al., 2003). Indeed, reliable tests for diagnosis of T. solium cysticercosis
in pigs are still lacking. Antibody detection only reflects exposure and not necessarily an
established infection. The use of the current antigen detection tests in pigs is hampered
by the cross reactions with other taeniid species. Furthermore, up to now there is no test
available that can distinguish between infections with viable cysts (active cysticercosis)
and infections with degenerated cysts (inactive cysticercosis). A diagnostic test differ-
entiating between active and inactive cysticercosis in pigs would be an important tool
to study transmission dynamics and immunity in epidemiological studies and to monitor
the effect of anthelmintic treatment or vaccination in control programs. In humans, this
differentiation would be a practical aid for clinical diagnosis and case management. Also,
a quantitative diagnostic assay would be a useful tool in epidemiological studies to assess
the infection burden and the risk of transmission of the disease. Moreover, the biggest
challenge would most likely be the development of a diagnostic assay with sufficient sensi-
tivity to detect cysticercosis in rural pigs with generally low levels of cyst burden (Sciutto
et al., 1998).
There is a clear need for better diagnostic assays for cysticercosis, especially for di-
agnosis in pigs. To develop such assays, serological markers that can be incorporated in
a diagnostic test need to be identified. Chapter 2 gives an overview of two recent tech-
nological developments applied in the experimental work of this thesis that can assist in
identifying such markers.
2FAO: Food and Agriculture Organization of the United Nations; WHO: World Health Organization;
OIE: World Organization for Animal Health
2
Laser beams and dromedaries. . .
Review of SELDI-TOF MS and Nanobodies
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2.1 General introduction
This chapter gives a short overview of the two techniques applied in the experimental
work of this thesis. Surface enhanced laser desorption and ionization time-of-flight mass
spectrometry (SELDI-TOF MS) is a recent MS-based technology that can be applied to
identify biomarkers e.g. for different disease states. Because of the promising results
obtained with SELDI-TOF MS for diagnosis of human African trypanosomiasis (sleeping
sickness) (Papadopoulos et al., 2004), this approach was chosen for the present work to
search for biomarkers that can distinguish between active and inactive cysticercosis, i.e.
infections with viable and degenerated cysts, respectively (Chapter 4). The first part of
this chapter shortly reviews the general methodology, along with some applications and
the current controversy on the use of SELDI-TOF MS.
The second part of this chapter focuses on the properties, production and applications
of so-called “Nanobodies” (Nb), recombinant single-domain antibody fragments derived
from the Heavy-chain antibodies naturally occurring in camelids. Since Kohler and Mil-
stein (1975) introduced the hybridoma technology, the availability of monoclonal antibod-
ies opened the way to the development of diagnostics and therapeutics. Nowadays, focus
tends to shift to the cloning and engineering of smaller antibody fragments by genetic
engineering. Because of their particular properties, Nbs are a valuable tool for the devel-
opment of antibody-based diagnostic and therapeutic applications. Moreover, Nbs often
recognize novel epitopes that are not recognized by conventional monoclonal antibodies.
We therefore chose this approach to isolate and characterize Nbs that can be used for
specific diagnosis of T. solium cysticercosis (Chapter 5).
2.2 Surface enhanced laser desorption and ionization
time-of-flight mass spectrometry (SELDI-TOF MS)
2.2.1 Introduction
The search for specific biomarkers to diagnose disease has evolved rapidly since the ad-
vent of proteomics. Proteomics in general deals with the large-scale study of gene and
cellular function directly at protein level. Proteins are vital parts of living organisms, as
they are the main components of the physiological metabolic pathways of cells. Under-
standing the proteome, the structure and function of each protein and the complexities
of protein-protein interactions will be critical for developing the most effective diagnostic
techniques and disease treatments in the future. During the early years of proteomics
and until relatively recently, profiling of protein expression in disease relied primarily
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on the use of two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), which was
later combined with mass spectrometry (Hanash, 2003). The potential of MS to yield
comprehensive profiles of peptides and proteins in biological fluids without the need to
first carry out protein separations has attracted interest. In principle, such an approach
is highly suited for biomarker identification because of reduced sample requirements and
high throughput. A recent development in this field, particularly for serum analysis, is the
technology referred to as surface enhanced laser desorption and ionization time-of-flight
mass spectrometry (SELDI-TOF MS), first introduced by Hutchens and Yip (1993).
2.2.2 General methodology
The SELDI-TOF MS technology consists of three major components: the ProteinChip
Array, the reader, and the data analysis software. The ProteinChip Array consists of
either 8 or 16 spots composed of a specific chromatographic surface (Figure 2.1). The
chromatographic surfaces are uniquely designed to retain proteins from a complex sample
mixture according to general or specific protein properties. Each spot is composed of
a chemically (anionic, cationic, hydrophobic, hydrophilic or metal ion) or biochemically
(antibody, receptor, DNA, enzyme, etc.) active surface (Merchant and Weinberger, 2000).
Biochemical surfaces are designed to interact specifically with a single, target protein and
are custom-made by using an open, preactivated platform on which a bait molecule is
immobilized. Chemically active surfaces retain whole classes of proteins and are commer-
cially available (Issaq et al., 2003). As such, chemically active surfaces are preferred for
biomarker discovery. The sample is dispensed onto the ProteinChip surface and to achieve
protein specificity a series of washes is applied with an appropriate buffer designed to elute
unbound proteins and interfering substances while retaining the proteins of interest (Issaq
et al., 2002). Energy-absorbing molecules, often referred to as “matrix”, are added and
the ProteinChip is inserted in the reader.
The ProteinChip Reader is a laser desorption ionization (LDI) time-of-flight (TOF)
mass spectrometer equipped with a pulsed, UV, nitrogen laser (Figure 2.2). The thermal
energy from the laser is transferred from the matrix to the sample proteins which irradiate
and then are desorbed/ionized. The ionized gaseous molecules enter the TOF MS region
of the instrument, which measures the mass-to-charge ratio (m/z) of each protein, based
on the time required for the ions to fly down the vacuum tube towards an oppositely
charged electrode (lighter ions travel faster through the TOF tube then heavier ions).
Each ion that strikes the electrode is registered as a component of the data spectrum that
emerges from the analysis. The output generated from the TOF MS analysis is a series of
peaks showing the relative abundance versus the molecular weights (MW) of the detected
proteins.
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Figure 2.1: ProteinChip Array with its different chromatographic surfaces. The upper
arrays represent chemically modified surfaces and the bottom arrays are biochemically
modified surfaces (Source: Ciphergen Basic Course).
Figure 2.2: Schematic of SELDI-TOF mass spectrometer. The time-of-flight mass
spectrometer measures the MW of the proteins retained on the ProteinChip Array. The
software associated with the instrument can display the result either as a spectrum, map
or gel view (Source: Issaq et al., 2002).
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One of the primary uses of SELDI-TOF MS is to identify differences in the protein
expression profiles of two or more distinct samples. The samples are often quite complex,
particularly in the field of biomarker discovery where protein profiles of clinical samples
are analyzed. The software can convert the MS peak traces to more simplified map views
or one-dimensional gel electrophoresis displays to simplify the identification of unique
peaks or those that display differences in protein abundance in one of the samples (Figure
2.2). The end result of a SELDI-TOF MS analysis is a list of the MW of proteins whose
relative abundance differs between two or more samples. The next step depends on the
specific application of the SELDI-TOF platform. If actual identification of the differ-
entially expressed proteins is required, most often the proteins need to be purified using
classical chromatography followed by identification using conventional high-resolution MS
(Issaq et al., 2003). However, a new ion source has been developed that allows the proteins
to be tryptically digested directly on the ProteinChip Array and the resultant fragments
identified by tandem MS (Issaq et al., 2002). An application that has generated much
interest in SELDI-TOF MS is its potential use as a diagnostic tool in the early detection
of diseases (Conrads et al., 2003). By surveying different population cohorts (i.e. dis-
eased vs healthy), unique protein abundance profiles can be produced. Specific proteomic
signatures can be distinguished by statistical analysis using powerful data-mining tools
(Petricoin et al., 2002c). Proteomic pattern analysis relies on the pattern of proteins
observed and does not rely on the identification of a traceable biomarker.
2.2.3 Applications
The versatility of SELDI-TOF MS has allowed its use in projects ranging from the iden-
tification of disease biomarkers to different biological applications such as the study of
biomolecular interactions (Hinshelwood et al., 1999), the characterization of posttransla-
tional modifications and phosphorylation states of proteins involved in signal transduction
pathways (Thulasiraman et al., 2004).
With regard to disease biomarker discovery, extensive research has been done on the
identification of biomarkers for the (early) diagnosis of different forms of cancer. A non-
exhaustive list can be found in Table 2.1. SELDI-TOF MS has also been used to discover
biomarkers for other diseases such as Alzheimer’s disease (Carrette et al., 2003), HIV-1-
associated dementia (Luo et al., 2003), Gaucher disease (Boot et al., 2004) and hepatitis
(Morra et al., 2007).
Examples of studies employing SELDI-TOF MS in the field of bacterial and parasitic
diseases are relatively scarce. Thulasiraman et al. (2001) studied virulence factors in
Yersinia pestis. The differential expression of proteins in Y. pestis grown at 26°C and
37°C was monitored. Two antigens were identified as catalase-peroxidase and Antigen 4.
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Hynes et al. (2003) performed proteomic profiling of Helicobacter species. They found
distinct profiles for the different strains. Also, Helicobacter pylori strains form culture
collections that had undergone numerous subcultures were almost identical, whereas the
profiles from fresh isolates were markedly different.
Papadopoulos et al. (2004) used proteomic signature analysis for the diagnosis of hu-
man African trypanosomiasis (HAT). The serum proteomic profiles of 85 patients with
HAT and 146 controls were compared and data analysis was done using 3 distinct tools
(tree-classifier, neural network and genetic algorithm). They reported an overall sensitiv-
ity and specificity of 100% and 98.6%; no individual biomarkers were identified.
Rioux et al. (2007) studied biomarkers during the first twelve weeks of Fasciola hepatica
infection in sheep. The goal was to identify biomarkers for early parasite invasion and
define biomarkers expressed within 5 weeks of infection since these could theoretically
be involved in establishment or suppression of host immunity. They noted significant
changes in biomarker patterns beginning within 3 weeks of infection; two biomarkers were
identified as transferrin and apolipoprotein A-IV.
Another study identified collagen-binding proteins produced by 4 different Lactobacil-
lus spp. (Howard et al., 2000). It has been proposed that the release of these and other
extracellular matrix-binding proteins prevent the colonization by infectious pathogens and
this might explain the beneficial effects of probiotic bacteria.
2.2.4 SELDI: subject of debate
SELDI-TOF MS technology is potentially a promising tool for the rapid identification
of disease-specific biomarkers and proteomic patterns. SELDI technology has significant
advantages over other proteomic technologies in that it has a very high throughput and the
amount of input material required for analysis is miniscule compared with more traditional
2D-PAGE (Wulfkuhle et al., 2003). Proteomic-based studies have offered real hope of new
marker discovery, but many initially promising studies have not been followed by wider-
scale validation and application (Banks, 2008).
Recently, there has been considerable controversy concerning the SELDI profiling ap-
proach. A major concern has been whether the SELDI-based approaches are reproducible,
other concerns deal with study design bias (Diamandis, 2004a; Hu et al., 2005; Coombes
et al., 2005a). Indeed, analysis of published data for ovarian cancer revealed the existence
of significant experimental bias (Sorace and Zhan, 2003; Baggerly et al., 2004a,b).
When comparing different studies on ovarian, prostate and breast cancer, it was noted
that there were discrepancies between the results of the different research groups (Dia-
mandis, 2003, 2004b; Xiao et al., 2005; Skytt et al., 2007). However, it was suggested
that different peaks were identified because of different methods and different approaches
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Table 2.1: Examples of studies applying SELDI-TOF MS for discovery of cancer
biomarkers.
Cancer type Study type Identified markers Reference
ovarian cancer patterna Petricoin et al., 2002a
marker IDb transferrin, Rai et al., 2002
haptoglobin precursor fragment,
immunoglobulin heavy chain
marker ID haptoglobulin-α Ye et al., 2003
pattern Vlahou et al., 2003
marker ID transthyretin, Kozak et al., 2003, 2005
beta-hemoglobin,
apolipoprotein A-I,
transferrin
marker ID apolipoprotein A-I, Zhang et al., 2004b
truncated transthyretin,
inter-α-trypsin inhibitor fragment
prostate cancer pattern Petricoin et al., 2002b
pattern Adam et al., 2002
pattern Qu et al., 2002
pattern Li et al., 2004
pattern Skytt et al., 2007
breast cancer pattern Li et al., 2002
marker ID complement component C3adesArg, Li et al., 2005
truncated C3adesArg
pattern Mendrinos et al., 2005
marker ID treatment responsive proteins: Heike et al., 2005
kininogen,
apolipoprotein A-II
colon cancer marker ID prothymosin-α Shiwa et al., 2003
head and neck cancer marker ID annexin V Melle et al., 2003
lung cancer pattern Zhukov et al., 2003
pancreas cancer pattern Koopmann et al., 2004
bladder cancer pattern Liu et al., 2005
colorectal cancer marker ID apolipoprotein C-I, Engwegen et al., 2006
albumin fragment,
apolipoprotein A-I
a Diagnosis based on differential proteomic patterns, no biomarker identification
b Individual biomarkers were identified
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to statistical analysis (Grizzle and Meleth, 2004). From this, it is clear that differences in
experimental set-up (pre- and post-analytical aspects) could be responsible for the lack
of agreement between different studies (Karsan et al., 2005). This was reviewed by Bons
et al. (2005) and a summary of these aspects is presented in Table 2.2.
Table 2.2: Pre- and post-analytical aspects important for protein profiling studies
(Source: Bons et al., 2005).
Pre-analytical aspects
Storage effects: freeze-thaw cycles, storage temperature
Use of serum or plasma
Sampling time: clotting time, spinning time, time between
spinning and storage
Sample preparation: denaturation, fractionation, depletion of
high abundance proteins
Calibration
Matrix
Post-analytical aspects
Patient population
Bioinformatics and biostatistics: peak detection, laser settings, data analysis
software
The National Cancer Institute/Early Detection Research Network sponsored a mul-
ticenter validation study of markers for the early detection of prostate cancer. In the
first-stage study analytical reproducibility of the SELDI platform was evaluated and
good cross-laboratory reproducibility could be achieved under strict operating proce-
dures (Semmes et al., 2005). In the next stage the intention was to test if the same
algorithm could discriminate between cancer and noncancer samples derived from inde-
pendent and geographically distinct nonoverlapping populations (McLerran et al., 2008a).
This could not be achieved because the diagnostic performance was compromised by bias.
When analyses were repeated using a new cohort of specimens and eliminating this bias,
discrimination between cancer and noncancer was again not achieved (McLerran et al.,
2008b). The authors concluded that the results from the previous studies (Adam et al.,
2002; Qu et al., 2002) were not generalizable. This validation study again emphasizes the
critical role of pre-analytical factors that can introduce bias.
Liotta and Petricoin (2008) stated that for proper clinical validation, the diagnostic
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protocol and the instrument must be fixed and standardized. Commercial MS technology
is highly competitive and new instruments and technologies are emerging several times a
year. Consequently, to prevent a diagnostic fingerprint profile, that is strictly dependent
on a particular MS technology, to become obsolete, diagnostic biomarker readouts need to
be generated that are independent of the measurement platform. In this case that means
sequencing and identification of the proteins underpinning the diagnostic peaks. Once
the proteins are identified, they can be measured by any suitable immunoassay. This
approach is now the major one used for biomarker discovery, rather than solely relying
on proteomic pattern analysis. However, another concern raised in this respect, is that
most, if not all, identified proteins thus far represent acute-phase reactants present in
high abundance in serum (see Table 2.1) and as such are of questionable clinical value
(Diamandis and van der Merwe, 2005; Diamandis, 2006).
So, what is the way forward? Careful study design, standardization/calibration and a
systematic characterization of pre-analytical and analytical effects will be required (Mas-
ter, 2005), as well as improving instrumentation and applying rigourous quality control
and quality assessment of SELDI data (Coombes, 2005; Hong et al., 2005). Protein pro-
filing can only become a reliable diagnostic tool if it fulfils the criteria for reproducibility
and standardization that are generally accepted for diagnostic tests in clinical chemistry.
There is a need for better characterization and careful description of the methods, includ-
ing technical details, to allow comparison between studies (Bons et al., 2005). Standard
protocols for proteomic studies using SELDI-TOF MS would be useful, however, recom-
mendations are not yet available. To summarize with the words of Coombes et al. (2005a):
serum proteomics profiling — a young technology that begins to mature. . .
Chapter 2 28
2.3 Nanobodies
2.3.1 Introduction
The discovery of hybridoma technology announced a new era in antibody research (Kohler
and Milstein, 1975). By fusing mouse plasma cells with myeloma cells, monoclonal an-
tibodies to different antigens can be produced and isolated. Besides the importance as
research tool, the availability of murine monoclonal antibodies opened the way to the de-
velopment of diagnostic and therapeutic applications. However, the application of mono-
clonal antibodies on a large scale suffers from some technical drawbacks such as expensive
production methods, inability to optimise the antibody by genetic engineering and the po-
tential immunogenicity of mouse antibodies when administered to humans (Carter, 2001).
Strategies have been developed to avoid this immune response, including fusion of mouse
variable regions to human constant regions as “chimeric” antibodies, “de-immunization”
by removal of T-cell epitopes and “humanization” by grafting mouse complementarity
determining region (CDR) onto human antibody scaffolds (Hudson and Souriau, 2003).
Some commercially available therapeutic antibodies include monoclonal antibodies to
CD25 (IL-2 receptor subunit) for management of allograft rejection (daclizumab, Zena-
pax; basiliximab, Simulect), TNF-α for treatment of Crohn’s disease and rheumatoid
arthritis (infliximab, Remicade) and to respiratory syncytial virus (palivizumab, Synagis)
(Elliott et al., 1994; van Dullemen et al., 1995; The IMpact-RSV Study Group, 1998; Vin-
centi et al., 1998). Alternative strategies now allow selection of fully human monoclonal
antibodies from transgenic mice carrying human immunoglobulin loci (He et al., 2002;
Babcock et al., 2006).
Recombinant DNA technology has allowed the cloning and genetic engineering of
antibody genes, which can then be expressed as recombinant antibodies in eukaryotic
cells. However, the first trials to produce antibodies in bacteria yielded disappointingly
low levels of functional molecules (Boss et al., 1984). To obtain good yields of active
antibody protein, it was necessary to change the antibody format from the full length
molecule, consisting of two multidomain heavy and light chains, to smaller versions like
the antigen binding fragment (Fab) or variable domain fragment (Fv) and in a later
stage single-chain Fv fragment (scFv, Fv fragment with a peptide linker connecting the
domains) (Figure 2.3) (Ward, 1993). Unfortunately, these scFv fragments have a reduced
affinity compared to the parent antibody, are prone to aggregation and proteolysis of the
linker sequence (Muyldermans, 2001).
In the past, antigen-binding fragments comprising the single conventional heavy chain
variable domain (VH) have also been generated (Ward et al., 1989). However, apart
from the reduced affinity for the antigen, removing the VL domain exposes the large
Chapter 2 29
hydrophobic surface of the VH rendering the VH molecule “sticky” and difficult to produce
in soluble form. Consequently, it has not been possible to generate single-domain VH
antibodies as a valid alternative to monoclonal antibodies.
2.3.2 Heavy-chain antibodies
Hamers-Casterman et al. (1993) noticed that a significant proportion of the natural anti-
body repertoire of camels, dromedaries and llamas consists of a unique type of antibodies
lacking light chains (Figure 2.3). These so-called Heavy-chain antibodies (HCAbs) are
fully functional in antigen binding, as opposed to mouse or human HCAbs, produced as
a result of a pathological disorder, known as heavy-chain disease (Seligmann et al., 1979).
Homodimeric HCAbs have also been documented in nurse shark (Greenberg et al., 1995)
and spotted ratfish (Rast et al., 1998). The heavy chains of HCAbs have a lower MW than
their conventional antibody counterparts due to the absence of the first constant domain
(CH1). This explains the absence of the light chain in HCAb, as the CH1 domain is the
anchoring point for the constant domain of the light chain (Padlan, 1994). Consequently,
the HCAbs bind their antigen by one single domain, the variable domain of the heavy
chain, referred to as VHH (to distinguish it from classic VH) instead of the paired VH
and VL domains (Muyldermans et al., 1994). As such, the VHH is the smallest func-
tional antigen-binding fragment (15 kDa) derived from a functional immunoglobulin. By
definition, Nanobodies (Nb) are recombinant VHHs with a known affinity for a particular
antigen. Adhering to this definition, in the next paragraphs we will use the term “VHH”
instead of “Nanobody”.
Approximately 50% of the serum IgG repertoire of dromedaries consists of Heavy-
chain antibodies (Hamers-Casterman et al., 1993); in llamas this is only 25–45% (van der
Linden et al., 2000). Different IgG fractions can be isolated by differential adsorption on
protein A and protein G immuno-adsorbents. According to the decreasing MW of the
heavy chain of the antibodies within these fractions, the IgGs were named IgG1, IgG2
and IgG3. The IgG1 fraction contains the conventional antibodies whereas the IgG2 and
IgG3 fractions are HCAbs (De Genst et al., 2006a). Differences in the hinge sequences
allow further differentiation of these IgG subclasses.
2.3.3 Properties
2.3.3.1 Sequence and structure of VHH
Sequence analysis demonstrated that the specific VHH gene is encoded in the germline
by a distinct set of V genes (Nguyen et al., 1998). Analysis of genomic and cDNA VHH
sequences shows that the CH1 domain is present in the genome but is spliced out during
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Figure 2.3: Schematic representation of conventional and Heavy-chain antibodies and
derived antigen binding fragments. VH, VHH = variable domain of the heavy chain,
VL = variable domain of the light chain, CH = constant domain of the heavy chain,
CL = constant domain of the light chain.
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mRNA processing probably due to point mutations in the donor splice site at the 3’ end of
the CH1 (Nguyen et al., 1999). Due to the fact that the light chain is missing in HCAbs,
combinatorial diversity (random joining of VH and VL) is not possible. Nevertheless, VHH
germline segments are highly diverse and rearranged VHHs are extensively diversified by
somatic mutation processes, leading to a broad antigen-binding repertoire (Nguyen et al.,
2000).
With regard to the amino acid sequence, VH and VHH domains share a high degree of
identity. The amino acid residues determining the typical immunoglobulin fold are very
well conserved (Vu et al., 1997). However, VHH carry a number of remarkable amino acid
substitutions in the framework-two region (Figure 2.4). These residues are extremely well
conserved in VH domains and are involved in forming the hydrophobic interface with VL
domains. The Val37Phe (or Tyr), Gly44Glu, Leu45Arg and Trp47Gly substitutions (in
going from VH to VHH) render this side of the domain more hydrophilic to compensate
for the absence of the VL domain (Muyldermans et al., 1994). Another noteworthy
substitution is the Leu11 to Ser in framework-1 region. This amino acid normally interacts
with the CH1 domain, which is missing in HCAbs. This suggests that the amino acids
located in this part of the VHH will be solvent exposed. The Leu11Ser mutation increases
the hydrophilicity and helps in keeping the VHH domain soluble (Muyldermans, 2001).
Besides the VH/VHH hallmark substitutions in the framework regions, the hypervari-
able regions of VHH also differ from VH (Vu et al., 1997). First, the hypervariable regions
CDR1 and CDR3 of VHH are on average longer than those of VH. Secondly, the long
CDR3 is most often connected by a disulfide bond to the CDR1 (Figure 2.4). Structural
analysis provides evidence that the antigen-binding loops of VHH exhibit a much larger
structural repertoire than observed for VH. The most striking difference in this respect is
that in VHH the long CDR3 loop tends to protrude form the VHH surface (Muyldermans,
2001).
2.3.3.2 Unique features of VHHs as compared to conventional antibody frag-
ments
The single domain nature of VHH gives rise to several unique features and advantages
for biotechnological applications. Besides the easy cloning and selection of VHHs from an
in vivo matured immune library using display technologies (See Production of antigen-
specific VHH, pg.34), there are other advantages such as the high expression yield and
ease of purification, the solubility and stability, the generation of antigen-specific, high-
affinity binders, the recognition of unique conformational epitopes and the homology to
human VH III sequences.
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Figure 2.4: Schematic representation of the gene sequence differences between VH
and VHH. The position of the CDR in between the framework regions is indicated. The
CDR1 and CDR3 of a VHH are larger than in VH genes, and they are often connected
by a disulfide bond (blue line). The hallmark amino acid substitutions in framework 1
and 2 are given. The numbering is according to the Kabat numbering (Kabat, 1988).
High expression yields and ease of purification. VHHs are expressed efficiently
as soluble and non-aggregating recombinant proteins due to their small size and hy-
drophilic substitutions in framework-2. When expressed in Escherichia coli grown in
shaking culture flasks, the yield is on average 10 times higher for VHH than most scFv
constructs (Arbabi-Ghahroudi et al., 1997). With other expression systems (e.g. Saccha-
romyces yeast culture) it is possible to obtain even higher production yields of more than
100 mg/l (Frenken et al., 2000). Recombinant VHH can easily be purified by directing
the expressed VHH toward the periplasm and subsequently extracting the periplasmic
proteins by simple osmotic shock (Skerra and Plu¨ckthun, 1988). When the recombinant
VHH contains a C-terminal histidine tag, further purification is done with immobilized
metal affinity chromatography (IMAC). Other procedures such as purification by Protein
A chromatography for llama VHH or production of VHH as inclusion bodies are also
possible (Muyldermans, 2001).
Highly soluble and stable single domain immunoglobulin fold. In contrast to
VH domains, VHHs are naturally soluble because of the hydrophilic amino acid substitu-
tions in framework 2 region. Furthermore, due to their single domain nature, the absence
of engineered structures such as linker sequences (which can cause aggregation as observed
for scFv) enhances solubility which results in better functional expression. VHH antibody
fragments are also extremely temperature stable: they retain most of their binding ca-
pacity after incubation at 37°C (Arbabi-Ghahroudi et al., 1997). Some VHHs have even
been shown to remain functional at 90°C (van der Linden et al., 1999). This high ap-
parent stability is mainly attributed to their efficient refolding after chemical or thermal
denaturation and to a lesser extent to an increased resistance to denaturation (Dumoulin
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et al., 2002).
Antigen-specific, high-affinity binders. VHHs, cloned from an immunized dromedary,
have been matured in vivo against the antigen. Therefore, no engineering is required to
produce high affinity binders and VHHs that bind antigen with affinity in the nanomo-
lar range are normally acquired (Muyldermans and Lauwereys, 1999). The affinities of
VHHs are generally comparable to those of conventional antibody fragments. Occasion-
ally, VHHs with affinity constants (KD) as low as 100 pM are isolated (Saerens et al.,
2004; De Genst et al., 2006b).
Recognition of unique conformational epitopes. The antigen-binding site of con-
ventional antibodies forms a planar or concave surface, depending on the antigen, being
a protein or hapten, respectively (Padlan, 1996). Besides these standard architectures,
the antigen-binding site of VHH also includes protruding loops, so that small hidden
epitopes can be targeted. Indeed, VHHs recognize unique epitopes that are currently
out of reach for conventional antibodies, e.g. conserved cryptic epitopes of infectious
agents (Stijlemans et al., 2004). Also, VHHs preferentially interact with the substrate
pocket of enzymes and can thus act as potential receptor agonist/antagonist. Several
VHHs that act as competitive enzyme inhibitors have been isolated against a variety of
enzymes including lysozyme, carbonic anhydrase, α-amylase, β-lactamase and T-cell ecto-
ADP-ribosyltransferase (Lauwereys et al., 1998; Conrath et al., 2001b; Koch-Nolte et al.,
2007). The ability to recognize these recessed antigenic sites has been attributed to their
smaller size and the ability of the protruding CDR3 loop to penetrate such sites (Desmyter
et al., 2001). However, the latter is possibly not the only mechanism to block the anti-
genic enzyme: the non-canonical conformation of the CDR1 loop might also interact with
cavities on the antigen surface (Muyldermans, 2001).
With respect to the antigen binding, the single-domain nature could be a disadvantage
for binding to small antigens such as haptens and peptides because these normally bind
in a groove or cavity at the VH-VL interface (Sundberg and Mariuzza, 2002). However,
VHHs that are capable of binding low MW haptens have also been isolated (Alvarez-
Rueda et al., 2007; Doyle et al., 2008).
Close homology to human VH fragments. As mentioned in the introduction, a
major drawback of current diagnostic and therapeutic antibodies is that they are of murine
origin, thus eliciting an immune response in the patient. The construction of chimeric,
humanized or veneered antibodies has resolved some of this toxicity. In this respect, the
unique features of VHH offer added value over conventional antibody fragments. The
sequence comparison of the human VH and dromedary VHH demonstrates their high
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degree of identity. The “humanization” of camel VHH is therefore more straightforward
as compared to their murine counterparts because they are smaller and more homologous
to human antibodies (Vu et al., 1997). Most of the substitutions other than the key camel-
specific substitutions in framework 2 can be replaced by the human sequence without
altering the performance of the VHH. The VHH will therefore be a good candidate to
humanize by veneering (Muyldermans, 2001). A universal humanized VHH framework
can then be employed with grafting of different antigen-binding loops (Saerens et al.,
2005b).
2.3.4 Production of antigen-specific VHH
In principle, antigen-specific VHH can be obtained by proteolysis of HCAb (polyclonal
VHH and VHH2), by direct cloning of the VHH genes from B-cells of immunized animals,
and from na¨ıve or synthetic libraries (Muyldermans, 2001). This review will focus on
cloning of recombinant VHH from an immunized animal, screening for antigen-specific
binders by phage display and panning, and production in E. coli (Figure 2.5), as demon-
strated by Arbabi-Ghahroudi et al. (1997). This is regarded as a general route to obtain
small antigen-specific binders. Other selection platforms and library types are reviewed
by Hoogenboom (2005).
2.3.4.1 VHH repertoire cloning
A dromedary (or another member of the Tylopoda) is immunized with the antigen of in-
terest according to standard immunization protocols. The blood of the animal is collected
and the peripheral blood lymphocytes are isolated. Saerens et al. (2004) demonstrated
that lymph node lymphocytes can also serve as B-cell source to construct antibody li-
braries. However, puncture and aspiration of a lymph node is a more cumbersome tech-
nique than simple blood collection.
Subsequently, mRNA is isolated from the lymphocytes and used as a template for
cDNA synthesis. Since the antigen-binding VHH is encoded by a single exon with homol-
ogous border sequences, the complete in vivo matured VHH repertoire of an immunized
animal can be amplified by one single set of primers contrary to cloning of scFv where
independent PCR are needed to amplify VH and VL and different sets of primers are
required to amplify the different gene VH and VL families (Muyldermans, 2001). The
method of cloning VHH is slightly complicated by the requirement to avoid the cloning
of camelid VH originating from conventional antibodies. Elimination of the VH genes
from the VHH gene pool can be accomplished by either using PCR primers that anneal
selectively on the hinge of the HCAb (van der Linden et al., 2000) or by first employing
Chapter 2 35
Figure 2.5: Schematic overview of cloning and selection of antigen-specific VHHs
from an immunized dromedary. See text for explanation (Adapted from: Muyldermans,
2001).
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a universal primer that amplifies all VHH and VH segments, the former lacking and the
latter containing the CH1 exon. These PCR fragments are then separated on agarose gel
and a second PCR with nested primers is employed to amplify the VHH and introduce
restriction enzyme sites. The amplified VHH genes are then cloned in the appropriate
expression vector, e.g. the pHEN4 phagemid vector (Figure 2.6), and a VHH library
containing the repertoire of the intact in vivo matured antigen binding sites is obtained.
2.3.4.2 Selection of antigen-specific VHH
The VHH libraries can be screened for presence of antigen-specific binders by a combi-
nation of phage display and biopanning. Display systems in general provide a physical
linkage between genotype (the VHH gene) and phenotype (antigen binding) to allow si-
multaneous selection of the genes that encode a protein with the desired binding function.
In phage display (McCafferty et al., 1990) the VHH is displayed on the surface of phila-
mentous phage as a fusion with the minor coat protein 3 of the virus, and the VHH gene
is housed within the virion (Figure 2.7). Co-infection with helper phages, that contain
the wild type genome, is necessary to produce complete phage particles displaying the
VHH at their tip. Using a process of biopanning, one can rescue phages that display VHH
that specifically binds to a target of interest (Hoogenboom and Chames, 2000). Briefly,
a simple method for biopanning involves incubating the phage particles on immobilized
antigen to allow phages displaying an antigen-specific VHH to bind. Non-binding phage
particles are washed away and those that are bound, are eluted by pH-shock. Infection
of bacteria with the binding phages results in phage amplification. Successive rounds of
biopanning enrich the pool of phages, with clones that specifically bind the target antigen.
Next, individual clones are screened e.g. in ELISA for antigen recognition. Solu-
ble VHH can be produced after either subcloning into a soluble expression vector (e.g.
pHEN6, Figure 2.6) or through the use of bacterial non-suppressor strains and appropri-
ate stop codons between the VHH fusion and the phage pIII gene (Muyldermans, 2001).
Production in E. coli can be done by secretion in the periplasmic space and release of the
soluble VHH by simple osmotic shock (Skerra and Plu¨ckthun, 1988).
2.3.5 Applications
The reduced size, improved solubility and higher stability of the camelid Heavy-chain
antibody fragments are of special interest for biotechnological and medical applications.
Several examples are given in the following paragraphs.
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Figure 2.6: Schematic representation of the phagemid vector pHEN4 and expression
vector pHEN6, the latter containing the Nanobody cAblys3 gene.
Figure 2.7: Schematic representation of M13 philamentous phage with a VHH (in red)
fused to its minor coat protein 3. The VHH gene is included in the phagemid genome.
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2.3.5.1 Biotechnological applications
Nanobodies as in vivo imaging agents The superior tissue penetration potential
of Nbs due to their small size, combined with high affinity target binding and rapid
clearance from the blood circulation favors their use as imaging agents. Cortez-Retamozo
et al. (2002) indeed demonstrated that Nbs efficiently target tumors and metastatic lesions
and that the excess of antibody is rapidly cleared from the blood circulation. Later on,
Nbs were successfully employed for in vivo radioimmunodetection of tumors (Gainkam
et al., 2008; Huang et al., 2008).
Detection probes in biosensors and usage in immuno-adsorbents The robust
property of Nbs against various denaturing conditions makes them extremely powerful as
immuno-adsorbents or as detection probes in biosensors. Probe regeneration sometimes
requires harsh regeneration conditions. The efficient refolding of Nbs from strongly dena-
turing conditions further supports their use in biosensor applications involving multiple
detection cycles (Saerens et al., 2008c).
Huang et al. (2005) developed a human prostate-specific antigen (PSA) biosensor based
on Nbs that could measure clinically relevant concentration of PSA. In other research,
Nbs were employed in competition ELISA assays to detect chloramphenicol and to detect
caffeine in beverages (Ladenson et al., 2006; Wesongah et al., 2007). Sherwood et al.
(2007) developed an antigen-capture assay for Marburg virus and demonstrated that Nbs
could be employed for effective and fast diagnostic development.
Modular building blocks in manifold constructs Bivalent (or multivalent) and
bispecific antibodies have many practical applications in immuno-diagnosis and therapy
(see 2.3.5.2 for examples). Due to the single domain nature of Nbs, they can be easily
tailored in different constructs (Figure 2.3). Bivalency or multivalency can allow anti-
bodies to bind to antigens with great avidity. Zhang et al. (2004a) constructed so-called
“pentabodies” by linking Nbs to the B-subunit of E. coli verotoxin, which self-assembles
to form a homopentamer. This pentamerization resulted in introduction of avidity and
dramatic increase of the functional affinity.
Bispecificity permits the cross-linking of two antigens. A bispecific construct can be
produced by tethering two antibody fragments by the structural upper hinge of a natu-
ral antibody. The individual moieties fully retained their binding capacity and binding
characteristics (Conrath et al., 2001a).
An extension of the above approach consists of replacing one of the antibodies by a
toxin or enzyme resulting in functional immunofusions, where the antibody is used as
delivery vehicle for the toxin or enzyme (Muyldermans, 2001).
Chapter 2 39
Intrabodies The intracellular expression of antibodies (“intrabodies”) is a powerful
strategy to inhibit in vivo function of selected molecules. Rothbauer et al. (2006) fused
Nbs to fluorescent proteins (“chromobodies”) and expressed them in living cells. These
chromobodies could recognize and trace antigens in different subcellular compartments.
Gueorguieva et al. (2006) constructed intrabodies directed against Bax, a proapoptotic
protein implicated in cell death involved in several neurodegenerative diseases. These
intrabodies were stably expressed in mammalian cells, were nontoxic to their host cells
and rendered them highly resistant to oxidative-stress-induced-apoptosis.
2.3.5.2 Therapeutic applications
Several examples of therapeutic Nbs are presented in Table 2.3. The Nbs exert their
therapeutic capacity through different mechanisms: either by simply neutralizing the
exogenous pathogen or toxin (Harmsen et al., 2005; Hmila et al., 2008), or through receptor
or enzyme inhibition (Roovers et al., 2007). Nanobodies were also isolated that prevent
protein aggregation (and sometimes even reduce already existing aggregates) which is
characteristic of certain protein aggregation disorders (Dumoulin et al., 2003; Verheesen
et al., 2006).
Another type of antibody-based therapy where Nbs can be a valuable tool is antibody-
dependent enzyme prodrug therapy (ADEPT) for the treatment of cancer (Cortez-Retamozo
et al., 2004). In ADEPT, an antibody specific to a tumor marker protein delivers a drug-
activating enzyme to the cancer. Subsequent intravenous administration of an inactive
prodrug results in drug activation and cytotoxicity only within the locale of the tumor.
There are more examples of Nbs directing drug activity to a specific site. For instance,
Nbs were isolated that target conserved, cryptic epitopes of the variant surface glyco-
protein (VSG) of trypanosomes. The Nbs were conjugated to a trypanolytic factor to
generate an immunotoxin with potential for trypanosomiasis therapy (Baral et al., 2006).
For their use in targeting drugs across the blood-brain barrier (BBB), Nbs were selected
that transmigrate the human BBB in an in vitro model and accumulate in the brain af-
ter intravenous injection in mice (Muruganandam et al., 2002). These could be used for
treatment of neurological disorders.
Although the short serum half-life of Nbs favors their use as imaging agents, this limits
their efficacy in many parenteral applications. Therefore, Nbs have been targeted to serum
proteins (e.g. albumin or immunoglobulin) using bispecific Nbs recognizing these serum
proteins in addition to the therapeutic target to prolonge serum half-life (Coppieters et al.,
2006; Roovers et al., 2007; Harmsen et al., 2008). Another approach to increase serum
half-life is ligation of the antibody to polyethylene glycol (PEG) (Harmsen et al., 2007).
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Table 2.3: Examples of therapeutic applications of Nanobodies (Nb).
Disease and/or pathogen Target Fusion partner Reference
Cancer carcinoembryonic β-lactamase Cortez-Retamozo et al., 2004
antigen
Cancer epidermal growth anti-albumin Nb Roovers et al., 2007
factor receptor
Human African Trypanosoma spp. truncated apo L-I Baral et al., 2006
trypanosomiasis
Foot and mouth disease FMD virus PEG Harmsen et al., 2007
Foot and mouth disease FMD virus anti-porcine Ig Nb Harmsen et al., 2008
Rotavirus diarrhea rotavirus none van der Vaart et al., 2006
Rotavirus diarrhea rotavirus Lactobacillus cell- Pant et al., 2006
surface anchor
E. coli diarrhea F4 fimbriae none Harmsen et al., 2005
S. mutans caries I/II adhesin none Kruger et al., 2006
Amyloid diseases lysozyme none Dumoulin et al., 2003
Oculopharyngeal nuclear poly(A)-binding none Verheesen et al., 2006
muscular dystrophy protein 1
Neurodegenerative diseases Bax none Gueorguieva et al., 2006
Rheumatoid arthritis TNFα anti-albumin Nb Coppieters et al., 2006
Scorpion toxin Aahl’ toxin none Hmila et al., 2008
N. meningitidis sepsis lipopolysaccharide none El Khattabi et al., 2006
Brain diseases cerebromicrovascular none Muruganandam et al., 2002
endothelial cells
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2.3.6 Conclusion
Since the discovery of Heavy-chain antibodies in 1993, the field of single-domain antibody
fragments has been rapidly growing. Nanobodies have many advantages for biotechno-
logical applications. They can be economically produced in micro-organisms and have a
high stability. Furthermore, they are highly suited for expression as multivalent, including
bispecific, constructs. Besides their therapeutic applications, they offer a valid alternative
to monoclonal antibodies for use in diagnostic assays. As such, Nbs could also be used to
develop a specific diagnostic test for cysticercosis.
Objectives
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The main objective of the thesis is to study serological responses in pigs and to
identify and develop tools for improved serodiagnosis of porcine cysticercosis. Indeed,
there is a need for diagnostic tests that can (1) quantify the infection level, (2) differentiate
between active and inactive cysticercosis and (3) specifically detect living T. solium cysts
in pigs.
Therefore, the specific sub-objectives are:
1. To link serological data (antibody and antigen responses) to parasitological findings
in experimentally infected pigs in order to study the host-parasite relationship
2. To study the relationship between number of cysts and titer of circulating antigen
in order to develop a quantitative diagnostic test
3. To identify novel biomarkers in serum of infected pigs that can distinguish between
active cysticercosis and inactive cysticercosis
4. To produce Nanobodies specific for T. solium that can be used for specific diagnosis
of porcine cysticercosis
Chapter 3 (“Serological responses in porcine cysticercosis: a link with the parasitolog-
ical outcome of infection”) deals with the first two sub-objectives. Chapter 4 (“Identifi-
cation of biomarkers for different stages of porcine cysticercosis using SELDI-TOF MS”)
addresses the third sub-objective. The fourth sub-objective is addressed in Chapter 5
(“Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticerco-
sis”).
3
Serological responses in porcine cysticercosis:
a link with the parasitological outcome of
infection
Adapted from:
N. Deckers, K. Kanobana, M. Silva, A.E. Gonzalez, H.H. Garcia, R.H. Gilman, P. Dorny
(2008) Serological responses in porcine cysticercosis: a link with the parasitological out-
come of infection. Int. J. Parasitol. 38, 1191–1198.
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3.1 Introduction
Immunodiagnostic assays can provide a useful tool for surveillance of cysticercosis infec-
tion during and after control programs. Transmission of the disease can be interrupted
by increased hygienic measures which are, however, difficult to implement in developing
countries. Therefore, alternative measures for reduction of transmission are being devel-
oped, such as health education, mass chemotherapy in humans and pigs, and vaccination
of pigs (Sarti et al., 1997; Garcia et al., 2007). Infected pigs treated with a single dose of
30 mg/kg of oxfendazole, became refractory to re-infection 3 months later (Gonzalez et al.,
1996, 1997, 1998). Another approach initiated by different research groups is vaccination
of pigs aiming at interrupting the parasite’s life cycle by preventing pigs from acquiring
the larval stage (Nascimento et al., 1995; Sciutto et al., 1995; Flisser and Lightowlers,
2001; Flisser et al., 2004; Gonzalez et al., 2005). A synthetic peptide-based vaccine has
also proved to have therapeutic activity (de Aluja et al., 2005).
Interventions based on immunization of pigs are not yet commonly applied. This is
partly due to a lack of understanding of the host-parasite interactions and the immune
mechanisms involved in resistance to the disease. Prerequisites to evaluate results of
immunization are (1) to understand whether all pigs equally acquire the disease upon
infection and (2) to determine how long metacestodes remain viable without intervention.
Thus, reproducible and standardized experimental infections with T. solium in pigs
are needed, both for vaccination studies and to learn more about the course and progress
of infection. Recently, the Cysticercosis Working Group in Peru succeeded in developing
a reproducible experimental model in pigs in which pigs are orally infected with a whole
proglottid embedded in a banana ball. The advantage of oral infection is that it mimics
the natural mode of infection. The use of a complete proglottid rather than eggs in
solution has the disadvantage that the number of eggs ingested by the animals might
differ. However, the infectivity of the eggs will also likely be more comparable with what
occurs under natural conditions.
In this chapter we report on the serological response of experimentally infected pigs
and an attempt was made to link the serological and the parasitological responses to
infection. In a second part of the study, we extended this link by investigating whether a
quantitative relationship could be established between the titer of circulating antigen in
the serum of animals and the number of viable cysts at necropsy.
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3.2 Materials and methods
3.2.1 Animals and experimental design 1
Eighteen piglets were purchased from a commercial cysticercosis-free farm in Lima, Peru
and maintained at specific pathogen free facilities of the School of Veterinary Medicine of
the San Marcos University (UNMSM) in Lima. Animals were housed individually and had
free access to water and feed. The cysticercosis-free status of the animals was confirmed
by analysis of pre-infection serum with the EITB (Tsang et al., 1991). Six piglets were
infected at the age of 1 month, six piglets at the age of 3 months, and six piglets at the
age of 5 months.
Animals received a single infective dose of T. solium eggs. Briefly, following a 1-week
period of becoming accustomed to eating banana and honey balls, all animals were infected
with one gravid proglottid embedded in a banana and honey ball. Following ingestion
of the banana ball, animals were observed for 2 h to ensure the infective dose was not
regurgitated. Animals were bled weekly during the first month p.i. and every 2 weeks
thereafter, until the end of the experiment. Animals were euthanized approximately 3
months p.i. A systematic dissection of the full carcass was then performed. The number
of cysts was enumerated and viable and degenerated cysts were differentiated. Viable
cysticerci had well-limited thin-walled cystic structures containing clear vesicular fluid
and a visible whitish protoscolex. Degenerated cysticerci were non-cystic but rather had
semi-solid caseous masses with no discernible parasite structures (Phiri et al., 2006). This
experiment was reviewed and approved by the Committee on Animal Research of the
School of Veterinary Medicine, UNMSM.
3.2.2 Animals and experimental design 2
In a second part of the study, we aimed to investigate whether a quantitative relationship
could be established between the total number of viable cysts found at necropsy and
the level of circulating antigen in serum. For this purpose, serum samples from different
experiments were used. All experiments were part of the research performed by the
Department of Preventive Medicine of the School of Veterinary Medicine, UNMSM.
The criteria for inclusion of the serum samples in the study were (1) the availability
of sufficient material and (2) the precise determination of the parasite burden (as well
as differentiation between degenerated and viable cysts) by detailed carcass dissection
following slaughter. This study included 98 porcine serum samples originating from 98
experimentally infected animals. The age of the animals varied between 3–12 months at
slaughter.
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3.2.3 Detection of circulating antigen
For experimental design 1, the B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al.,
2000) was performed twice. First, the standard protocol was used as described previously
(Dorny et al., 2000) with a few modifications: incubation steps were reduced from 1 h to
30 min (coating) or 15 min (other steps); all incubations were done on a shaking plate
except for the last step (substrate); streptavidin-horseradish peroxidase (HRP) (Jackson)
diluted 1/10, 000 was used as the conjugate.
In a second step, serum samples from infected animals were not pre-treated with
trichloro acetic acid (TCA) but used at dilutions of 1/10 and 1/100 in PBS supplemented
with 0.5% Tween 20 (Merck) (PBS-T) to enable a quantitative determination of levels of
circulating antigen. Preliminary results (data not shown) demonstrated that omitting the
pre-treatment did not affect the test results. The cut-off for the first assay was determined
using serum samples of Peruvian pigs known to be negative for porcine cysticercosis. The
cut-off value was calculated based on the mean ODs of eight negative reference pig sera
(Sokal and Rohlf, 1981). The cysticercosis-negative status of the pigs used for negative
control samples was determined by (1) detailed carcass dissection and (2) no antibodies
in the EITB for T. solium cysticercosis (Tsang et al., 1991).
In the second assay, a reference standard curve was constructed using serial dilutions
of ES products of T. saginata (TsagES) that were initially used for the development of
the monoclonal antibodies (Brandt et al., 1992). The dilutions were made in PBS-T.
A reference curve was included on each ELISA plate. The concentration of circulating
antigen was calculated following the transformation of the OD value using the equation
of the reference curve (quantitative ELISA for circulating antigen). Results from the
different groups were compared.
For experimental design 2, the quantitative ELISA for circulating antigen was used
with serum samples diluted 1/200.
3.2.4 Total IgG detection by ELISA
The ELISA for detection of serum antibodies was performed using crude metacestode
antigen of T. crassiceps. Taenia crassiceps cysticerci (Toi strain, kindly provided by
Chernin, (1975), and maintained in laboratory mice by two to four passages per year)
were harvested from the peritoneal cavity of mice (Swiss A strain) approximately 90 days
after experimental infection. The antigen was prepared according to Nunes et al. (2000).
This test is based on the cross-reactivity of antigens between Taenia species and also
yields a positive reaction in pigs infected with T. hydatigena. However, this ELISA was
only performed on serum samples from the animals from experimental design 1 that were
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known to be free of T. hydatigena infection. The ELISA was performed according to
Nunes et al. (2000) with some minor modifications: all steps except the incubation of
the substrate were done at 37°C on a shaking plate, 30 min incubation for the coating of
the antigen, 15 min for the other incubation steps; blocking was done using PBS, pH 7.2
containing 0.05% Tween 20 and 2% newborn calf serum; test serum was diluted 1/200 in
blocking fluid; anti-pig IgG (whole molecule) peroxidase conjugate (Sigma A-9417) was
used at a dilution of 1/20, 000 in blocking fluid; OD was read at 492/655 nm. All samples
were run 2-fold. On each plate two cysticercosis positive pig serum samples and eight
negative pig serum samples were run. The cut-off was determined as the mean OD of the
eight negative controls plus 3SD.
3.2.5 Data analysis
The calculation of the standard curve and the statistical analyses were performed using
the STATA statistical software, release 7.0 (Stata Corporation 2001, College Station, TX).
Correlations between parameters were measured with the Pearson’s correlation coefficient
for linear correlation on normally distributed data. The confidence level was set at P <
0.05.
3.3 Results
3.3.1 Infection
The total number of cysts as well as the number of viable and calcified cysts found at
necropsy are shown in Table 3.1. Both within and between age groups, a large variation
in the number of cysts was found in each animal. The total numbers of cysts (number
of viable cysts) ranged between 0–6246 (0–6210), 0–1364 (0–556) and 136–2913 (0–105)
in the animals infected at 1, 3 and 5 months of age, respectively. At least one cyst was
found in four of the six pigs infected at 1 month, in five out of the six pigs infected at
3 months and in all pigs infected at 5 months of age. From the pigs that had at least
one parasite, these included viable cysts in only one of the pigs infected at 5 months of
age, compared with eight of the 10 pigs infected at earlier age levels (P < 0.05). From
the total cysts recovered at necropsy, 98% were degenerated in the animals infected at 5
months of age, compared with 55% in the animals infected at 3 months of age and only
2.7% in the animals infected at 1 month of age.
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Table 3.1: Number and classification of cysts following necropsy of piglets infected
with Taenia solium at the age of 1, 3 or 5 months.
Agea Animal no. Total no. of No. of viable No. of degenerated
cysts cysts cysts
1 month
8115 6,246 6,210 36
8116 3,199 3,195 4
8113 2,038 1,946 92
8114 302 112 190
8117 0 0 0
8118 0 0 0
average 1,964.2 1,910.5 53.7
% of total no. 97.3% 2.7%
3 months
8112 1,364 167 1,197
8108 581 556 25
8110 367 228 139
8109 314 231 83
8111 7 0 7
8107 0 0 0
average 438.8 197.0 241.8
% of total no. 44.9% 55.1%
5 months
8101 2,913 105 2,808
8105 1,724 0 1,724
8102 831 0 831
8103 597 0 597
8106 582 0 582
8104 136 0 136
average 1,130.5 17.5 1,113.0
% of total no. 1.5% 98.5%
a Age of animal when infected with T. solium. All animals were euthanized 3 months p.i.
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3.3.2 Levels of circulating antigen
The kinetics of the serum antigen levels measured by the standard assay revealed a steep
increase of circulating antigen levels in four of the six animals infected at 1 month of
age, resulting in a plateau level in the antigen ratio between 1 and 2 weeks p.i., which
was maintained until necropsy of the animals (Figure 3.1). No circulating antigen was
detected in the serum of pigs numbers 8117 and 8118, infected at 1 month of age.
Four of the six animals infected at 3 months of age had high levels of circulating
antigen. The increase in their circulating antigen levels was slower compared with the
animals infected at 1 month of age, with a plateau level in the antigen ratio reached 3
weeks p.i.
Antigen levels in animals infected at 5 months of age remained low except in two
animals (pigs numbers 8106 and 8101) in which they started to increase 3 weeks p.i. In
only one of these two animals was a high antigen ratio measured up to necropsy.
To enable the measurement of a quantitative difference in antigen levels between the
different age groups, serum samples obtained at 3, 6 and 10 weeks p.i. were diluted
1/10 and 1/100 and used in the quantitative ELISA for circulating antigen. The lowest
concentration of detectable antigen was 3.9 ng/ml. The individual calculated values are
depicted in Table 3.2 showing that levels reached were markedly higher in the animals
infected at 1 month of age compared with animals infected at 3 and 5 months of age.
3.3.3 Total IgG ELISA with T. crassiceps antigen
The kinetics of the total Ig levels is shown in Figure 3.1. Serum antibody levels appeared
to follow a reverse kinetics compared with circulating antigen. Antibody titers were
highest in animals infected at 5 months of age, starting to increase as early as 3 weeks p.i.
Following a steep increase, the antibody response in these animals declined from 8 weeks
p.i. onwards (Figure 3.1C). In the animals infected at 1 and 3 months of age (Figure 3.1A
and B, respectively) antibody levels increased slowly and remained substantially lower
compared with the older age group. In addition, a decline in antibody titers at the time
of slaughter was only observed in pigs numbers 8110 and 8112 (infected at 3 months of
age).
3.3.4 Relationship between antigen titers and number of cysts
A total of 98 serum samples obtained from pigs with variable numbers of viable cysts
(= 45), degenerated cysts only (= 14) and no cysts (= 39) were tested in duplicate. A
serial dilution of TsagES yielded a standard curve that was subsequently used to calculate
the concentration of antigen in the serum samples. The relationship between the number
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Figure 3.1: The serological antigen () and antibody () response of 1-month-old
(A), 3-months-old (B) and 5-months-old (C) piglets after oral infection with one Tae-
nia solium proglottid. Sera were analyzed weekly during the first month p.i., and every
2 weeks thereafter: time points depicted are 0, 1, 2, 3, 4, 6, 8, 10 and 12 weeks p.i. Anti-
gen levels are expressed as ratio = OD value of sample/cut-off value (calculated based
on the mean OD value (492 nm) of eight non-infected control samples). Antibody values
are expressed as OD values as measured with the Taenia crassiceps antibody ELISA.
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Table 3.2: Concentration of circulating antigen (ng/mL) at 3, 6 and 10 weeks p.i.
(WPI) in serum of piglets infected with Taenia solium at the age of 1, 3 or 5 months.
Agea Animal no. 3 WPI 6 WPI 10 WPI
1 month
8115 119.32 154.39 147.7
8116 13.49 127.52 132.69
8113 ≤ 3.90 15.28 87.5
8114 8.71 82.3 142.5
8117 ≤ 3.90 4.1 ≤ 3.90
8118 ≤ 3.90 ≤ 3.90 ≤ 3.90
3 months
8112 ≤ 3.90 ≤ 3.90 13.1
8108 ≤ 3.90 6.43 40.4
8110 ≤ 3.90 4.87 13.27
8109 ≤ 3.90 ≤ 3.90 13.67
8111 ≤ 3.90 ≤ 3.90 4.12
8107 ≤ 3.90 ≤ 3.90 4.1
5 months
8101 ≤ 3.90 21.37 79.73
8105 ≤ 3.90 ≤ 3.90 4.1
8102 ≤ 3.90 ≤ 3.90 ≤ 3.90
8103 ≤ 3.90 ≤ 3.90 4.1
8106 ≤ 3.90 ≤ 3.90 ≤ 3.90
8104 ≤ 3.90 ≤ 3.90 ≤ 3.90
a Age of animal when infected with T. solium. All animals were euthanized 3 months p.i.
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of viable cysts and the concentration of circulating antigen is shown in Figure 3.2, resulting
in a regression line with a Pearson’s correlation coefficient of 0.89 (R2 = 0.81, n = 98, P <
0.001).
 
Figure 3.2: The correlation between the concentration of circulating antigen and
the number of viable cysts in Taenia solium infected animals and non-infected control
animals (n = 98). Antigen concentrations were calculated following transformation of
the OD value using the equation of a reference curve obtained after serial dilution of
Taenia saginata excretion-secretion products.
3.4 Discussion
Experimental infections with T. solium in pigs are a prerequisite to improve current un-
derstanding of the pathogenesis of the disease (Flisser et al., 2002). Recently, an oral
infection model was developed in which piglets of defined age levels (1-, 3- and 5-months-
old) are infected with a whole proglottid embedded in a banana ball. Although it does
not allow determination of the exact level of infection, the use of a whole proglottid has
the advantage that it mimics the natural mode of infection. Animals infected at 1 month
of age harbored mainly viable cysts upon oral infection with one proglottid, whereas in
piglets infected at 5 months of age most cysts were degenerated. The outcome of the
infection in animals infected at 3 months of age was intermediate, with a more equili-
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brated distribution of viable and degenerated cysts. The current study was carried out
to investigate whether this model could also be used to study host-parasite relationships
and the mechanisms underlying resistance to infection in more detail. An attempt was
made to link the parasitological findings to serological data. In a second part of the study,
the preliminary observation that levels of circulating antigen seemed to be related to the
number of viable cysts was tested more extensively using more animals.
Although detailed carcass dissections at necropsy revealed a high variation in numbers
of cysts, the trend was that the number of viable cysts decreased with the age at which
the animals were infected. The presence of viable cysts in tissues of infected pigs was
monitored by means of an ELISA for the detection of circulating antigen (Brandt et al.,
1992). The kinetics of the antigen levels throughout the course of the infection differed
markedly between the three age groups of the experimental infection model. In the
younger animals a fast increase (starting 1 week p.i.) in titers of circulating antigen was
observed in most animals, reaching a plateau as early as 2 weeks p.i. This demonstrates
that antigen can be produced well before viable cysts are fully developed, which takes
approximately 3 months (Pawlowski, 2002). An interesting observation was that animals
with viable cysts at necropsy (nine animals) had invariably high antigen levels, whereas
animals with no cysts (three animals) or only degenerating cysts (six animals) had low
or nil antigen levels. The transient rise of circulating antigen in pig number 8107, which
was negative at necropsy, probably suggests that the infection was aborted early in its
course. The lack of circulating antigen in the other necropsy-negative animals indicates
that cysts never established in these animals.
Antigen levels in pigs infected at younger ages not only increased faster but also
reached higher levels than in older animals, and were associated with weaker antibody
responses. Based on the presence of viable cysts and the higher antigen levels in the
younger animals one could hypothesize that cysts circumvent a host immune response in
the younger animals, develop faster and remain viable for a longer period of time. In
addition, the rapid increase in antibodies in the older animals may be responsible for the
abrogation of the development of cysts, which then immediately evolve to a caseous and
degenerated status. The classical view of the evolution of cysticercosis lesions assumes
that they all pass through the established viable stage, but recently the hypothesis that
a substantial proportion of parasites are destroyed in early phases was also put forward
to explain the distinct outcome of infection of human NCC (Garcia et al., 2003b).
Overall, our observation that higher total Ig titers are present in animals with a
higher proportion of degenerated cysts contrasts with other observations showing that
antibodies were mostly found in cases with live and involuting parasites, but only very
few antibodies were detected in conjunction with degenerated cysts (de Aluja et al., 1996;
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Flisser et al., 2002). Another striking difference in the antibody response was that in
all animals infected at 5 months of age, and in two out of the six animals infected at 3
months of age, antibody levels were already decreasing at the time of necropsy (84 days
p.i.). Upon experimental infection of pigs with 100, 000 T. solium eggs de Aluja et al.
(1996) also observed a decrease in antibody titers starting from 92 days p.i. However, even
at a lower level, antibody titers remained positive up to 280 days p.i. A full comparison
between experiments is not feasible as differences may have occurred at the level of the
animals (breed), the parasites (difference in infectivity) and infection mode (100, 000 eggs
versus a full proglottid).
The conclusion that the presence of antibodies is influenced by the stage of the parasite
is also true for our study, but we would associate higher antibody responses with cyst
degeneration. In addition, a role for antibodies is suggested by the rapid increase to high
antibody titers associated with an abrogated development of cysts in the older animals.
Although evidence for a role of antibodies in inhibition of the development of T. solium
parasite stages has not yet been reported for porcine cysticercosis, in mice infected with
T. crassiceps, antibodies were shown to have a crippling effect (Garcia et al., 2001a).
In T. saginata infection in cattle, the evidence for age resistance has been conflicting
(reviewed by Rickard and Williams, 1982). Early reports, using animals that may have
been free of prior exposure, demonstrated that although resistance (as related to the ability
to become infected and the number of developing cysts) did not develop with age, older
animals appeared to have an increased proportion of degenerated cysts (Penfold, 1937;
Urquhart, 1961 cited by Rickard and Williams, 1982). This coincides with our findings.
Whether the lower numbers of cysts in the older animals are artefacts or reflect the
true situation is difficult to interpret as experiments with out-bred animals are inherently
exposed to a high amount of variability (Hein and Griebel, 2003) and only a small number
of animals were included in this study. Alternatively, the reduction in numbers of cysts
in the older animals may have resulted from more effective innate immune responses in
these animals. All animals were naive prior to infection, originating from a cysticercosis-
free area, excluding exposure to T. solium. This implies an important role for the innate
immune response in the initial struggle between the host and the parasite. This is further
supported by the abrogation of the viability of cysts at a very early stage of infection, too
early to be the result of acquired immunity.
In a second part of the study, we investigated whether the suggested relationship be-
tween levels of circulating antigen and numbers of viable cysts, as was observed in the
experimental infection model, could be strengthened with the analysis of a higher number
of serum samples obtained from a more heterogeneous set of pigs infected with T. solium.
Despite the variation in ages of animals, in experimental versus natural infections a signif-
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icant correlation between the number of viable cysts and the concentration of circulating
antigen was found. A significant correlation does not necessarily implicate a causal rela-
tionship but we may conclude that the variation in antigen concentration in the serum of
animals can be partly explained by the number of viable cysts recovered at necropsy. A
more detailed analysis revealed that a threshold in number of cysts is required for finding
this relationship (data not shown). In animals with degenerated cysts only, or less than
a total number of 100 cysts, the relationship was less consistent. A threshold of 100 cysts
was arbitrarily chosen and might need to be refined. The necessity of a threshold can
easily be explained by the sensitivity of our assay. Although it proved able to detect one
viable cyst (Dorny et al., 2004b), up to now, we do not know whether this is entirely
reproducible. Maybe the age and development stage of the cysts also play a role in this
regard. In addition to the number of viable cysts, the concentration of circulating antigen
could be influenced by both host-derived and parasite factors such as the immune status
of the host, the location and size of the cysts or genetic differences.
4
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SELDI-TOF MS
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4.1 Introduction
The advent of proteomics has brought with it new technologies enabling the discovery of
biomarkers that can be used to diagnose diseases. A recent development in this field is
SELDI-TOF MS, a technology that enables the generation of protein profiles from complex
biological samples such as serum (Merchant and Weinberger, 2000). The analytical plat-
form used is the ProteinChip Biomarker System-II (BioRad). In this technique, proteins
are bound to the chromatographic surface of the chip array through different physico-
chemical interactions. A nitrogen laser desorbs the protein/energy-absorbing molecule
mixture from the array surface, enabling the detection of the proteins captured by the
array. By comparing the protein profiles in samples under different biological conditions
(e.g. healthy versus infected) specific biomarkers can be identified (Xiao et al., 2005).
Here, the ProteinChip platform was used to discover biomarkers for different stages of
T. solium cysticercosis in pigs. Up to now, there are no diagnostic tests available that can
differentiate between infections with viable cysts (active cysticercosis) and degenerated
cysts (inactive cysticercosis). A diagnostic test differentiating between active and inactive
cysticercosis in pigs would be an important tool to study transmission dynamics and
immunity in epidemiological studies and to monitor the effect of anthelmintic treatment
or vaccination in control programs. In humans, this differentiation would be a practical
aid for clinical diagnosis and case management.
In the previous chapter, we reported different antibody and antigen kinetics in exper-
imentally infected piglets linked to the age of infection and the parasitological findings.
Consequently, we hypothesized that there are biomarkers present in the serum specific
for these different phenotypes (active and inactive cysticercosis) that could be used as
a diagnostic tool. To test this hypothesis, we analyzed serum samples from experimen-
tally infected pigs using the ProteinChip platform to identify novel biomarkers that could
contribute to the differentiation between active and inactive cysticercosis.
However, questions have been raised about SELDI-TOF technology for protein pro-
filing, particularly in terms of reproducibility and experimental bias (Sorace and Zhan,
2003; Baggerly et al., 2004b; Diamandis, 2004b). To address these issues, a second sample
set comprising 86 serum samples from naturally infected pigs was analyzed to validate
the biomarkers discovered in the experimentally infected animals.
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4.2 Materials and methods
4.2.1 Serum samples
4.2.1.1 Experimental infections
Serum samples from experimentally infected pigs described in the previous chapter, were
also used in this study (Chapter 3, 3.2.1 “Animals and experimental design 1”, p.46).
Briefly, the samples were collected after experimental infection of three groups of six
piglets each of 1, 3 and 5 months old, respectively. The animals were orally infected
with a full proglottid of T. solium. Serum samples were collected weekly during the
first month p.i. and every two weeks thereupon. Twelve weeks p.i. the animals were
slaughtered. A total dissection of the carcasses was performed to determine parasite
burden and a differentiation was made between viable and degenerated cysticerci. Serum
samples collected prior to infection and at week 12 p.i. were used in this study.
4.2.1.2 Field infections
Serum samples from 86 naturally infected pigs were collected in Zambia (n = 27) and
Peru (n = 59). The Zambian pigs had been purchased at the Chibolya slaughter slab in
Lusaka and from villages in the Eastern Province. After slaughter, a complete dissection
of half the carcasses together with the complete heart, tongue, head and neck muscles,
psoas muscles, diaphragm, lungs, kidneys, liver, brains and eyes was performed to count
cysticerci. Each slice was less than 0.5 cm thick so that all fully developed cysts would
be revealed. For those muscle groups where cysts were only counted in half of the car-
casses, the total number of cysts was calculated by multiplying the detected unilateral
number by two. Cysts were classified according to their macroscopic appearance as either
viable (translucent, fluid-filled with invaginated protoscolices) or degenerated (caseous or
calcified). The estimated age of the pigs varied between 6 months and several years; pigs
of both sexes were sampled. All the pigs from the Lusaka market were crosses of Large
White and Landrace breeds. Pigs from the Eastern province were all of local breed.
The Peruvian serum samples were gathered from the serum bank at the Veterinary
Faculty of UNMSM. After slaughter, the full carcasses and internal organs were completely
dissected with each slice less than 0.5 cm thick. The total number of cysts was enumerated
and their viability was assessed as described above. Information on breed, age and sex of
these pigs was not available.
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4.2.1.3 Heterologous infections
A total of 25 sera from pigs infected with T. saginata asiatica (n = 6), T. hydatigena
(n = 7), Trichinella spiralis (n = 5) and Trypanosoma congolense (n = 7), collected from
the serum bank of the Animal Health Department of the Institute of Tropical Medicine
Antwerp (ITMA) were also included in the study. All samples were aliquoted (50 µl) and
stored at -80°C prior to this study.
4.2.2 Sample fractionation
All binding and washing steps were performed using a bioprocessor device (Bio-Rad) and
the Biomek 2000 workstation (Beckman Coulter, Fullerton, CA). Prior to fractionation,
20 µl of serum samples were mixed with 30 µl of U9 buffer (9 M urea, 2% CHAPS and
50 mM Tris-HCl pH 9) in a 96 well v-bottom plate. The samples were fractionated by
pH using the ProteinChip serum fractionation kit (Bio-Rad). The kit consists of a 96-
well filtration plate with Q HyperD F anion exchange beads that require rehydration and
equilibration before use. The samples were eluted in a stepwise manner, by altering the
pH of the wash buffer, until six fractions were collected (flow through + pH 9, pH 7, pH 5,
pH 4, pH 3 and organic phase). Each of the six fractions was collected twice and the two
collections were pooled. The pooled fractions were divided over 2 separate standard v-
bottom 96-well plates, to reduce the number of freeze-thaw cycles. After fractionation,
plates were stored at -20°C until use.
4.2.3 ProteinChip preparation
The fractionated serum samples were bound randomly on the chips to avoid introduction
of systematic bias. Each chip included a quality control (QC) sample of pooled standard
non-infected pig serum (originating from healthy pigs reared on a commercial farm in
Belgium) and blank spots were included across the bioprocessor as negative controls.
4.2.3.1 WCX ProteinChip array preparation (CM10 ProteinChip)
Spots were equilibrated two times with 150 µl of CM binding/washing buffer (0.1 M
sodium acetate, pH 4). Ten microlitres of fractionated serum sample was incubated in
90 µl of binding buffer (0.1 M sodium acetate) for 30 min on a shaker at room temperature.
Afterwards, arrays were washed three times with 150 µl binding buffer and two times
with de-ionized water to remove unbound serum proteins. After air-drying, 1 µl of energy
absorbing matrix (saturated sinapinic acid (Sigma, St. Louis, MO) in an aqueous solution
containing 50% acetonitrile and 0.5% trifluoroacetic acid) was added twice to each spot.
The surface was allowed to air-dry between each application.
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4.2.3.2 IMAC ProteinChip array preparation (IMAC30 ProteinChip)
Spots were first charged with 50 µl 0.1 M copper sulphate for 5 min followed by a first
wash with 200 µl de-ionized water to remove the unbound metal. A second wash was done
with 150 µl of neutralisation buffer (0.1 M sodium acetate, pH 4) and a last wash with
de-ionized water. Each wash was performed by 5 min incubation at room temperature.
Arrays were then incubated 2 times with 150 µl binding buffer (0.1 M sodium phosphate,
0.5 M NaCl pH 7) for 5 min. Ten microlitres of fractionated serum sample was spotted
onto arrays with 90 µl of binding buffer for 30 min on a shaker at room temperature.
After binding, washing and addition of energy absorbing matrix was done as described
above.
4.2.4 Data acquisition and processing
ProteinChip arrays were analyzed in the PBS-IIc ProteinChip Reader (Bio-Rad) equipped
with an autoloader to perform mass analysis. The m/z spectra were collected after
determining the optimal laser settings for each fraction, distinguishing between low and
high MW range. For each fraction 19 different settings were tested on pooled samples
(laser intensity varied from 150 to 220 and detector voltage from 2,650 to 2,950). The best
setting for each fraction was selected based on the S/N ratio, intensity and resolution of
20 manually selected peaks present in the different spectra.
The data were collected using an automated protocol. Each chip was analyzed in two
consecutive runs: the first run for the low mass range, followed by a second run with
higher intensity and sensitivity for the high mass range. Each spot was analyzed from
position 20 to 80, delta 5, with 5 shots per position preceded with two warming shots
(laser intensity 200 for the low mass range and 210 for the high mass range) and focus mass
was set at the optimization centre. The optimization range was set at 2,000–20,000 Da
for the low mass range and 20,000–50,000 Da for the high mass range.
4.2.5 Data analysis
The serum samples were classified in different groups to find distinguishing biomarkers.
The first group consisted of the samples from the experimentally infected pigs prior to
infection (control sera, “group C”), a second and third group consisted of the samples from
these same pigs that developed viable cysts (“group V”) or only degenerated cysts (“group
D”), respectively. Serum samples from naturally infected animals with only degenerated
cysts were designated as “group Df”; serum samples from animals with viable cysts as
“group Vf”. The last group consisted of serum samples from pigs with different parasitic
infections (heterologous group). For each protein cluster P-values were calculated using
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the Mann-Whitney U test for 2 sample groups and the Kruskal-Wallis H test for 3 sample
groups.
The spectra were calibrated externally using the ProteinChip protein calibrant kit
(Bio-Rad) containing 10 different calibrants with MW ranging from 5,733.6 Da (bovine
insulin) to 147,300 Da (bovine IgG). The spectra were normalized to total ion current after
baseline subtraction. The average (µ) of the normalization coefficients was calculated and
spectra with normalization coefficients ≥ 2µ were excluded from further analysis.
Analyses were performed in 2 steps. First, the Biomarker Wizard feature of the
ProteinChip software (v3.2) and ProteinChip Data Manager Software (v2.1) (Bio-Rad)
were used to create peak clusters and calculate P values for differences between different
groups for each identified peak cluster. A peak cluster was recorded if a given peak was
found in ≥ 10% of the spectra in one group. Automatic peak detection was performed
using cut-off settings of 3× S/N for the first pass and 2× S/N for the second pass. The
cluster mass window was set at 0.3% of the peak mass for the low mass range (2,500–
100,000 Da) and at 2% of the peak mass for the high mass range (10,000–200,000 Da). As
a quality control, peak clusters with P values < 0.05 were visually inspected and manually
relabelled. After relabeling, the intensity values of the duplicates were averaged and exact
P values for differences in average peak intensity between groups were calculated (second
pass analysis). Reproducibility for QC samples was evaluated as CV (CV = σ/µ× 100%
with σ the standard deviation and µ the mean) for m/z and peak intensities in intervals
of 2,500–100,000 Da (laser intensity 200) and 10,000–200,000 Da (laser intensity 210) by
automatic clustering of m/z values differing by a maximum of 0.3 and 2.0%, respectively,
using the Biomarker Wizard software. Noise was calculated within the respective mass
region and software settings were S/N = 5 and minimum peak threshold = 50%.
4.2.6 Protein purification and identification
Serum was fractionated using the ZOOM ® IEF Fractionator (Invitrogen) according
to the manufacturer’s instructions. Briefly, serum was first prepared in order to solu-
bilize, denature and reduce serum proteins prior to IEF fractionation. The prepared
sample was loaded into the assembled ZOOM ® IEF Fractionator and the protein sam-
ple was separated into well-resolved fractions based on the pI of each protein (pH range
from 3–10). The fractions were then desalted using the methanol/chloroform precipi-
tation method. The precipitated protein samples were dissolved in SDS sample buffer
(containing 2-mercaptoethanol) and run on a 12% Bis-Tris gel according to the method
of Laemmli (1970). Gels were fixed with fixer solution for 2 h and afterwards stained
overnight with Coomassie to visualize the bands. Destaining with distilled water was
performed until the bands were clearly visible. The Coomassie-stained protein bands
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were excised from the gel: each band was further cut into cubes (approx. 1 mm)
and placed into 1.5 ml eppendorf tubes. Trypsin digestion and liquid chromatography
(LC)-MS/MS analysis were performed with an Agilent 1100 liquid chromatograph con-
nected to a QSTAR mass spectrometer (Sciex-Applied Biosystems). Product ion spec-
tra were automatically stored on all multiple-charged peptides recognized by the first
quadrupole in the QSTAR. Database searches were performed using MASCOT search
engine (http://www.matrixscience.com) using carbamidomethyl for Cys modification
and oxidation of methionine as the other modification. Public domain databases (NCBI)
were scanned for protein identification.
4.3 Results
4.3.1 Infection status of the animals
The infection status of the 18 experimentally infected piglets is summarized in Table 3.1
of the previous chapter (p.49). Examination of the carcasses showed that 6 animals had
only degenerated cysts and 9 animals had mixed infections (viable + degenerated cysts).
None of the animals had only viable cysts. Parasites did not establish in three animals;
therefore only their pre-infection serum samples were used in this study. For two animals
the pre-infection sera were not available and for another animal the serum collected at
week 12 p.i. was missing. In total, there were 16 pre-infection sera (group C), 5 samples
at week 12 p.i. from animals with only degenerated cysts (group D) and 9 samples at week
12 p.i. from animals with at least one viable cyst (group V) (Table 4.1). The animals
were classified in the three groups solely based on the necropsy result.
From the 27 samples of the naturally infected Zambian pigs, there were 6 animals
with only degenerated cysts, 8 animals with only viable cysts and 13 animals with mixed
infections. The cyst burden varied from 1 to 2,932 cysts. From the 59 Peruvian samples,
15 animals harbored only degenerated cysts, 7 animals only viable cysts and 37 animals
had mixed infections. The cyst burden varied from 1 to 5,336 cysts. Animals with at least
one viable cyst were classified in group Vf (viable phenotype), regardless of the number of
degenerated cysts present, since these animals can still actively transmit the disease. In
summary, group Df (degenerated phenotype) comprised 21 samples and group Vf (viable
phenotype) comprised 65 animals (Table 4.1).
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Table 4.1: Summary of serum samples used in the study. No. control = number
of samples from pigs prior to experimental infection; No. Degenerated = number of
samples from pigs with only degenerated cysts; No. Viable = number of samples from
pigs with only viable cysts; No. Mixed = number of samples from pigs with mixed
infections (viable and degenerated cysts).
Origin Total no. samples No. Control No. Degenerated No. Viable No. Mixed
Experimental infection 30 16 5 0 9
Group: C D V
Field samples Zambia 27 – 6 8 13
Field samples Peru 59 – 15 7 37
Total: 21 65
Group: Df Vf
4.3.2 Discovery of Protein Biomarkers in the experimental sam-
ples
In a preliminary study (data not shown), a few samples of each group were bound on a
CM10 ProteinChip array and all the 6 fractions were analyzed. The fractions yielding
the most satisfactory results (i.e. the most differentiating biomarkers) were selected for
further analysis: fractions 1 (pH9 and flow through), 4 (pH4) and 6 (organic) for analysis
on CM10 ProteinChip arrays. In addition, the organic fraction was also selected for
analysis on IMAC30 ProteinChip arrays.
Of the total number of 440 sample spectra collected, the normalization coefficients of
12 spectra did not pass the “twice the average rule” (normalization coefficient ≥ 2µ) and
were rejected from further analysis.
4.3.2.1 First pass analysis
Viable versus degenerated EDM was done for (1) group D versus group C and
(2) group V versus group C and P-values were calculated for the individual biomarkers.
Significant biomarkers (P < 0.05) were selected for group D (degenerated phenotype) and
group V (viable phenotype), respectively. Thereafter, the three groups (D, V, C) were
taken together for EDM and P-value calculation. Biomarkers for degenerated and viable
phenotype that remained significant were selected for second pass analysis (4.3.2.2).
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Infected versus non-infected By performing EDM and P-value calculation of the
three groups simultaneously, biomarkers for infected phenotype could be identified. A
biomarker was specific for infected animals if there was a similar expression level in both
group D and group V when compared to group C. At this stage, the results were compared
to the results of the preliminary study to assess the robustness and reproducibility of the
biomarkers: overall, results were comparable.
4.3.2.2 Second pass analysis
After manually relabeling the peaks, statistical analysis was done in the same way as in
the first round of EDM: (1) group D versus group C, (2) group V versus group C, (3)
three groups simultaneously. This resulted in 30 significant (P < 0.05) biomarkers (Table
4.2). Thirteen of these were biomarkers for the viable phenotype, 9 were biomarkers for
the degenerated phenotype and 8 were biomarkers for the infected phenotype. Twenty
six out of the 30 biomarkers (86.7%) had increased serum expression and 4 out of the 30
biomarkers (13.3%) had decreased serum expression. The biomarkers were checked for
their specificity against the heterologous sample group by performing a separate round of
EDM (results not shown). This yielded 15 markers potentially specific for cysticercosis:
3.60 kDa, 3.63 kDa, 7.26 kDa and 8.60 kDa in CM10 pH 9 fraction; 4.99 kDa, 12.3 kDa,
12.5 kDa, 12.7 kDa and 27.7 kDa in CM10 pH 4 fraction; 3.2 kDa, 5.57 kDa, 28.5 kDa
and 55.9 kDa in CM10 organic fraction; 10.2 kDa and 10.6 kDa in IMAC organic fraction.
The representative spectral views and gel views of three biomarkers (3.60 kDa, 3.63 kDa
and 5.57 kDa) are presented in Figures 4.1 and 4.2.
4.3.2.3 Identification of protein biomarkers
Five biomarkers were identified (Table 4.2). The 3.63 kDa, 12.3 kDa and 15 kDa biomark-
ers were identified as C-terminal fragment of the alpha and beta chain of clusterin (ac-
cession no. Q29549), N-terminal fragment of vitronectin (accession no. P48819) and
C-terminal fragment of apolipoprotein A-I (Apo A-I, accession no. P18648), respectively.
In addition, the 22.5 kDa biomarker was shown to be the N-terminal fragment of lecithin-
cholesterol acyltransferase (LCAT) with accession no. P30930, appearing in its dimerised
form. All these biomarkers had an elevated serum expression in pigs infected with viable
cysts (viable phenotype). Another biomarker, appearing at 10.3 kDa and with elevated
serum expression in pigs infected with degenerated cysts, was identified as the N-terminal
fragment of haptoglobin (accession no. Q8SPS7).
Chapter 4 66
Figure 4.1: Example of the 3.60 kDa and 3.63 kDa protein biomarkers as discovered by
SELDI-TOF analysis (CM10 ProteinChip Array) of serum samples from experimentally
infected pigs. The 3.60 kDa biomarker is present in serum samples from pigs with
only degenerated cysts at necropsy (degenerated phenotype). Note the absence of the
biomarker in the pre-infection control samples and serum samples from pigs with viable
cysts at necropsy. The 3.63 kDa biomarker is present in serum samples from pigs with
viable cysts at necropsy (viable phenotype). (A) Spectral view of the protein profiles
in the range 3–4 kDa. (B) Close-up spectral view (range 3,500–3,700 Da). (C) Gel
view. D = sera from experimentally infected pigs with degenerated cysts; V = sera
from experimentally infected pigs with viable cysts; C = pre-infection control sera.
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Figure 4.2: Example of the 5.57 kDa protein biomarker as discovered by SELDI-TOF
analysis (CM10 ProteinChip Array) of serum samples from experimentally infected
pigs. The biomarker is present (arrow) in serum samples from pigs with viable cysts
at necropsy (viable phenotype) (A) Spectral view of the protein profiles in the range
3.5–9 kDa. (B) Close-up spectral view (range 5,450–5,700 Da). (C) Gel view. D = sera
from experimentally infected pigs with degenerated cysts; V = sera from experimentally
infected pigs with viable cysts; C = pre-infection control sera.
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Table 4.2: Overview of significant biomarkers after SELDI-TOF analysis of serum
samples from experimentally infected pigs.
MW (kDa)a P value Phenotypeb Chip type Fraction Biomarker identification
3.20 * 0.027 D + CM10 Organic
3.60 * 0.021 D + CM10 pH 9
3.63 * 0.009 V + CM10 pH 9 Clusterin
4.03 0.030 V – CM10 Organic
4.99 * 0.004 I + CM10 pH 4
5.57 * 8.1× 10−4 V + CM10 Organic
7.26 * 0.004 V + CM10 pH 9
8.60 * 0.032 V + CM10 pH 9
9.24 0.013 I + CM10 pH 4
9.43 0.004 I + CM10 pH 4
9.46 0.018 V + CM10 pH 4
10.2 * 0.014 D + IMAC30 Organic
10.3 0.040 D + CM10 Organic Haptoglobin
10.5 0.038 D + CM10 pH 9
10.6 0.034 V + CM10 pH 9
10.6 * 0.016 D + IMAC30 Organic
12.3 * 0.003 V + CM10 pH 4 Vitronectin
12.5 * 0.015 V – IMAC30 Organic
12.6 0.001 V – CM10 pH 4
12.7 * 0.017 I + IMAC30 Organic
12.8 0.004 I + CM10 pH 4
15.0 0.012 V + CM10 pH 9 Apo A-I
16.1 4.5× 10−4 I + CM10 pH 4
19.9 0.047 D + IMAC30 Organic
22.5 0.021 V + CM10 pH 4 LCAT
27.7 * 0.005 I + CM10 pH 4
27.9 0.035 V – IMAC30 Organic
28.5 * 0.010 D + CM10 Organic
41.6 0.002 I + CM10 pH 4
55.9 * 0.009 D + CM10 Organic
a * = biomarker specific for T. solium cysticercosis
b D= biomarker for degenerated phenotype; V = biomarker for viable phenotype; I = biomarkers for
infected phenotype; + = upregulated biomarker; – = downregulated biomarker
Chapter 4 69
4.3.3 Discovery of protein biomarkers in the field samples
Of the total number of 688 sample spectra collected, the normalization coefficients of 36
spectra did not pass the “twice the average rule” (normalization coefficient ≥ 2µ) and
were rejected from further analysis. The average (inter-assay) CV value for peak intensity
and mass to charge ratios were 43.2% and < 0.40%, respectively.
4.3.3.1 First pass analysis
Viable versus degenerated EDM was performed for differentiation of group Df and
group Vf in 2 different runs: (1) for the field samples from Peru and (2) for the field
samples from Zambia. Only biomarkers that were significant (P < 0.05) in both runs were
selected. Then, all the field samples were pooled in one group and again EDM analysis
was done. Biomarkers for degenerated and viable phenotype that remained significant
were selected for second pass analysis.
Infected versus non-infected Group C was included in the analysis to provide a
reference expression level. By performing EDM and P-value calculation of the three
groups simultaneously (group Df, group Vf and group C) biomarkers for the infected
phenotype could be identified.
4.3.3.2 Second pass analysis
Significant peaks were manually relabelled in all spectra and another round of EDM was
done. Again, statistical analysis was done and the different groups were compared: (1)
group Df versus group C, (2) group Vf versus group C and (3) these three groups simulta-
neously. The biomarkers that passed the second round of EDM (P < 0.05) were compared
to the biomarkers for the experimental samples. Analysis of the field samples resulted
in 10 biomarkers that were significant (P < 0.05) in the samples originating from both
Zambia and Peru (Table 4.3). Molecular weights ranged from 8.09 kDa to 158.1 kDa and
in the pH 4 fraction (CM10) no significant biomarker was found. There were 3 biomarkers
for the viable phenotype, 4 biomarkers for the degenerated phenotype and 3 biomarkers
for the infected phenotype. Fifty percent had increased serum expression and 50% had
decreased serum expression. Comparison with the significant biomarkers for the experi-
mental samples showed that 3 biomarkers were significant in both sample sets: 8.60 kDa
in the pH 9 fraction (CM10), 28.5 kDa and 55.8 kDa in the organic fraction (CM10).
However, the peak profiles (relative normalized intensities for the different groups) were
not consistent in the two sample sets (Figure 4.3). In the experimental sample group,
the 8.6 kDa marker had a significant elevated serum expression in the samples of pigs in-
Chapter 4 70
fected with viable cysts, whereas in the field sample group, it had a significant decreased
serum expression in samples from pigs with degenerated cysts and pigs with viable cysts.
The 28.5 kDa and 55.8 kDa markers had a significant elevated serum expression in the
experimental samples of pigs infected with degenerated cysts, whereas in the field sample
group, they had a significant decreased serum expression in samples from pigs with viable
cysts. The other biomarkers from the experimental sample set were either absent or not
significant in the field sample set (results not shown).
Table 4.3: Overview of significant biomarkers after SELDI-TOF analysis of 86 serum
samples from naturally infected pigs in Zambia and Peru and comparison with biomark-
ers found after SELDI-TOF analysis of 30 serum samples from experimentally infected
pigs.
Field samples Experimental samples
MW (kDa) Chip type Fraction P value Phenotypea P value Phenotypea
8.09 CM10 Organic 0.002 D + > 0.05 na
8.60 CM10 pH 9 0.003 I – 0.032 V +
14.0 IMAC30 Organic 0.004 D + no cluster na
14.04 IMAC30 Organic 0.036 D + > 0.05 na
14.1 CM10 Organic 0.003 D + > 0.05 na
16.2 CM10 pH 9 0.007 V – > 0.05 na
28.5 CM10 Organic 0.048 V – 0.010 D +
54.3 CM10 pH 9 2.6× 10−4 I – > 0.05 na
55.8 CM10 Organic 0.004 V – 0.009 D +
158.1 CM10 pH 9 1.2× 10−4 I + > 0.05 na
a D= biomarker for degenerated phenotype; V = biomarker for viable phenotype; I = biomarker for
infected phenotype; + = upregulated biomarker; – = downregulated biomarker; na = not applicable
4.4 Discussion
In this study we aimed to identify biomarkers in serum of pigs infected with T. solium that
differentiate pigs with viable cysts (active disease) from pigs harboring only degenerated
cysts (inactive disease) and secondly biomarkers that differentiate infected pigs from non-
infected pigs. We used SELDI-TOF MS technology to profile the serum proteome.
The set up was as follows: (1) identification of potential biomarkers in a set of well
defined serum samples from experimentally infected pigs (including the respective pre-
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Figure 4.3: Box-and-whisker diagrams of the peak intensities of 3 biomarkers dis-
covered by SELDI-TOF analysis (CM10 ProteinChip Array) of serum samples of pigs
experimentally or naturally infected with Taenia solium. The left panels (1A, 2A, 3A)
represent the experimental sample group (groups C, D and V), the right panels (1B, 2B,
3B) the field sample group (groups C, Df and Vf). (1) 8.6 kDa marker. In the experi-
mental sample group, the 8.6 kDa marker has a significant elevated serum expression in
the samples of pigs infected with viable cysts, whereas in the field sample group, it has
a significant decreased serum expression in samples from pigs with degenerated cysts
and pigs with viable cysts. (2) 28.5 kDa marker. In the experimental sample group,
the 28.5 kDa marker has a significant elevated serum expression in the samples of pigs
infected with degenerated cysts, whereas in the field sample group, it has a significant
decreased serum expression in samples from pigs with viable cysts. (3) 55.8 kDa marker.
In the experimental sample group, the 55.8 kDa marker has a significant elevated serum
expression in the samples of pigs infected with degenerated cysts, whereas in the field
sample group, it has a significant decreased serum expression in samples from pigs with
viable cysts.
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infection samples), (2) assessment of their specificity by analyzing serum samples from
heterologous infections and (3) validation of the biomarkers by analyzing serum samples
from naturally infected pigs. The different sample groups were processed randomly to
avoid introduction of systematic bias.
In the experimental sample set 30 significant biomarkers were identified of which 15
biomarkers were potentially specific for porcine cysticercosis. However, only three of the
biomarkers discovered in the experimental samples were significant in the field sample set
(8.60 kDa in the pH 9 fraction (CM10), 28.5 kDa and 55.8 kDa in the organic fraction
(CM10)). In addition, the peak profiles of these three biomarkers differed between the
two sample sets. We were thus not able to validate the identified biomarkers.
Several technical and biological confounding factors may influence reproducibility of
SELDI-TOF results: differential handling and/or processing of the samples, variations
in mass spectrometer stability and protein chip performance, biological variability of the
study subjects (e.g. sex, age, nutritional level and concurrent infections), inappropriate
statistical design, among others. We tried to address these issues through our experi-
mental set up, however some causes of variability could not be accounted for, e.g. the
handling and storage of the field samples. Moreover, the baseline biological variability of
samples collected in field conditions is a potential bottleneck when validating new diag-
nostic techniques. Various environmental, nutritional and physiological factors have an
important impact on the pathogenesis of diseases. Especially in helminth infections, often
characterized by down regulation of host immunity and harmonious host-parasite inter-
play (Maizels and Yazdanbakhsh, 2003), this baseline biological variability could have
a major impact on the proteome and prevent extrapolation of serum profiling results
between different sample groups.
A few studies applied SELDI-TOF technology to the study of biomarkers of parasitic
diseases such as human African trypanosomiasis (HAT) (Papadopoulos et al., 2004) and
fasciolosis in sheep (Rioux et al., 2007). The former study applied three different data-
mining tools to identify proteomic signatures that could distinguish between HAT patients
and controls without identifying individual biomarkers. They reported a sensitivity and
specificity of 100% and 98%, respectively; however in this format the test is too expensive
and impracticable for field use. Furthermore, these promising results still remain to be
confirmed. The latter study aimed to identify diagnostic biomarkers for early parasite
invasion. Two of the biomarkers were identified as transferrin and Apo A-IV. Up to now,
these authors have not identified a biomarker that could be diagnostic of early infection
or that may act as a marker of intensity of infection nor were they able to detect a serum
biomarker corresponding to the main parasite biomarker in bile (isotypes of Fasciola
hepatica cathepsin L).
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In this study, five biomarkers discovered in the experimental sample group were iden-
tified, four of which (3.63 kDa biomarker (clusterin), 12.3 kDa biomarker (vitronectin),
15 kDa biomarker (Apo A-I) and 22.5 kDa biomarker (LCAT)) had an increased serum ex-
pression in animals infected with viable cysts, one identified biomarker (10.3kDa biomarker
(haptoglobin)) had an increased serum expression in animals infected with degenerated
cysts. Clusterin (complement cytolysis inhibitor or CP40) inhibits complement-mediated
cell lysis (Berge et al., 1997) and enhances TGF-β-induced-transcriptional activity (Lee
et al., 2008). TGF-β inhibits macrophage activation and can lead to the induction of
Th2-type cells and immune suppression (Maizels and Yazdanbakhsh, 2003). Vitronectin
(S-protein) also inhibits the membrane-damaging effect of the terminal cytolytic comple-
ment pathway (Johnson et al., 1994; Milis et al., 1993). Apo A-I, a negative acute-phase
protein in pigs (Carpintero et al., 2005), is a major component of high density lipoprotein
(HDL) in plasma and a potent activator of LCAT, a central enzyme in the extracellular
metabolism of plasma lipoproteins involved in the synthesis of HDL (Hill and McQueen,
1997). HDL is known to have anti-inflammatory effects through inhibiting endothelial
cell expression of cytokine-induced leukocyte adhesion molecules (Cockerill et al., 1995,
2001).
Taenia solium cysticercosis is characterized by a long lasting immune response oc-
curring concomitantly to the presence of living parasites that develop immune evasion
mechanisms to survive within an immunocompetent host (Correa et al., 1999a; Flisser
et al., 2002). The different mechanisms are not yet clear; however inhibition of comple-
ment by paramyosin has already been observed (Laclette et al., 1992). The parasite also
seems to mediate some kind of immune depression or a shift to a Th2-type cell response
(Terrazas et al., 1998). Our results seem to confirm this state of immune depression
in pigs infected with viable cysts on three levels: complement inhibition (clusterin and
vitronectin), inhibition of leukocyte migration (Apo A-I and LCAT) and induction of
Th2-type response and immune suppression through TGF-β (clusterin). However, con-
sidering the lack of correlation with the biomarkers in the field samples, this needs to be
studied more thoroughly.
During the late phase of host-parasite immune interaction, the parasite is destroyed by
an inflammatory reaction; the reasons for this are not well understood. In this respect, we
observed the upregulation of a 10.3 kDa biomarker identified as N-terminal fragment of
haptoglobin in animals with degenerated cysts. Haptoglobin is an important acute-phase
protein in pigs and marker for inflammation (Chen et al., 2003; Parra et al., 2006). From
the five identified biomarkers only the 3.63 kDa biomarker (clusterin) and the 12.3 kDa
biomarker (vitronectin) seem to be specifically linked with cysticercosis infection. How-
ever, further studies are necessary to assess the direct effect of parasite establishment
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on the upregulation of these two biomarkers. The differential expression profile of the
other identified biomarkers (apo A-I, LCAT and haptoglobin) is most likely the result of
aspecific epiphenomena related to the infection, since these biomarkers were not specific
for cysticercosis after comparison with the heterologous samples (Table 4.2).
From this, it is clear that SELDI-TOF technology can provide useful insights in the
biology and underlying mechanisms of host-parasite interactions in cysticercosis. However,
for biomarkers to have diagnostic value, they not only should have discriminatory power
between different classification groups (infections with viable or degenerated cysts), but
also should be specific for a certain disease state, both under experimental and field
conditions.
5
Nanobodies, a promising tool for
species-specific diagnosis of Taenia solium
cysticercosis
Adapted from:
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Muyldermans, P. Dorny (2008) Nanobodies, a promising tool for species-specific diagnosis
of Taenia solium cysticercosis. Int. J. Parasitol. doi:10.1016/j.ijpara.2008.10.012
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5.1 Introduction
Serodiagnosis of cysticercosis can be done by detecting antibodies or circulating parasite
antigen. The current immunodiagnostic test that detects parasite antigen is a sandwich
ELISA using monoclonal antibodies raised against ES products of the larval stage of
T. saginata, the beef tapeworm (Harrison et al., 1989; Brandt et al., 1992; Van Kerck-
hoven et al., 1998). This assay only detects living cysts and is genus-specific, enabling
diagnosis of infection with any Taenia species (Dorny et al., 2003). This is not a con-
straint for diagnosis in humans as they can only be infected with the larval stage of
T. solium. However, pigs can also be infected with T. hydatigena (Dorny et al., 2004b)
and T. saginata asiatica (Geerts et al., 1992), which are of no, or less importance for
human health. Obviously, the antigen detection ELISA does not differentiate between
these species in pigs. A specific serodiagnostic test in pigs is needed for epidemiological
studies and monitoring of control programs.
Nanobodies (Nbs), camelid-derived single-domain antibody fragments (Hamers-Casterman
et al., 1993; Arbabi-Ghahroudi et al., 1997), constitute an alternative to monoclonal anti-
bodies. Nbs often recognize novel epitopes that are not readily accessible to conventional
antibodies because of the larger antigen-binding site of the latter (Conrath et al., 2001b;
Stijlemans et al., 2004; De Genst et al., 2006b). In addition, Nbs display a high affinity
and specificity for their target antigens, are extremely stable (Muyldermans and Lauw-
ereys, 1999; van der Linden et al., 1999; Dumoulin et al., 2002) and can be easily tailored
in manifold constructs (Conrath et al., 2001a; Saerens et al., 2008a) making them excel-
lent tools in diverse medical and biotechnological applications. In this chapter we report
the generation, selection and characterization of Nbs that do not cross-react between
T. solium and T. hydatigena. We provide evidence of their high potential as tool for
species-specific diagnosis of T. solium cysticercosis in pigs.
5.2 Materials and methods
5.2.1 Antigens
A total antigen extract was prepared from viable T. solium cysts from naturally infected
pigs. Cysticerci were recovered upon necropsy of the animals and washed in PBS. The
cyst fluid from individual cysts was aspirated and pooled. The collected solution was
centrifuged twice at 3,000 g for 30 min at 4°C. Protease inhibitors (Complete, Roche) were
added to the final supernatant (TsAg) according to the manufacturer’s recommendation.
A similar procedure was used for the preparation of T. hydatigena antigen (ThAg).
An enriched fraction of T. solium antigen was prepared by partially purifying TsAg
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by ion exchange chromatography on a Mono S cation exchange column (High S car-
tridge, BioRad) and Mono Q anion exchange column (High Q cartridge, BioRad) using a
low-pressure chromatography system (ECONO system, BioRad). The homogeneity and
apparent MW of the purified fractions were analyzed by SDS-PAGE according to the
method of Laemmli (1970). Proteins were visualized by silver staining. Based on the
appearance on one-dimensional (1D) gel, similar fractions were pooled and concentrated.
The purified fraction used for immunization was designed as TsPur.
Taenia saginata somatic antigens (TsaAg), T. crassiceps cyst fluid (TcrAg) and
Trichinella spiralis ES antigens (TspAg) were provided by the Animal Health Depart-
ment, ITMA. All protein concentrations were determined by the method of Bradford
(1976).
5.2.2 Serum samples
Taenia solium-positive serum samples were obtained from 24 heavily infected (tongue
positive) pigs purchased at the Chibolya slaughter slab in Lusaka (Zambia). The pigs were
humanely slaughtered and their carcasses were inspected for the presence of T. solium
and T. hydatigena cysts. Taenia hydatigena-positive serum samples were obtained from
8 experimentally infected pigs; the samples were kindly provided by M. Lightowlers,
University of Melbourne, Australia. Negative pig serum samples were obtained from the
serum bank at ITMA.
5.2.3 Immunization of animals
Two adult dromedaries (Camelus dromedarius) kept at the Central Veterinary Research
Laboratory (Dubai, U.A.E.) were immunized with TsPur and TsAg, respectively. The an-
imals received six subcutaneous injections of 100 µg of protein at weekly intervals (Lauw-
ereys et al., 1998), mixed with an equal volume of Gerbu adjuvant (Gerbu Biotechnik
GmbH). Three days after the last injection, unclotted blood was collected and trans-
ported to the Brussels laboratory. Peripheral blood lymphocytes (PBLs) were isolated
with Lymphoprep (Nycomed). PBLs were counted and aliquots of 5 × 106 cells were
pelleted and stored at -80°C.
5.2.4 Nanobody library construction and selection of binders
The Nb libraries were constructed as described previously (Conrath et al., 2001b; Saerens
et al., 2004). Basically, mRNA was isolated from the PBLs and cDNA was cloned by
reverse transcriptase (RT)-PCR with a dN6 primer. All VH domains, including the VHH
domains from Heavy-chain antibody IgG2 and IgG3 isotypes, were amplified with the
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primers CALL001 and CALL002 (Conrath et al., 2001b). The VHH gene fragments (cod-
ing for the Nbs) were purified from agarose gel and re-amplified using nested primers con-
taining the restriction sites for PstI and NotI restriction enzymes. The final PCR products
were cloned into the phagemid vector pHEN4 according to the methods of Saerens et al.
(2004) and transformed in electro-competent E. coli TG1 cells. The Nb repertoire was
expressed on phage after infection with M13K07 helper phages. Specific virions against
TsAg were enriched by three consecutive rounds of in vitro selection on microtiter 96 well
plates coated with antigen (10 µg/well). In order to obtain T. solium-specific binders
not cross-reacting with T. hydatigena, the panning procedure was modified slightly. To
remove the binding activity to cross-reactive ThAg, virions were pre-absorbed on ThAg
(10 µg/well). Only these virions that did not bind to ThAg were used in the enrichment
procedure with TsAg. The TsAg-bound phage particles were eluted with 100 mM tri-
ethylamine (pH 10.0). The eluate was neutralized with 1 M Tris-HCl (pH 7.4) and used
to infect exponentially growing E. coli TG1 cells. After three rounds of panning, poly-
clonal phage ELISA was performed to monitor the success of selection. Pools of virions
from each round were incubated on antigen-coated and non-coated wells. Binding was
detected using an anti-M13-HRP conjugate (Amersham Biosciences). Monoclonal phage
ELISA was used to identify individual positive clones, which were then sequenced to iden-
tify unique Nb genes. Expression in the periplasm and purification of Nb was performed
as described previously (Conrath et al., 2001b). The Nbs were subsequently tested for
antigen recognition in ELISA.
5.2.5 Nanobody protein production
The selected Nb clones were recloned into the expression vector pHEN6 (Conrath et al.,
2001b), using restriction enzymes PstI and BstE II. The plasmid constructs were trans-
formed into E. coli WK6 cells. Production of recombinant Nbs and purification of the
periplasmic extracts was done as described previously (Saerens et al., 2004). The fi-
nal yield was determined from the UV absorption at 280 nm, and the theoretical mass
extinction coefficient.
5.2.6 Binding specificity
To assess the specificities of the Nbs, microtiter plates (Nunc) were coated with dif-
ferent antigen preparations (TsAg, ThAg, TsaAg, TcrAg, TspAg) at a concentration
of 5 µg/ml. Residual protein-binding sites were blocked with 2% skimmed milk in PBS.
Nanobodies were biotinylated (Biotin Protein Labeling Kit, Roche) according to the man-
ufacturer’s recommendations. Biotinylated Nbs were added to each well (5 µg/ml). Detec-
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tion was performed with streptavidin-HRP conjugate (Jackson) and o-phenylenediamine
dihydrochloride (OPD, Dako).
5.2.7 Binding affinity
For affinity determination, different concentrations of the selected Nbs, ranging from 1 µM
to 15.6 nM were added to a CM5 chip (BIAcore) to which 2000 RU of TsAg had been
coupled. All measurements were performed using a flow rate of 30 µl/min in HBS buffer
(10 mM Hepes pH 7.5, 150 mM NaCl, 3.5 mM EDTA and 0.005% Tween-20). Bound Nbs
were eluted with 10 mM glycine-HCl pH 2.0. The kinetic and equilibrium parameters (kon,
koff and KD) were determined with the BIAevaluation software version 4.1 (BIAcore).
5.2.8 Western blotting and TsAg protein identification
TsAg was run on a 15% SDS-PAGE gel (Laemmli, 1970) and transferred to nitrocel-
lulose membrane (Hybond). Blocking of the membrane strips was done overnight in
PBS-Tween 0.5% + 5% skimmed milk at room temperature. All following incuba-
tions were done in PBS-Tween 0.5% + 2% skimmed milk during 1 h at 37°C. Biotiny-
lated Nbs (20 µg per strip) were detected by streptavidin-HRP conjugate (1/5,000) and
3,3,5,5-tetramethylbenzidine (TMB, KPL) as substrate. TsAg was also transferred to a
polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Millipore) after electrophoresis
and stained with 0.5% Coomassie blue R250 in 40% methanol and 5% acetic acid. The
bands on PVDF corresponding to the bands recognized by the Nbs were cut out and
the eluted proteins were identified through N-terminal sequencing (Edman degradation).
The resulting amino acid sequence was subjected to a search using the BLAST algorithm
(Altschul et al., 1997).
To confirm the result of the TsAg protein identification, immunodetection was assessed
for Ts14, Ts18var1, TsRS1 and TsRS2 (four synthetic proteins belonging to the 8 kDa
diagnostic protein family (Hancock et al., 2003)) blotted on nitrocellulose membrane.
Strips containing the synthetic proteins were incubated overnight at 4°C with 15 µg of
biotinylated Nb diluted in PBS-Tween 0.5% + 5% skimmed milk. Detection of protein-
associated Nb was done. Additional strips were incubated with serum from rabbits im-
munized against TsAg (provided by ITMA) and detected by goat-anti-rabbit-peroxidase
conjugate and TMB substrate. The strips were kindly provided by Dr. Wilkins, Centers
for Disease Control and Prevention (CDC), Atlanta, USA.
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5.2.9 Epitope mapping
The complementation epitope groups of Nbs were investigated in competition ELISA.
Non-biotinylated homologous and heterologous Nbs were diluted in a previously deter-
mined sub-saturating level dilution of biotinylated Nb, to analyze the binding-inhibition
of the marked Nb (Harlow and Lane, 1988). Briefly, after coating of the microtiter plates
with TsAg and blocking (see supra) a mixture of the same biotinylated Nb (1.25 µg/ml
for Nbsol130, Nbsol68, Nbsol71 and Nbsol41; 5 µg/ml for Nbsol60, Nbsol62 and Nbsol111;
0.04 µg/ml for Nbsol52) and increasing concentrations (up to 200 µg/ml) of homologous
or heterologous Nb were added. Streptavidin-HRP was used as conjugate and OPD as
substrate. Decreasing OD when using increasing concentrations of a competing Nb indi-
cate a competition for the same or overlapping epitope. The threshold for competition
was set at a 50% reduction in OD when adding 200 µg/ml of competing Nb, compared
with the OD of the biotinylated Nb in absence of competing Nb (OD = 100%).
To confirm the interaction observed in the competition ELISA between Nbsol60, Nb-
sol62 and Nbsol71 and Nbsol130 and Nbsol41, respectively, dilution series of biotinylated
Nbsol60, Nbsol62 and Nbsol71 (starting from 20 µg/ml) were tested in an ELISA with and
without the presence of either Nbsol130 or Nbsol41 at a constant concentration (20 µg/ml).
After coating of the plates with TsAg and blocking, the Nbs were incubated for 1 h at
RT. Detection was done with streptavidin-HRP and OPD as substrate.
5.2.10 Antigen capturing
Pairs of Nbs were tested in various combinations in sandwich ELISA to assess the captur-
ing of antigens present in cyst fluid (TsAg and ThAg) or pooled serum samples (T. solium-
positive, T. hydatigena-positive and negative serum). Briefly, plates were coated with the
first (capturing) Nb at 10 µg/ml. After blocking and incubation of either cyst fluid
or serum, captured antigens were detected by a second, biotinylated Nb (5 µg/ml) and
streptavidin-HRP. Serum samples were pretreated with trichloroacetic acid (TCA) before
incubation (De Jonge et al., 1987). Preliminary tests indicated that this approach pro-
duced better results than serum samples diluted in PBS (results not shown). To confirm
that Nbs were able to capture serum antigen, an inhibition ELISA for the detection of
antigen was performed as described by Harlow and Lane (Harlow and Lane, 1988). Briefly,
after determining the optimal concentrations by titration, plates were coated with TsAg
(1.25 µg/ml). Biotinylated Nb was added to the sample solution and pre-incubated for 1 h
at RT. The sample solution consisted of either PBS, PBS spiked with TsAg, TCA treated
negative serum, TCA treated negative serum spiked with TsAg or TCA treated positive
serum. After blocking, the sample solution was added and bound Nbs were detected by
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streptavidin-HRP conjugate.
5.2.11 Animal ethical approval
All animal treatment was according to the guidelines of the local Animal Care Committee
and supervised by a veterinary surgeon.
5.3 Results
5.3.1 Selection of Ag-specific Nbs
The VHH gene fragments of the Heavy-chain antibodies from the immunized dromedaries,
coding for the Nanobodies were cloned. Two different libraries of, respectively, 7.5× 106
(for dromedary 1 immunized with TsPur) and 3.9 × 107 transformants (for dromedary
2 immunized with TsAg) were obtained. Within the first library, 100% of the clones
contained a vector with a VHH gene insert of the appropriate size as determined by PCR.
For the second library, 80% of the clones had an insert of proper size. The Nb repertoires
of both libraries were expressed on phages and selection of phage particles expressing a
specific antigen-binding Nb was performed. Three rounds of panning were performed on
TsAg coated on microtiter plates after pre-adsorption on ThAg. A clear enrichment of
specific phages during these consecutive rounds of panning was observed. After the third
round of panning, 336 individual colonies were screened for antigen recognition in ELISA.
Twenty-six clones were positive in this screening ELISA. The nucleotide sequence analysis
of the Nbs revealed 17 distinct binders. A total of eight different TsAg binders (Nbsol)
were selected for further work (Nbsol41, Nbsol52, Nbsol60, Nbsol62, Nbsol71, Nbsol68,
Nbsol111, Nbsol130), based on their reactivity in the screening ELISA (results not shown).
The deduced amino acid sequences of the Nbs are shown in Figure 5.1. All of the binders
are derived from the Heavy-chain antibody specific VHH germline genes (Nguyen et al.,
2000), as they contain the hallmark amino acid substitutions in frameworks 1 and 2.
The disulfide bridge, frequently occurring between CDR1 and CDR3 in dromedary Nbs,
was present in all clones except Nbsol68. In Nbsol41 and Nbsol130 the disulfide bridge
occurred between CDR3 and FR2 (cysteine residue at position 50).
5.3.2 Production and purification of the different binders
The Nbs were produced as soluble protein after re-cloning into expression vector pHEN6
and transformation into E. coli WK6 cells. The single-domain antibody fragments, car-
rying a His6 tag, are transported into the periplasm of E. coli and subsequently purified
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1               10    20              30              40                  50    
|********|*********|******   ***|********   *|*********|*****
<----------------- FR1-IMGT ---------->       <CDR1-IMGT->      <------ FR2-IMGT ------>
DVQLQESGG.GSVQAGGSLRLSCVAS   GYTF....RRST   MGWFRRAPGKECEPVST
DVQLQESGG.GSVQAGGSLRLSCVAS   GYTF....GRST   MGWFRRAPGKECEAVST
DVQLQESGG.GSVQTGGSLRLSCATS   GFPS....SNYC   MAWFRQAPGKEREKVAI
DVQLQESGG.GSVQTGGSLRLSCATS   GFPS....SNYC   MAWFRQAPGKEREKVAI
DVQLQESGG.GSVHPGGSLRLSCTTS   GFPS....SNYC   MAWFRQAPGKEREKVAI
DVQLQESGG.GSVQAGESLRLSCAAS   GYTI....STAC   MGWFRQAPGKEREGVAA
DVQLQESGG.GSVQAGGSLRLSCVYS   GYAY....RPAC   MGWFRQTPGKEREGVAS
DVQLQESGG.GSVQVGGSLRLACAIS   ADTY....SIYS   MGWFRQAPDKEREGVAA
       60                70              80            90                100   
****|*****   ****|*********|*********|*********|****
<CDR2IMGT>   <----------------------------FR3-IMGT------------------------->
ITSD...GNT   NYSDSVK.GRFTSSRDNAKNTVYLQMNSMKSEDTAVYYC
ITGD...SNT   NYSDSVK.GRFTSSRNNAKNTIYLQMNSLTSEDTAVYYC
ISTA..GGTT   NHAESVK.GRFTISRDNSKNTVYLQMNSLKPEDTASYFC
ISTA..GSTT   NVAESVK.GRFTISRDNPKNTVYLQMNSLKPQDTASYFC
ISTA..GGTT   NHAESVK.GRFTISRDNSKNTVYLQMNSLKPEDTASYFC
ISGS..GRTT   YYGASGK.GRFTISRDNAKNTVYLQMNSLKPEDTAIYYC
INSG..TSTT   YYADSVK.GRFTISQDNAKNTMYLQMNSLKPEDTAIYYC
IHIG..GGYT   GYADSVK.GRFTISRDNAKNTVYLQMDSLKPEDTAVYYC
         110                                 120       
*****|*123456*123456*****   **|********
<------------ CDR3-IMGT ------------>      <-FR4-IMGT->
AALTRIPGDSDYAHPRPCSNYGWGY   WGQGTQVTVSS Nbsol41 A
AALTRQPGESDYAHPRPCSNYGWGY   WGQGTQVTVSS Nbsol130
AAIDCRN......NV.....GTPQY   WGQGTQVTVSS Nbsol60 B
AAIDCRN......NV.....GTPQY   WGQGTQVTVSS Nbsol62
AAIDCRN......NV.....GTPQY   WGQGTQVTVSS Nbsol71
AAKDKDGRYC...GNYS...PTYDY   WGQGTQVTVSS Nbsol52 C
AADDTYCTSF...SWRRL..SRWNY   WGQGTQVTVSS Nbsol111 
AAATSRR......L......SGYNY   WGQGTQVTVSS Nbsol68 D
Figure 5.1: Amino acid sequence of the isolated Nanobodies from two dromedary
immune libraries against Taenia solium antigen (TsAg), named Nbsol. The IMGT
numbering and CDR designation are used (The International Immunogenetics Infor-
mation System, http://imgt.cines.fr). A to D denote the different epitope-binding
groups based on the results of competition ELISA.
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from the periplasmic extract by immobilized-metal affinity chromatography. The yield of
purified product varied from 0.1 to 12 mg/liter of culture, depending on the actual Nb.
5.3.3 Binding specificity
The result of the ELISA with heterologous antigens is shown in Figure 5.2. The Nbs
were highly specific for T. solium antigen and no cross reactivity with T. hydatigena,
T. saginata, T. crassiceps or T. spiralis was observed.
Figure 5.2: Specificity of Nanobodies raised against Taenia solium cyst fluid tested
in ELISA with cyst fluid from T. solium (TsAg) and Taenia hydatigena (ThAg),
Trichinella spiralis excretion-secretion antigens (TspAg), Taenia saginata somatic anti-
gens (TsaAg) and Taenia crassiceps cyst fluid (TcrAg).
5.3.4 Binding affinity
The affinity of all Nbs for TsAg was determined by surface plasmon resonance on a
BIAcore 3000. The association of each Nb with the antigen was recorded. Except for
Nbsol68, the binding kinetics yielded kon values in the range of (7.9 × 104 – 3.1 × 106)
M−1s−1 and koff values of (5.7× 10−4 – 1.2× 10−2) s−1 (Figure 5.3). From these kinetic
rate constants corresponding KD values ranging from 154 nM to 185 pM were calculated.
Nbsol68 is removed from Figure 5.3 because of its high equilibrium dissociation constant
(KD = 6.8µM).
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Figure 5.3: Rate plane with Isoaffinity Diagonals (RaPID) plot of the Taenia solium
antigen (TsAg) binding Nanobodies (Nb). The kinetic rate values kon and koff for a par-
ticular Nb as determined by biosensor measurements are plotted on a two-dimensional
diagram so that Nbs located on the same diagonal line have identical KD values.
5.3.5 Western blot and protein identification
Figure 5.4A shows the results of the Western blot with TsAg on nitrocellulose membrane.
All Nanobodies recognize the same protein bands. Nbsol60 and Nbsol62 only show a very
faint reactivity with TsAg on Western blotting. After electrophoresis, blotting of TsAg on
PVDF membrane and staining, the two protein bands between the 64.2 kDa and 48.8 kDa
markers and 37.1 kDa and 25.9 kDa markers, respectively, were cut out of the membrane
and sequenced (Figure 5.4B). Both the high MW band (± 50 kDa) and the low MW band
(± 32kDa) contained the same N-terminal amino acid sequence (EKNKPKDVA). The
resulting sequence showed a 100% identity with six glycoproteins (GenBank accession nos.
ABI20731, AAM00204, AAF25005, AAM00206, AAM00208, AAX32918) all representing
the 14 kDa diagnostic glycoprotein from the 8 kDa diagnostic protein family (Greene
et al., 2000; Hancock et al., 2003; Lee et al., 2005). Figure 5.4C shows the results of
Western blotting with the synthetic 8 kDa proteins. Nbsol130, Nbsol41, Nbsol52, Nbsol60,
Nbsol62, Nbsol68 and Nbsol111 react with Ts18var1 protein. Only two Nbs, Nbsol130
and Nbsol41, recognized the Ts14 protein as well as TsRS2. None of the Nbs recognized
TsRS1.
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Figure 5.4: Western blotting with Taenia solium-specific Nanobodies (Nb). (A) Im-
munodetection of T. solium cyst fluid with Nbs after 15% SDS-PAGE and blotting on
nitrocellulose membrane. Two major bands of approximately 50 and 32 kDa (marked
with asterisks) were consistently recognized. Only Nbsol60 and Nbsol62 show a low
reactivity with the antigen. The position of the MW markers is indicated. (B) Blotting
of T. solium cyst fluid on polyvinylidene fluoride (PVDF) membrane and stained with
Coomassie blue after 15% SDS-PAGE. The bands marked with an asterisk were cut out
and identified by N-terminal sequencing, they both contained a 14 kDa glycoprotein.
(C) Immunodetection of the 8 kDa diagnostic glycoproteins Ts14 (a), Ts18var1 (b),
TsRS1 (c) and TsRS2 (d) with Nbs (RHS: rabbit hyperimmune serum raised against
T. solium cyst fluid).
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5.3.6 Epitope mapping
The results of the competition ELISAs are summarized in Table 5.1. Nbsol41 and Nb-
sol130 showed mutual competition to bind the epitopes on TsAg, which was expected
based on the high sequence identity in their respective CDR regions. This also holds
true for Nbsol60, Nbsol62 and Nbsol71: these Nbs have identical CDR sequences and also
recognized the same epitope when tested in ELISA. Interestingly, the binding of Nbsol60,
Nbsol62 and Nbsol71 to the epitope was enhanced when adding high concentrations of
either Nbsol41 or Nbsol130 (Figure 5.5A). This phenomenon was confirmed by testing
Nbsol60, Nbsol62 and Nbsol71 in ELISA in dilution series with or without adding a con-
stant concentration of either Nbsol41 or Nbsol130 (Figure 5.5B). In the presence of one
of the latter Nbs, a higher reactivity was noted for Nbsol60 and Nbsol62 and to a lesser
extent Nbsol71. Nbsol52, Nbsol71 and Nbsol111 were able to inhibit the binding of Nb-
sol68 to the antigen (with biotinylated Nbsol68 as the detected Nb), but reversely there
was no competition (with biotinylated Nbsol52, Nbsol71 or Nbsol111 as detected Nbs and
Nbsol68 as competing Nb). This was also observed for Nbsol52 and Nbsol111: Nbsol52
was able to inhibit the binding of Nbsol111 to the antigen, but reversely there was no
competition (with biotinylated Nbsol52 as detected Nb). Taken together, the Nbs can be
categorized in four different epitope-binding groups: Nbsol41 and Nbsol130 bind to an
identical epitope (group A); Nbsol60, Nbsol62 and Nbsol71 also share an identical epitope
(group B), the epitopes for Nbsol52 and Nbsol111 are overlapping (group C) and Nbsol68
binds to a unique epitope (group D).
5.3.7 Antigen capture
All pairs of Nbs were tested two by two in a sandwich ELISA for detection of TsAg and
ThAg. Eleven sandwich combinations were selected; on average, the OD of TsAg wells
was 11-fold higher than the OD of ThAg wells (results not shown). Figure 5.6A shows
the results of the four best performing combinations. No clear distinction was noticed
between the different serum samples. Furthermore, there was a high background signal
(not shown). To confirm that the Nbs were capable of capturing serum antigens, they were
all tested in an inhibition ELISA with the biotinylated Nbs mixed in sample solutions
containing either PBS, PBS spiked with TsAg, T. solium-negative serum, T. solium-
negative serum spiked with TsAg, T. solium-positive serum and T. hydatigena-positive
serum. The free Nb was captured on microtiter plate-coated TsAg and detected via its
biotin (Figure 5.6B). Antigens present in the sample solution inhibit the binding of the Nbs
to the antigen immobilized on the plate resulting in a lower OD compared with the PBS
sample solution (0% inhibition). Under these conditions, Nbsol52 differentiated T. solium-
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Figure 5.5: Epitope mapping of Taenia solium-specific Nanobodies (Nb). (A) Com-
petition ELISA for the detection of T. solium cyst fluid using biotinylated Nbsol60
as detector antibody. Increasing concentrations of non-biotinylated competing Nb are
added. OD is presented as percentage positivity (ODNbsol60(5µg/ml) = 100%). (B)
ELISA using a dilution series of biotinylated Nbsol60 as detector antibody. A constant
concentration of either Nbsol130 or Nbsol41 is added to confirm the interaction be-
tween the Nbs: enhanced binding of Nbsol60 is noticed in presence of either Nbsol130
or Nbsol41. OD is presented as percentage positivity (ODNbsol60(5µg/ml) = 100%).
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positive samples from T. solium-negative and T. hydatigena-positive serum samples. The
other Nbs gave similar results as shown for Nbsol41 in Figure 5.6B, whereby on average
there was low binding inhibition in the TsAg-spiked PBS samples (average inhibition of
41%) and high binding inhibition in all of the serum samples, with no clear distinction
between negative, positive or spiked serum samples.
Figure 5.6: Antigen capturing by Nanobodies (Nb). (A) Sandwich ELISA with Nbs
for the detection of Taenia solium (TsAg) and Taenia hydatigena (ThAg) cyst fluid
and serum antigens (negative serum, serum from T. solium and T. hydatigena-infected
pigs). The four best combinations are presented here, the first Nb noted is the capturing
antibody, the second is the detector antibody. (B) Inhibition ELISA for the detection
of TsAg in PBS and serum antigen (negative serum, negative serum spiked with TsAg,
serum from T. solium and T. hydatigena-infected pigs).
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5.4 Discussion
This study demonstrates the feasibility to isolate a panel of T. solium-specific Nbs from a
dromedary immunized with T. solium cyst fluid. We have adapted the panning procedure
to eliminate Nbs that cross react with T. hydatigena, without a priori knowledge of the
proteins present in the crude antigen mix (Saerens et al., 2008b). Epitope mapping
by competition ELISA showed that the Nbs are categorized in four complementation
groups. Differences between Nbs from the same epitope group are most likely to be due
to differences in affinity for the epitope. Interestingly, the prior binding of Nbsol130
and Nbsol41 (group A) to the antigen enhanced the subsequent association of Nbsol60,
Nbsol62 and Nbsol71 (group B). Probably the Nbs of group A induced a conformational
change within the antigen and/or fix a more appropriate epitope architecture for the
group B Nbs (Saerens et al., 2004).
We identified the protein as T. solium 14 kDa diagnostic glycoprotein (Ts14), belong-
ing to the 8 kDa glycoprotein family (Hancock et al., 2003). These 8 kDa antigens are
the diagnostic proteins seen at 14, 18, and 21 kDa on the Western blot for cysticercosis
(Tsang et al., 1989) and are also found in the bands at 24 and 39 to 42 kDa. Recent stud-
ies indicate that the 8 kDa proteins and other T. solium low-molecular-weight proteins
are in fact part of an ES-type hydrophobic ligand-binding protein (Saghir et al., 2000; Lee
et al., 2007). Western blot with the synthetic 8 kDa polypeptides did not fully confirm
our initial result of protein identification (Ts14). Nbs reacted preferably with Ts18var1
(except for Nbsol71); only the group A Nbs (Nbsol41 and Nbsol130) also reacted with
Ts14 and TsRS2. However, given the level of similarity within this family of proteins
(Greene et al., 2000), it is possible that the Nbs reacted with both Ts14 and Ts18var1 in
the first immunodetection blot assay. Possibly, we have sequenced Ts14 because it occurs
more frequently in the larger heteromeric molecule as a subunit (Lee et al., 2005).
The ability of Nbsol52 to be used both as capturing and detecting Nbs in a sandwich
ELISA indicates that Ts18var1 forms either homo- or heterodimers via disulfide bond
formation through its cysteine residues (Greene et al., 2000). Not all Nbs were able to
capture antigen in the sandwich ELISA. For Nbsol68, this can be explained by its low
affinity for the antigen (KD = 6.8µM). This also explains the observations in the com-
petition ELISA where biotinylated Nbsol68 competes effectively with Nbsol52, Nbsol71
or Nbsol111 for the binding of the antigen but not the other way around. Despite its low
affinity, Nbsol68 did perform well in both the direct ELISA and Western blot.
Preliminary results of the sandwich ELISA to detect antigens in serum from naturally
infected pigs indicated a high background signal, preventing the assessment of the real
reactivity. However, in the inhibition ELISA, Nbsol52 was capable of capturing antigens
present in serum of T. solium-infected pigs. This can be explained by the fact that in
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this test format capturing of the antigens is performed in solution. Also, Nbsol52 showed
the highest affinity for the antigen (KD = 185pM), determined by the BIAcore binding
studies. The other Nbs were not able to capture the antigen in solution (low inhibition in
the TsAg-spiked PBS sample). Furthermore, their binding to the microtiter plate bound-
TsAg was inhibited by (aspecific?) proteins present in all of the serum samples. These
results suggest that affinity for the epitope is more important than the actual epitope
recognized. This is probably due to the complexity of the antigen that consists of a
heteromerous association of different subunits (Lee et al., 2005).
Using purified polypeptides, such as the synthetic 8 kDa proteins (Hancock et al.,
2003), for immunization and panning could result in the selection of more Nbs with
higher affinities, thus improving the sensitivity of the assay.
This study demonstrates the feasibility of employing Nbs to develop an antigen de-
tection assay specific for T. solium cysticercosis, after a further determination of the
analytical sensitivity and test performance (diagnostic sensitivity and specificity). The
introduction of Nbs, with their high (thermo-)stability and low production cost compared
to conventional monoclonal antibodies (Frenken et al., 2000; Muyldermans, 2001), offers
additional benefits to design an affordable field-assay for use in countries where cysticer-
cosis is endemic.
6
General discussion, conclusions and
recommendations
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6.1 Introduction
The main objective of the present thesis was to study serological responses in pigs and to
identify and develop tools for improved serodiagnosis of porcine cysticercosis. More specif-
ically, the aim in chapter 3 on one hand was to link serological data (antibody and antigen
responses) to parasitological findings in experimentally infected pigs in order to study the
host-parasite relationship and on the other hand to study the relationship between num-
ber of cysts and titer of circulating antigen in order to develop a quantitative diagnostic
test. In chapter 4, SELDI-TOF MS technology was applied to identify novel biomarkers
in serum of infected pigs that can distinguish between active cysticercosis and inactive
cysticercosis. Finally in chapter 5, Nanobodies specific for T. solium were produced that
can be used for specific diagnosis of porcine cysticercosis. The objective of this chapter is
to discuss the findings of the present thesis in a more general context of host-parasite im-
mune interactions and implications for immunoassay development. The advantages and
disadvantages of the applied methodology are discussed and further research priorities are
identified.
6.2 Serological responses in experimentally infected
pigs
In Chapter 3, circulating antibody and antigen kinetics were measured in experimentally
infected pigs aged 1, 3 and 5 months at infection and linked with the parasitological out-
come of infection. The simultaneous testing of circulating antigen and antibody resulted
in some important observations: (1) circulating antigen is produced by cysts long before
they are fully developed, (2) in some older animals with degenerated cysts at necropsy,
the low levels of circulating antigen suggest that cysts were destroyed at very early stage
during infection, (3) the rapid development of antibody response and subsequent abro-
gation of the infection in older animals is likely the result of a more efficient (innate)
immune response compared to younger animals.
This age-dependent resistance has important repercussions for using vaccination as a
strategy in control programs (Flisser et al., 2004; Gonzalez et al., 2005). Further research
is required to determine the age at which piglets should be vaccinated. Up to now, most
immunological research has been done on T. crassiceps in murine cysticercosis (Villa and
Kuhn, 1996; Terrazas et al., 1998, 1999, 2005; Mooney et al., 2000; Toenjes and Kuhn,
2003), but more information is needed on both the mucosal and systemic immune response
in pigs.
The use of both antigen and antibody detection allows a better understanding of
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transmission dynamics and the modeling of the generated data. This can shed new light
on incidence, frequency of exposure, establishment rate and immunity. These data should
provide a solid basis for decision making on control measures to be taken.
In this respect, a recent community-based survey was performed by our group in
Ecuador’s southern Andean province of Loja, measuring antibody and antigen levels in
approximately 800 inhabitants aged between 1 and 98 years (Praet et al., in preparation).
The results showed that antibody and antigen profiles strongly depend on the age of the
individuals. The number of antibody positives progressively increased till the age of 40
to become stable later. A simulation model taking into account a difference between
primary and secondary humoral response induced by first or subsequent contact with the
parasite could reproduce this progressive increase in younger individuals. They also noted
a higher proportion of antigen-ELISA positives in individuals older than 60 years. In other
words, viable cysts are more frequent in older individuals. This could be explained by
the fact that a weaker immune system in the elderly facilitates the establishment and
maintenance of viable cysts. At first sight, this is in disagreement with our observations
in experimentally infected pigs. In field conditions however, viable cysts are often found in
older pigs (Phiri et al., 2002). This could be explained by a less efficient immune response
in these animals due to malnutrition or possibly the occurrence of subsequent infections.
In the study in humans, no information was collected on individuals younger than 1 year
old. Combining the results of the studies in pigs and humans, one could speculate that
both very young and elderly individuals are more prone to infection with viable cysts due
to the immature and senescent immune system, respectively. In any case, there seems to
be a delicate balance between immune response and cyst development. Further studies
are necessary to confirm this.
In the second part of the study, we observed a significant relationship between the
number of cysts and the titer of circulating antigen in pigs. This is promising in view
of the development of an assay to quantify the progress of an active T. solium infection.
Such an assay would also be a useful tool in epidemiological studies to assess the infection
burden and the risk of transmission of the disease. Handali et al. (2004) showed that
antibody titers measured by the FAST-ELISA with sTs18VAR-1 seemed to correlate well
with viability of the cysts. The use of specific antibody-detection assays combined with
circulating antigen detection could improve our understanding of this relationship.
6.3 Biomarkers for active and inactive cysticercosis
In chapter 3, we reported different antibody and antigen kinetics in experimentally in-
fected pigs linked to the parasitological outcome of infection. Several studies correlate
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antibody titers with infection by viable cysts (de Aluja et al., 1996; Flisser et al., 2002;
Handali et al., 2004). We, however, observed higher antibody titers in animals with a
higher proportion of degenerated cysts. To elucidate these contradictory results, we fur-
ther wanted to investigate these different phenotypic profiles. We used serum proteomic
profiling by SELDI-TOF MS to identify biomarkers specific for these different disease
states (active cysticercosis with viable cysts and inactive cysticercosis with degenerated
cysts). Thirty biomarkers were identified in serum samples from experimentally infected
pigs but none of these biomarkers could be validated by analyzing serum samples from
naturally infected pigs.
Serum proteomic profiling is an emerging paradigm to generate a set of biomarkers
diagnostic for a certain disease state. Petricoin et al. (2002a) published their seminal
study using SELDI-TOF MS to profile the serum proteome of ovarian cancer patients and
reported a set of 5 discriminatory biomarkers yielding a sensitivity of 100% and specificity
of 95%. Since this first report, several published studies have applied similar technology to
various cancers (Li et al., 2002; Adam et al., 2002; Qu et al., 2002; Petricoin et al., 2002b;
Liu et al., 2005; Engwegen et al., 2006) and parasitic diseases (Papadopoulos et al., 2004;
Rioux et al., 2007). The main advantage of SELDI-TOF technology is the capability of
high throughput screening of complex samples in search for potential biomarkers. The
main issue when setting up a SELDI-TOF experiment will be, however, to meet the
necessary requirements with regard to the number of samples, choice of control samples,
processing and handling of samples.
There has been more and more published criticism of SELDI-TOF MS methodol-
ogy raising questions about sensitivity and especially reproducibility (Diamandis, 2003,
2004a,b; Baggerly et al., 2004b). Also, in some SELDI-TOF experiments, the presence of
systematic bias distorted the results: discriminatory peaks were shown not to reflect the
different disease stages but rather the run dates of the samples or the sample collection
protocols (Sorace and Zhan, 2003; Baggerly et al., 2004a; Hu et al., 2005). Other authors
also failed to confirm previous results with SELDI-TOF MS for the diagnosis of prostate
cancer (Skytt et al., 2007). They state that several rather small case control studies have
reported excellent validity for prostate cancer detection, but no studies have replicated
these initial findings. Some authors claim that the Bio-Rad SELDI PBS II platform per se
is not able to deliver the kind of reproducibility required for clinical testing and that the
software possesses algorithmic weaknesses that can reduce the effective sensitivity of the
instrument (Petricoin and Liotta, 2003; Coombes et al., 2005a). Researchers have been
developing other methods for processing mass spectra (Coombes et al., 2003; Qu et al.,
2003; Yasui et al., 2003a,b; Malyarenko et al., 2005; Morris et al., 2005; Coombes et al.,
2005b), but these techniques are not so user-friendly and the results are often difficult to
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interpret.
In chapter 4, five biomarkers in the experimental sample group were identified as
clusterin, vitronectin, Apo A-I, LCAT and haptoglobin, respectively. Diamandis (2004b)
listed the positively identified candidate biomarkers by mass spectrometry for various
forms of cancer. Most identified proteins represent acute-phase reactants produced by the
liver in response to inflammation. These proteins are present in extremely high abundance
in serum and concentration differences between the disease states are extremely small and
of doubtful clinical value. Deep proteome profiling (after depletion of high-abundance
serum proteins) could proof to be a more valuable approach for detecting potential serum
biomarkers (Au et al., 2007; Desrosiers et al., 2007).
One should bear in mind that a statistically significant biomarker is not equal to a
clinically significant biomarker, i.e. suitable for use in a (SELDI-TOF derived) diagnostic
assay. Considering the cost and reproducibility problems of this proteomic technology,
a significant improvement in relation to established biomarkers is needed to justify the
industrial development of this new generation of markers (Morra et al., 2007).
Proteomic profiling by SELDI-TOF MS could be a valuable starting point for im-
munological research and to investigate host-parasite interactions. To be applicable in a
diagnostic setting, however, biomarkers need to be meticulously validated in different pop-
ulations. In chapter 4 we observed a considerable discordance between experimental and
field settings. The collection of sufficient samples that comply to the strict requirements
for MS-based technology, could prove to be a serious bottleneck in biomarker discovery
studies.
6.4 Specific diagnosis of porcine cysticercosis
Since serum proteomic profiling with SELDI-TOF MS did not result in cysticercosis-
specific biomarkers that could be used for devising a new diagnostic assay, focus was
shifted to improving the specificity of the current monoclonal antibody-based Ag-ELISA
(Brandt et al., 1992; Dorny et al., 2002). Due to the genus-specificity, cross reactions with
other taeniid spp. hamper the use of this test in pigs (Dorny et al., 2003).
In chapter 5, a panel of eight T. solium specific Nanobodies were identified, charac-
terized and tested for specific diagnosis of porcine cysticercosis. One Nb in particular
(Nbsol52), showed high potential for use in inhibition-ELISA.
A diagnostic assay that can specifically detect viable T. solium cysticerci in pigs would
at present be a valuable tool for descriptive epidemiological research to identify regions
of active transmission of the disease. Tongue inspection could also be used as a rapid
assessment tool for this purpose, however, the sensitivity is by far inferior to serological
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screening (Dorny et al., 2004b). Researchers are more and more shifting from descriptive
research to implementation and evaluation of different intervention trials such as human
mass chemotherapy, pig vaccination, pig cysticercosis treatment, infrastructure develop-
ment, as well as health education campaigns (Sarti and Rajshekhar, 2003; Gonzalez et al.,
2005; Ngowi et al., 2008). In this context, a specific antigen detection assay in pigs can
contribute to the monitoring and evaluation of these different control strategies.
In the long run, a pen side test that is able to provide a relatively fast result for each
animal individually, would be preferable. A test format such as lateral flow immunochro-
matographic assay would be most suited for this application. This way, pigs harboring
viable cysts can be identified immediately and given anthelmintic treatment on the spot.
Treating infected pigs with a single-dose of oxfendazole (30 mg/kg) has been proven to
effectively kill cysts and clear the meat 12 weeks after therapy (Gonzalez et al., 1996,
1998); the drug has, however, little or no effect on brain cysts (Sikasunge et al., 2008b).
Furthermore, treated animals seem to be protected from new infections for at least three
months (Gonzalez et al., 2001). Given the relatively short life span of pigs, this could
prove to be a sustainable control strategy in combination with other intervention mea-
sures. On the same account, the development of a bed side test for the diagnosis of human
cysticercosis would be of great value for clinical case management in a hospital setting
and for field based control programs.
A diagnostic test for T. solium cysticercosis would have to be suitable for use in
endemic areas, these are often rural and remote areas in tropical conditions. This im-
plies that the test should be cheap, easy to use and preferably cold chain independent.
Nanobodies are most suitable for this purpose. For one they are very stable: three Nbs
retained 100% activity after 1 week incubation at 37°C (Arbabi-Ghahroudi et al., 1997),
other Nbs were still able to specifically bind antigen at temperatures as high as 90°C
(van der Linden et al., 1999). Therefore it seems that Nbs will have a very good “shelf-
life” and there will be no need for a cold chain. Nanobodies are efficiently expressed as
soluble recombinant proteins. In high cell-density fermentation, a production level of over
1 g/l should be feasible (Muyldermans, 2001). As such, production costs will be much
lower than for conventional monoclonal antibodies. Furthermore, Nbs can be tailored in
different constructs and as such can be adapted to the required test format. Tailoring
of the T. solium specific Nbs obtained in chapter 5 will be done to improve the assay.
Generating bivalent constructs or Nbs linked to the Fc domain of IgG improves the im-
mobilization of Nbs on hydrophobic ELISA plates (Conrath et al., 2001a; Saerens et al.,
2005a). Other possibilities are the generation of pentavalent constructs or CDR grafting
in an universal Nanobody scaffold (Zhang et al., 2004a; Saerens et al., 2005b).
In chapter 5, we have used crude T. solium cyst fluid to construct the dromedary
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immune library and screen for T. solium specific Nbs. Another approach could be us-
ing either crude cysticercal ES antigens or purified recombinant or synthetic peptides
for library construction and/or screening. We have already panned the dromedary 2 li-
brary using crude T. solium ES antigens but this did not result in selection of additional
Nanobodies. Characterization and comparison of cysticercal ES proteins of different taeni-
ids might lead to the identification of novel target antigens for the development of a specific
antigen detection ELISA. To date, only a few studies have reported the characterization
of ES antigens (Ko and Ng, 1998; Espindola et al., 2002; Baig et al., 2005), but to our
knowledge no extensive proteomic studies have been carried out. The two currently used
antigen detection ELISAs, the HP10 (Harrison et al., 1989) and the B158/B60 ELISAs
(Draelants et al., 1995; Van Kerckhoven et al., 1998), detect a carbohydrate epitope and
a partly protein/partly carbohydrate epitope, respectively, present on the surface and in
the secretions of T. saginata cysticerci, but the actual protein has not been identified yet.
The T. solium Nbs recognized one or more synthetic peptides of the 8 kDa protein
family (Hancock et al., 2003). These are well known proteins present in the diagnostic
bands of the EITB Western blot for cysticercosis diagnosis (Tsang et al., 1989). As such,
using these synthetic peptides for library construction and/or panning could result in the
identification of additional Nanobodies.
6.5 Conclusions and recommendations
This study demonstrates the feasibility of (1) identifying serological markers that can
differentiate between active and inactive cysticercosis and (2) developing a specific test
for the diagnosis of T. solium cysticercosis. The first priority – well within reach now
we have T. solium specific Nanobodies at our disposal – is the further development of a
specific antigen-ELISA and adaptation to a pen side (or bed side) test.
The availability of an improved antigen detection assay provides clear prospects for
epidemiological and immunological studies, follow-up of intervention studies and clinical
monitoring in humans. In epidemiological studies, it can provide accurate information on
sites of active transmission and risk factor assessment. Follow up of cyst longevity is possi-
ble in immunological studies and monitoring of control programs. In clinical cysticercosis
cases in humans, it is a valuable decision making tool to start anthelmintic treatment and
for follow-up of treatment efficacy.
However, more fundamental research is warranted to elucidate host-parasite interac-
tions and identify good target antigens for diagnosis. Work is in progress to sequence
the complete T. solium genome. Up to now, the complete mitochondrial genome has
been sequenced (Nakao et al., 2003), 24,790 expressed sequence tags (EST), 177 mRNA
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and 162 genomic nucleotide sequences are identified 1. Once the full genome has been
sequenced, this will provide valuable baseline data for conducting further studies. A pro-
teomics study comparing ES products of T. solium, T. hydatigena, T. saginata could lead
to the identification of specific diagnostic antigens.
There is also a need to further elucidate the immune response in Taenia infections,
not only in the murine model of cysticercosis, but also in porcine and human cysticercosis.
The experimental infection model developed by the Cysticercosis Working Group in Peru
provides interesting possibilities for this purpose. Studying the immune response in pigs
could possibly serve as a valuable model for human cysticercosis. Indeed, several studies
indicate that the pig is suitable as animal model for immunology, despite the anatomical
particularities of the porcine immune system (Duchene et al., 2008; Herbert et al., 2008;
Rothkotter, 2008).
1Genome project data available from: http://www.ncbi.nlm.nih.gov/sites/entrez?db=
genomeprj
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Taenia solium taeniosis/cysticercosis is an important (re)emerging zoonotic helminth
infection in developing countries. The general introduction of chapter 1 outlines briefly
the life cycle of the parasite, impact of cysticercosis and its control. The remaining part
of this chapter presents an update of the data available in the literature regarding diag-
nosis of cysticercosis and taeniosis. Focus is put on immunodiagnostic tools. Measuring
antibody or antigen responses provides different information on the course of infection.
In general, antibody detection assays only reflect exposure to the parasite whereas anti-
gen detection assays indicate the presence of living parasites. The first objective of this
thesis was to link serological data (antibody and antigen responses) to parasitological
findings in experimentally infected pigs in order to study the host-parasite relationship
(objective 1).
The current monoclonal antibody based antigen-ELISA detects circulating parasite
antigens, which indicate the presence of living cysts. However, no information is available
on whether this test has potential for quantitating the number of viable cysts present or
whether it is merely a qualitative measurement. Hence, the second objective was to study
the relationship between number of cysts and titer of circulating antigen in pigs in order
to develop a quantitative diagnostic test (objective 2).
Diagnostic tests for porcine cysticercosis were recently validated based on a Bayesian
approach. In a recent report by FAO, WHO and OIE, the development of more sensitive
and specific diagnostic tests for use in pigs was stated as one of the research priorities for
taeniosis/cysticercosis. For one, there is no test available that can distinguish between
infections with viable cysts (active cysticercosis) and infections with degenerated cysts
(inactive cysticercosis). Therefore, the third objective of this thesis was to identify novel
biomarkers in serum of infected pigs that can distinguish between active and inactive
cysticercosis, using surface enhanced laser desorption and ionization time-of-flight mass
spectrometry (SELDI-TOF MS) (objective 3).
Another gap in the diagnosis of porcine cysticercosis is the fact that the use of the
antigen-ELISA in pigs is hampered by cross reactions with other taeniid species. Hence,
the last objective was to produce Nanobodies (camelid derived single domain antibody
fragments) specific for T. solium that can be used for diagnosis of porcine cysticercosis
(objective 4).
Chapter 2 gives a short overview of the two techniques used in the experimental work
of this thesis (objectives 3 and 4, respectively). In the first part the general methodology
of SELDI-TOF MS is presented along with examples of applications for disease biomarker
discovery. Furthermore, critical reviews raising concerns regarding the reliability of the
SELDI-TOF MS approach for biomarker discovery are discussed.
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The second part of this chapter discusses the properties of Nanobodies compared to
conventional antibody fragments, and the production and selection of antigen-specific
Nanobodies. Finally, a short overview of biotechnological and therapeutic applications is
given.
In chapter 3, antibody and antigen levels were determined in experimentally infected
pigs and linked to the parasitological outcome of infection. In the experimental model, 3
groups of pigs aged respectively 1, 3 and 5 months at infection were infected with a full
proglottid. The 1-month old animals developed mainly viable cysts, the 5-month old ani-
mals mainly degenerated cysts, whereas the 3-month old animals showed an intermediate
profile. All animals harboring viable cysts at necropsy had high antigen levels, whereas
animals harboring no cysts or only degenerated cysts, had low or nil antigen levels. Anti-
gen levels increased more rapidly in 1-month old animals harboring viable cysts than in
5-month old animals harboring viable cysts. Also, the antigen levels reached were higher
in the animals infected at 1 month of age compared with animals infected at 3 and 5
months of age. Serum antibody levels appeared to follow a reverse kinetics compared
with circulating antigen. Antibody titers were highest in animals infected at 5 months of
age. In the animals infected at 1 and 3 months of age, antibody levels increased slowly
and remained substantially lower compared with the older age group. These results indi-
cate the presence of an age-dependent immune response: an efficient antibody response
in older animals prevents the establishment of fully developed viable cysts whereas in
younger animals the immune system cannot adequately react to the infection resulting in
the establishment of viable cysts (accompanied by high circulating antigen levels).
In the second part of this chapter, a quantitative ELISA for measuring the concen-
tration of circulating antigen was constructed using a reference standard curve of serial
dilutions of ES products of T. saginata. A significant correlation between the number
of viable cysts and the concentration of circulating antigen was found. This result is
promising in view of the development of an assay to quantify the progress of an active
T. solium infection.
In chapter 4, serum samples from the same experimentally infected pigs were analyzed
by SELDI-TOF MS to identify biomarkers that can distinguish between infections with
viable cysts and infections with degenerated cysts. Thirty discriminating biomarkers were
found: 13 specific for the viable phenotype, 9 specific for the degenerated phenotype and
8 specific for the infected phenotype (either viable or degenerated cysts). Five biomark-
ers were identified as clusterin, lecithin-cholesterol acyltransferase (LCAT), vitronectin,
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haptoglobin and apolipoprotein A-I. The possible function of the identified biomarkers is
discussed with regard to host-parasite immune interactions.
An attempt was made to validate the biomarkers by analyzing serum samples from
naturally infected pigs. Only 3 of the biomarkers were also significant in the field samples;
however, the peak profiles were not consistent among the two sample sets. Thus, it was
not possible to validate the biomarkers. Possible explanations for this event are presented
in the discussion.
In chapter 5, Nanobodies were cloned following immunization of 2 dromedaries with
T. solium cyst fluid and 8 T. solium specific Nanobodies were selected after phage display
and biopanning. Their binding characteristics and potential for the diagnosis of porcine
cysticercosis were investigated.
The Nanobodies were highly specific for T. solium and no cross reactions with T. hy-
datigena, T. saginata, T. crassiceps and T. spiralis were observed. Affinity measurements
by BIAcore binding studies resulted in equilibrium dissociation constants (KD) in the pi-
comolar range for Nbsol52, in the micromolar range for Nbsol68 and in the nanomolar
range for the 6 remaining Nanobodies. Western blotting of T. solium cyst fluid and
immunodetection with the Nanobodies was performed. After transfer to a PVDF mem-
brane and N-terminal sequencing of the proteins in the bands corresponding to the bands
recognized by the Nanobodies, the target antigen was identified as 14 kDa diagnostic gly-
coprotein. Immunodetection was also assessed of the synthetic Ts14, Ts18var, TsRS1 and
TsRS2 peptides. The Nanobodies preferably reacted with Ts18var1, only 2 Nanobodies
also reacted with Ts14 and TsRS2. The complementation epitope groups of Nanobodies
were investigated in competition ELISA. This way, the Nanobodies could be categorized
in four different epitope-binding groups. Furthermore, the prior binding of the group A
Nanobodies to the antigen seemed to induce a conformational change within the antigen
and/or fix a more appropriate epitope architecture for the group B Nanobodies. Antigen
capturing was assessed by testing the Nanobodies in various combinations in sandwich
ELISA. The Nanobodies were able to distinguish between T. solium and T. hydatigena
cyst fluid, however, there was no clear distinction between serum samples from T. solium
infected pigs, T. hydatigena infected pigs and negative pigs. Next, the Nanobodies were
tested in inhibition ELISA for the detection of circulating antigen. One Nanobody (Nb-
sol52) was able to differentiate between the different serum samples.
These results indicate the high potential of the selected Nanobodies for species-specific
diagnosis of T. solium cysticercosis, after further assay optimization and validation.
Finally in chapter 6 the obtained results are put into a broader perspective, and
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the advantages and disadvantages of the applied methodology are discussed. The general
conclusions and recommendations for future work are presented.
The results of the present thesis demonstrate the feasibility to identify serological
markers that can lead to improved diagnosis of porcine cysticercosis. To further eluci-
date host-parasite interactions and identify alternative target antigens for diagnosis, more
fundamental research should be conducted. Therefore, the immune response in Taenia
infections should be investigated, as well as comparative mapping of the parasite’s pro-
teome.
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Taenia solium taeniose/cysticercose is een belangrijke opkomende zoo¨notische wormin-
fectie in ontwikkelingslanden. In de algemene inleiding van hoofdstuk 1 worden kort de
cyclus van de parasiet, impact en controle van cysticercose toegelicht. Het overig deel van
dit hoofdstuk verschaft een update van de informatie over de diagnose van cysticercose en
taeniose beschikbaar in de literatuur, met nadruk op de immunodiagnostische methoden.
Detectie van antistoffen of antigeen levert verschillende informatie over het verloop van
een infectie. In het algemeen weerspiegelt antistofdetectie enkel voorafgaand contact met
de parasiet. Antigeendetectie tests daarentegen geven een indicatie over de aanwezigheid
van levende parasieten. De eerste doelstelling van deze thesis betracht om serologische
gegevens (antistof- en antigeenrespons) te linken aan parasitologische bevindingen in ex-
perimenteel ge¨ınfecteerde varkens om op deze manier de interactie tussen gastheer en
parasiet te bestuderen (doelstelling 1).
De huidige antigeen-ELISA gebaseerd op monoklonale antistoffen detecteert circulerende
parasietantigenen die duiden op de aanwezigheid van levende cysten. Het is echter niet
bekend of deze test ook potentieel biedt om het aantal levende cysten te kwantificeren of
enkel een kwalitatief resultaat geeft. Daarom was de tweede doelstelling het bestuderen
van de relatie tussen het aantal cysten en de titer van circulerend antigeen in varkens met
het oog op de ontwikkeling van een kwantitatieve diagnostische test (doelstelling 2).
Diagnostische tests voor porciene cysticercose zijn recentelijk gevalideerd door mid-
del van Bayesiaanse analyse. In een recent rapport van de FAO, WGO en OIE werd de
ontwikkeling van sensitievere en specifiekere diagnostische testen voor varkens naar voor
geschoven als e´e´n van de onderzoeksprioriteiten voor taeniose/cysticercose. Er is om te
beginnen geen test beschikbaar die het onderscheid kan maken tussen infecties met levende
cysten (actieve cysticercose) en infecties met gedegenereerde cysten (inactieve cysticer-
cose). De derde doelstelling van deze thesis was dan ook om in serum van ge¨ınfecteerde
varkens nieuwe biomerkers te identificeren die een onderscheid kunnen maken tussen ac-
tieve en inactieve cysticercose. Hiervoor werd gebruikt gemaakt van “surface enhanced
laser desorption and ionization time-of-flight” massa spectrometrie (SELDI-TOF MS)
(doelstelling 3).
Een andere tekortkoming in de diagnose van porciene cysticercose is het feit dat het ge-
bruik van de antigeen-ELISA in varkens gehinderd wordt door de aanwezigheid van kruis-
reacties met andere Taenia species. De laatste doelstelling was dan ook het produceren
van “Nanobodies” (enkel domein kameelantilichaamfragmenten) specifiek voor T. solium
die gebruikt kunnen worden voor diagnose van porciene cysticercose (doelstelling 4).
Hoofdstuk 2 geeft een kort overzicht van de twee technieken gebruikt in het experi-
menteel werk van deze thesis (doelstellingen 3 en 4, respectievelijk). In het eerste gedeelte
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wordt de algemene methodologie van SELDI-TOF MS aangehaald, alsook voorbeelden van
toepassingen op het vlak van ziekte-specifieke biomerkeridentificatie. Bovendien worden
enkele kritische besprekingen onder de loupe genomen die hun bezorgdheid uiten over de
betrouwbaarheid van de SELDI-TOF MS technologie voor de ontdekking van biomerkers.
Het tweede gedeelte van dit hoofdstuk handelt over de eigenschappen van Nano-
bodies in vergelijking met conventionele antilichaamfragmenten en de productie en selectie
van antigeenspecifieke Nanobodies. Tenslotte volgt een kort overzicht van verschillende
biotechnologische en therapeutische toepassingen.
In hoofdstuk 3 werden in experimenteel ge¨ınfecteerde varkens de antistof- en antigeen-
gehaltes bepaald en gelinked aan de parasitologische uitkomst van de infectie. In het
experimenteel model werden 3 groepen varkens van respectievelijk 1, 3 en 5 maanden oud
ge¨ınfecteerd met een volledige proglottide. De 1 maand oude dieren ontwikkelden voor-
namelijk levende cysten, de 5 maand oude dieren vooral gedegenereerde cysten, terwijl de
3 maand oude dieren een intermediair profiel vertoonden. Alle dieren die op het moment
van de lijkschouwing levende cysten hadden, vertoonden een hoge antigeenrespons. De
dieren die geen of enkel gedegenereerde cysten hadden, vertoonden geen of slechts een lage
antigeenrespons. De antigeengehaltes namen sneller toe in de 1 maand oude dieren met
levende cysten dan in de 5 maand oude dieren met levende cysten. De antigeengehaltes
waren ook hoger in de dieren ge¨ınfecteerd op de leeftijd van 1 maand vergeleken met de
dieren ge¨ınfecteerd op 3 en 5 maanden leeftijd. Het gehalte aan serumantistoffen leek een
omgekeerde kinetiek te vertonen vergeleken met circulerend antigeen. De antistoftiters
waren het hoogst in de 5 maand oude dieren. In de 1 en 3 maand oude dieren namen
de antistofgehaltes slechts traag toe en bleven aanzienlijk lager vergeleken met de oudere
dieren. Deze resultaten wijzen op een leeftijdsafhankelijke immuunrespons: een efficie¨nte
antistofrespons in de oudere dieren verhindert de vorming van volledig ontwikkelde levende
cysten. In jongere dieren daarentegen kan het immuunsysteem niet adequaat reageren op
de infectie met als gevolg de ontwikkeling van levende cysten (vergezeld van hoge gehaltes
circulerend antigeen).
In het tweede deel van dit hoofdstuk werd een kwantitatieve ELISA ontwikkeld voor
de bepaling van de concentraties circulerend antigeen. De test werd ontwikkeld aan de
hand van een standaardcurve van een serie¨le verdunning van T. saginata excretie secretie
produkten. Er werd een significante correlatie gevonden tussen het aantal levende cysten
en de concentratie van circulerend antigeen. Dit resultaat is veelbelovend met het oog op
de ontwikkeling van een kwantitatieve test voor de opvolging van een actieve T. solium
infectie.
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In hoofdstuk 4 werden dezelfde serumstalen van de experimenteel ge¨ınfecteerde
varkens geanalyseerd d.m.v. SELDI-TOF MS om biomerkers te ontdekken die het onder-
scheid kunnen maken tussen infecties met levende cysten en infecties met gedegenereerde
cysten. Er werden zo 30 biomerkers gevonden: 13 specifiek voor het fenotype “levend”, 9
specifiek voor het fenotype “gedegenereerd” en 8 specifiek voor het fenotype “ge¨ınfecteerd”
(ge¨ınfecteerd met levende of gedegenereerde cysten). Vijf biomerkers werden ge¨ıdenti-
ficeerd als clusterine, lecithine-cholesterol acyltransferase, vitronectine, haptoglobine en
apolipoprote¨ıne A-I. De mogelijke functie van de ge¨ıdentificeerde biomerkers wordt be-
sproken met betrekking tot gastheer-parasiet immuuninteracties.
Er werd gepoogd om de biomerkers te valideren door analyse van serumstalen van
natuurlijk ge¨ınfecteerde dieren. Slechts 3 biomerkers waren ook significant in deze groep
serumstalen. De piekprofielen waren echter niet consistent in de twee groepen. Vali-
datie van de biomerkers was aldus niet mogelijk. Mogelijke verklaringen hiervoor worden
geopperd in de discussie.
In hoofdstuk 5 werden Nanobodies gekloond na immunisatie van 2 dromedarissen
met T. solium cystevloeistof. Na faagdisplay en biopanning werden er acht T. solium spe-
cifieke Nanobodies geselecteerd. Hun bindingseigenschappen en potentieel voor diagnose
van porciene cysticercose werden onderzocht.
De Nanobodies waren zeer specifiek voor T. solium en er werden geen kruisreacties
waargenomen met T. hydatigena, T. saginata, T. crassiceps en T. spiralis. Affiniteits-
metingen d.m.v. BIAcore bindingstudies resulteerden in evenwichtsdissociatieconstan-
ten (KD) in de grootte-orde van picomolair voor Nbsol52, micromolair voor Nbsol68 en
nanomolair voor de overige zes Nanobodies. Er werd een Western blot uitgevoerd met
T. solium cystevloeistof gevolgd door immunodetectie met de Nanobodies. Na transfer
naar een PVDF membraan en N-terminale sequenering van de prote¨ınen in de banden cor-
responderend met de banden herkend door de Nanobodies, werd het herkende antigeen
ge¨ıdentificeerd als 14 kDa diagnostisch glycoprote¨ıne. Er werd tevens immunodetectie
van de synthetische peptiden Ts14, Ts18var1, TsRS1 en TsRS2 uitgevoerd. De Nano-
bodies reageerden bij voorkeur met Ts18var1, enkel 2 Nanobodies herkenden ook Ts14
en TsRS2. De complementaire epitoopgroepen van de Nanobodies werden onderzocht in
een competitie ELISA. Op deze manier konden de Nanobodies onderverdeeld worden in
4 verschillende epitoopgroepen. Bovendien induceerde de voorafgaande binding aan het
antigen van de groep A Nanobodies schijnbaar een conformatieverandering in het anti-
gen en/of veroorzaakte dit een betere epitooparchitectuur voor de groep B Nanobodies.
De mogelijkheid om met de Nanobodies antigeen te capteren werd onderzocht door deze
in verschillende combinaties te testen in een sandwich ELISA. De Nanobodies waren in
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staat om een onderscheid te maken tussen cystevloeistof van T. solium en T. hydatigena.
Het was echter niet mogelijk om op deze manier een duidelijk onderscheid te bekomen
tussen serumstalen van varkens ge¨ınfecteerd met T. solium of T. hydatigena en negatieve
varkens. De Nanobodies werden vervolgens getest in een inhibitie ELISA voor antigeende-
tectie. Ee´n Nanobody (Nbsol52) was in staat om te differentie¨ren tussen de verschillende
serumstalen.
Deze resultaten wijzen op het grote potentieel van de geselecteerde Nanobodies voor
de specifieke diagnose van T. solium cysticercose, na verdere aanpassing en validatie van
de test.
Tot slot worden in hoofdstuk 6 de behaalde resultaten in een breder perspectief
geplaatst. De voor- en nadelen van de toegepaste methodologie, de algemene conclusies
en de aanbevelingen worden besproken.
De resultaten van deze thesis tonen aan dat het mogelijk is om serologische merkers te
identificeren die gebruikt kunnen worden voor een verbeterde diagnose van porciene cys-
ticercose. Om de gastheer-parasiet interacties verder uit te diepen en nieuwe diagnostische
antigenen te identificeren, is meer fundamenteel onderzoek nodig. De immuunrespons
tegen Taenia infecties dient daarom verder bestudeerd te worden, evenals vergelijkend
onderzoek van het proteoom van de parasiet.
